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Abstract 
Background 
Rearranged L-Myc Fusion, Rlf, was recently identified as a novel epigenetic 
modifier from a mouse N-ethyl-N-nitrosourea mutagenesis screen.  The mice used in 
this study carry a multi-copy green fluorescent protein (GFP) transgene linked to an 
erythroid specific α-globin promoter that is sensitive to epigenetic silencing.  Three 
independent mouse lines, MommeD8, MommeD28 and MommeD34, with mutations 
in Rlf were each found to have decreases in the percentage of red blood cells 
expressing GFP, suggesting Rlf acts an epigenetic modifier and plays a role in 
transcriptional activation.  Our study is the first to reveal a role for Rlf in epigenetics, 
and currently very little is known about the function of Rlf.  These are the first 
available mouse mutants that can be utilised to study the molecular and phenotypic 
consequences of Rlf inactivation.  
 
Results 
Using a combination of RNA sequencing, chromatin immunoprecipitation 
sequencing and whole genome bisulphite sequencing, I have shown Rlf acts as an 
epigenetic modifier. Rlf plays a critical role in heart development as determined by 
histology and this may be mediated via alteration to the Notch signalling pathway, as 
determined by RNA sequencing. These effects do not appear to be accumulated 
trasngenerationally.  
 
Conclusion  
The results presented in this thesis indicate Rlf plays an important role during 
development and inactivation of Rlf alters the transcriptome, methylome and 
phenotype in the mouse. 
 
Keywords  
Epigenetics, gene expression, heart development, methylation, Rearranged L-Myc 
Fusion, transcription, transgenerational epigenetics. 
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PMSF Phenylmethylsulfonyl fluoride 
Pogz Pogo transposable element with Znf domain  
Ppar-γ Peroxisome proliferator-activated receptor gamma  
Prss50 Protease, serine 50 
Psma8 Proteasome subunit alpha type 8 
PWS Prader-Willi syndrome 
qRT-
PCR Quantitative real-time reverse-transcription polymerase chain reaction 
RIN RNA integrity number 
RISC RNA induced silencing complex 
Rlf Rearranged L-myc fusion 
Rlf-DMR Rlf differentially methylated region 
RNA Ribonucleic acid 
RNAi RNA interference 
RNA-seq RNA sequencing 
rpm Revolutions per minute 
rt Room temperature 
s Seconds 
SANT Swi3, Ada2, N-Cor And TFIIIb Domain 
SCLC Small cell lung cancer 
SDS Sodium dodecyl sulfate (lauryl sulfate sodium salt) 
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SEM Standard error of the mean 
SET Su(Var)3-9 and enhancer of zeste 
siRNA Short interfering RNA 
Sirt6 Sirtuin 6 
Smad3/6 Smad family member 3/6 
Smarca Swi/Snf Related, Matrix Associated, Actin Dependent Regulator of 
Chromatin, Subfamily A 
Smchd1 Structural maintenance of chromosomes flexible hinge domain 
containing 1  
SOB Super optimal broth 
su Sumoylation 
SWI/SNF Switch/sucrose non-fermentable 
TAE Tris, Acetic Acid and EDTA Buffer 
TBE Tris, Boric Acid and EDTA Buffer 
Tbx5 T-box 5
TET Ten eleven translocation enzyme
TFB I Transformation buffer I
TFB II Transformation buffer II
Timd2 T-cell immunoglobulin and mucin domain containing 2
tsDMR Tissue specific differentially methylated region
TSS Transcription start site
U Units
ub Ubiquitylation
Ube3a Ubiquitin protein ligase e3a
Uhrf1 Ubituitin like with phd and ring finger domains
V Volts
Vldlr Very low density lipoprotein receptor
X-gal 5-bromo-4-chloro-3-indoyl-d-galactoside
Xic X chromosome inactivation centre
Xist X inactive specific transcript
Zfp462 Zinc finger protein 462
βactin Beta-actin gene
8th June 2016
QUT Verified Signature
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Chapter 1: Introduction  
1.1 EPIGENETIC MODIFICATIONS 
 
Epigenetics refers to the study of changes in gene expression that are heritable 
and occur without changes in the underlying DNA sequence, as reviewed in (Dupont 
et al., 2009).  Epigenetic modifiers are genes that are involved in establishing and 
maintaining the epigenetic state of the genome.  They are known to play critical roles 
in development and disease (Chai et al., 2005; Chowdhury et al., 2011; Howard et 
al., 2007; Li et al., 1992; Stopka & Skoultchi, 2003).  Epigenetic mechanisms that 
regulate gene expression include DNA methylation, histone and nucleosome 
modifications, chromatin remodelling protein complexes and non-coding RNA (Allis 
et al., 2007).  The basic repeating unit of chromatin is the nucleosome, which 
consists of 147 base pairs of DNA wrapped around an octameric histone core 
containing two copies of histones H2A, H2B, H3 and H4 (Kornberg & Thomas, 
1974; Luger et al., 1997).  Chromatin is then packaged either into euchromatin, 
loosely packed chromatin associated with gene activation, or heterochromatin tightly 
packed chromatin associated with gene silencing, Figure 1.1 (Jones et al., 2008).  
Although the importance of epigenetic modifications is now clear, the mechanisms 
by which these modifications are established and maintained is still not fully 
understood.   
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Figure 1.1: A schematic diagram of epigenetic modifications.  
Modifications such as DNA methylation, histone modifications, chromatin remodelers and non-coding RNA can alter gene expression.  The 
nucleosome (inset) is the basic repeating unit of chromatin, consisting of DNA wrapped around an octameric histone core containing two copies 
of the histones H2A, H2B, H3 and H4; chromatin is then packaged into either heterochromatin or euchromatin. 
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1.1.1 DNA methylation  
 
DNA methylation primarily occurs at the 5’ position of a cytosine located next 
to a guanine (CpG dinucleotides), but may also occur in a non-CpG context as has 
been reported in mouse and human embryonic stem cells (Lister et al., 2009; 
Ramsahoye et al., 2000).  This review will focus upon CpG methylation, which has 
been studied the most extensively.  The presence of DNA methylation is commonly 
associated with gene silencing. There is increasing evidence of silencing occurring 
prior to methylation (Lock et al., 1987; Ohm et al., 2007; Schlesinger et al., 2007).   
 
DNA methylation  
There are three DNA methyltransferases (DNMTs) responsible for assembling 
methylation marks, the maintenance methyltransferase DNMT1 and the de novo 
methyltransferases DNMT3A and DNMT3B (Lei et al., 1996; Okano et al., 1999; 
Okano et al., 1998).  DNMT1 is recruited to hemimethylated DNA by UHRF1, 
ubiquitin-like with PHD and ring finger domains 1, and then methylates the CpG site 
on the opposite strand.  This process allows for DNA methylation patterns to be 
maintained following DNA replication (Bestor, 1992; Bostick et al., 2007).  In 
comparison DNMT3A and DNMT3B act as de novo methyltransferases, establishing 
new DNA methylation patterns that are important in development (Okano et al., 
1999).   
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DNA demethylation  
DNA demethylation has been observed following fertilisation of the zygote and 
during the development of primordial germ cells (Mayer et al., 2000; Oswald et al., 
2000).  DNA demethylation may be passive, whereby newly synthesised DNA is not 
methylated following replication due to the absence of functional DNMT1 (Oswald 
et al., 2000).  Alternatively, DNA demethylation may occur through the active 
erasure of methylation marks, the mechanism of which was unknown until recently 
following the identification of TET (Ten-eleven translocation) family of enzymes 
(Ito et al., 2011; Tahiliani et al., 2009).  TET1-3 proteins have the ability to convert 
5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which may then be 
reverted to unmodified cytosine through replication dependent depletion of 5hmC 
(Ito et al., 2011; Tahiliani et al., 2009; Valinluck & Sowers, 2007).  Alternatively, 
5hmC can be further converted to 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) which can be recognised by thymine DNA-glycosylase and undergo base 
excision repair through the DNA repair pathway, resulting in the regeneration of 
unmodified cytosine (He et al., 2011; Nabel et al., 2012). More recently it has been 
shown active demethylation by TET3 in the zygote, does not require thymine DNA-
glycosylase activity, but an alternate mechanism downstream is occurring (Guo et 
al., 2014). Although whether this downstream mechanism is the decarboxylation of 
5caC, dehydroxymethylation of 5hmC or base excision repair is still unknown (Chen 
et al., 2012; Hajkova et al., 2010; Schiesser et al., 2012).  
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1.1.2  Histone modifications 
Histones can undergo post translational modifications that lead to alterations in 
chromatin conformation, and in turn, gene expression, as reviewed in (Strahl & Allis, 
2000).  This review will focus upon methylation, acetylation and phosphorylation, 
however other histone modifications also include ubiquitylation, sumoylation and 
adenosine diphosphate ribosylation.  Table 1.1 lists the nomenclature for describing 
histone amino acid modifications, as reviewed in (Xhemalce et al., 2006).  
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Table 1.1 Histone amino acid modification nomenclatures. 
Modification Amino acid modified Single letter amino acid Degree of modification Abbreviation Example of modification 
Acetylation Lysine K Mono ac H3K56ac 
Methylation 
Lysine K Mono me1 H3K4me1 
Lysine K Di me2 H3K4me2 
Lysine K Tri me3 H3K4me3 
Arginine R Mono me1 H3R2me1 
Arginine R Di-symmetric me2s H3R2me2s 
Arginine R Di-asymmetric me2a H3R2me2a 
Phosphorylation 
Serine or 
Threonine or 
Tyrosine 
S/T/Y Mono ph H3S10ph 
Ubiquitylation Lysine K Mono ub1 H2AK119ub1 
Sumoylation Lysine K Mono su H2BK6su 
ADP ribosylation Glutamate E Mono ar1 H2BE2ar1 Glutamate E Poly arn H2BE2arn 
Table 1.1: Histone modifications are written beginning with the name of the histone (e.g. H3 for histone 3), followed by the single letter amino 
acid abbreviation and its position within the protein (e.g. K56 for lysine 56), and the abbreviated modification (e.g. ac for acetylation). Adapted 
from Xhemalce et al., 2006, review.  
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Histone methylation  
Histone methylation has been shown to occur on arginine, lysine and histidine 
residues.  Lysine methylation has been well studied and this residue can undergo 
mono- (me1), di- (me2) or tri- (me3) methylation (Rosenfeld et al., 2009).  Whilst 
methylation of histone 3 lysine 4 (H3K4), H3K36 and H3K79 are associated with 
transcriptional activation, methylation of H3K9 and H3K27 are associated with 
transcriptional repression (Rosenfeld et al., 2009).  The presence of H3K9me3 in 
particular has been identified as a hallmark of heterochromatin and thus gene 
silencing (Peters et al., 2003).  Lysine residues are able to be methylated by SET-
domain containing and DOT1L-like (DOT1-like histone H3K79 methyltransferase) 
proteins, whilst they can be demethylated by amine oxidases and jumonji C domain 
containing proteins (Feng et al., 2002; Rea et al., 2000; Shi et al., 2004; Tsukada et 
al., 2006).  Although, in most cases, it is not yet known whether the addition or 
removal of chromatin marks are the cause or consequence of changes to chromatin 
structure.  
 
Although histone methylation is carried out by different proteins to those 
participating in DNA methylation, the presence of one modification may influence 
the other (Tjeertes et al., 2009). For example, studies have shown the histone 
methyltransferase G9a catalyses methylation of H3K9, recruits DNMT3A and 
DNMT3B, enabling de novo DNA methylation and resulting in gene inactivation 
(Feldman et al., 2006). Separate studies have also shown DNA methylation directs 
the methylation of H3K9 and prevents H3K4 methylation, leading to a closed 
chromatin state  (Eden et al., 1998; Hashimshony et al., 2003).  Other research has 
shown that knockdown of specific SET (suppressor of variegation, enhancer of zeste 
 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 33 
and trithorax) domain histone methyltransferases in plants and fungi results in a loss 
of DNA methylation at specific regions (Jackson et al., 2002; Tamaru & Selker, 
2001).  
 
Histone acetylation  
Acetylation of lysine residues is regulated by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs).  The presence of acetylation is 
commonly associated with active transcription, whilst the absence of this 
modification is associated with transcriptional repression (Kouzarides, 2007).  HAT 
enzymes are able to modify multiple lysine residues, utilising acetyl CoA to transfer 
an acetyl group to the lysine.  This neutralises the positive charge, weakening the 
interaction between the histone and DNA, enabling transcription, as reviewed in 
(Yang & Seto, 2007).  Whilst most histone modifications occur on the histone tails, 
acetylation has also been observed at a lysine residue within the histone core.  The 
lysine H3K56 points towards the DNA major groove within the nucleosome and 
acetylation is believed to alter histone/DNA interactions similar to acetylation of N-
tail lysines (Tjeertes et al., 2009).   
 
There are four classes of HDACs based upon their structure, sequence and 
domain organisation.  Class I comprises HDACs 1, 2, 3 and 8.  These proteins are 
ubiquitously expressed and predominantly localised to the nucleus (Taunton et al., 
1996).  Class II includes HDACs 4, 5, 6, 7, 9 and 10.  These HDACs have restricted 
expression patterns and have the ability to move between the cytoplasm and the 
nucleus (McKinsey et al., 2000; Vega et al., 2004).  Class III HDACs, also known as 
sirtuins, rely upon NAD+ (nicotinamide adenine dinucleotide) for their activity.  
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Sirtuins are ubiquitously expressed and can deacetylate histone and non histone 
substrates (Frye, 1999).  Class IV, containing only HDAC11 is expressed in the 
brain, heart, muscle, kidney and testis, but little is currently known about its function 
(Gao et al., 2002; Liu et al., 2008).   
 
Histone phosphorylation  
While a large number of studies have analysed histone acetylation there is still 
much to be learned about histone phosphorylation.  Histone phosphorylation can 
occur on serines, threonines and tyrosines, primarily located on histone tails, and is 
commonly found alongside other histone modifications (Fischle et al., 2005; 
Xhemalce et al., 2006).  For example, the presence of H3S10ph next to H3K9me3 
disrupts HP1α/chromatin binding during M phase of the cell cycle (Fischle et al., 
2005).   Histone phosphorylation is believed to have similar effects on transcription 
as histone acetylation, one example being the presence of phosphorylation on 
H3T118 reducing DNA/histone binding, and increasing DNA accessibility to 
transcriptional machinery (North et al., 2011).  
 
1.1.3  Histone variants 
There are variants for each of the core histones as well as the linker histone H1, 
which binds to the nucleosome at the DNA entry-exit point (Vignali & Workman, 
1998).  Replacement of the histone proteins with histone variants has been shown to 
alter nucleosome stability, chromatin formation and also to play roles in DNA repair 
(Chakravarthy & Luger, 2006; Yoda et al., 2000).  Histones H2A and H3 have 
diversified the most in eukaryotic evolution and will be discussed here (Malik & 
Henikoff, 2003; Thatcher & Gorovsky, 1994).  
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There are five histone H2A variants in humans; these include H2A.Z, H2A.X, 
macroH2A.1, macroH2A.2 and H2A.Bbd.  H2A.Z is conserved throughout evolution 
and has multiple functions, it is associated with active transcription and sites 
undergoing histone exchange, and localises to transcriptional start sites (TSS) (Barski 
et al., 2007; Hatch & Bonner, 1988; Jin et al., 2009; Zlatanova & Thakar, 2008).  
H2A.Z containing nucleosomes are also less stable than nucleosomes containing 
canonical H2A due to structural differences altering the H3/H4 docking domain 
(Suto et al., 2000).  H2A.X has been found to play an important role in genome 
stability.  Following DNA damage, H2A.X is phosphorylated by DNA dependent 
protein kinases.  This phosphorylation is required to recruit DNA damage repair 
machinery (Paull et al., 2000; Rogakou et al., 1999).  Unlike H2A.Z the presence of 
macroH2A variants give rise to more stable nucleosomes and are associated with 
transcriptional repression (Chakravarthy & Luger, 2006; Changolkar & Pehrson, 
2002; Muthurajan et al., 2011).  H2A.Bbd has only been found in mammals to date, 
and displays similar properties to H2A.Z.  This variant localises to TSS, is associated 
with transcriptional activation, and inclusion of H2A.Bbd into the nucleosome 
creates a less stable nucleosome due to disruption of the H3/H4 docking domain 
(Gautier et al., 2004; Soboleva et al., 2012; Tolstorukov et al., 2012).  
 
The histone H3 variants - H3.1, H3.3 and CENP-A (centromere protein A) 
each have differing characteristics.  H3.1 is commonly associated with repressive 
histone marks, whilst H3.3 is associated with active transcription (Hake & Allis, 
2006; Mito et al., 2005).  H3.3 has also been found to replace H3.1 at active genes 
and co-localise with H2A.Z at the promoters of active genes (Jin et al., 2009).  In 
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comparison to these two variants CENP-A replaces the canonical H3 at the 
centromere and is required for maintenance of the centromere (Yoda et al., 2000).  
 
1.1.4 Chromatin remodelling complexes 
Chromatin remodelling complexes utilise ATP hydrolysis to restructure 
nucleosomes via sliding, ejection or repositioning (Dai et al., 2009; Kitagawa et al., 
2011; Stopka & Skoultchi, 2003).  The four families of chromatin remodelling 
complexes are SWI/SNF (switching defective/sucrose nonfermenting), ISWI 
(imitation switch), CHD (chromodomain, helicase, DNA binding), and INO80 
(inositol requiring 80).  
 
SWI/SNF complexes are large, containing 8-14 subunits and a catalytic 
subunit, SMARCA4 or SMARCA2 (SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin subfamily A, members 4 and 2) (Mohrmann & 
Verrijzer, 2005). ISWI complexes are smaller, consisting of 2-4 subunits with either 
SMARCA5 or SMARCA1 (SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin subfamily A, members 1 and 5) as the catalytic subunit 
(Strohner et al., 2001).  CHD complexes contain 1-10 subunits and have two 
tandemly arranged chromodomains on the N-terminus of the catalytic subunit, as 
reviewed in (Clapier & Cairns, 2009).  In humans the CHD1 complex consists of just 
the catalytic subunit CHD1, whilst the NuRD complex is made up of many subunits 
(Delmas et al., 1993; Xue et al., 1998).  INO80 complexes are also large and consist 
of over 10 subunits.  They contain an ATPase domain that is split by a long insertion 
located in the middle of the domain and a helicase SANT (switching-defective 
protein 3, adaptor 2, nuclear receptor co-repressor, transcription factor IIIB) 
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associated domain, both of which are important for the recruitment of accessory 
subunits and complexes to INO80 (Clapier & Cairns, 2009).  Chromatin remodelling 
complexes may be involved in a number of processes including gene regulation, 
DNA replication and chromatin assembly, and it is the combination of accessory and 
catalytic subunits that define the processes in which a complex may be involved 
(Park et al., 2006).  
 
1.1.5  RNA mediated silencing 
RNA interference (RNAi) refers to the degradation of messenger RNA 
(mRNA) product by double stranded RNA (dsSRNA) homologous in sequence to the 
RNA product (Fire et al., 1998). It can also broadly refer to the ability of small RNAs 
to modify chromatin and alter gene expression (Moazed, 2009).  Long dsRNAs are 
processed into 22 nucleotide short interfering RNAs (siRNAs) by the RNase III 
ribonuclease, Dicer.  The siRNA then binds Argonaut proteins within the RNA 
induced silencing complex (RISC), directing them to a complementary RNA and 
targeting them for degradation or transcriptional silencing (Elbashir et al., 2001; 
Meister et al., 2004; Moazed, 2009).  Micro RNAs (miRNAs) are similar to siRNAs 
in that they act through the same RNA interference pathway. However, miRNAs 
arise from RNA transcripts that are folded back on themselves to form short hairpin 
loops (Bevilacqua & Blose, 2008).   
 
A third class of small RNAs is PIWI (P-element induced wimpy testis) 
interacting RNAs (piRNAs).  They are 26-30 nucleotides long, but unlike other small 
RNAs, have not been found to have a dsRNA precursor or require Dicer (Das et al., 
2008; Houwing et al., 2007).  In mice piRNAs have been shown to target transposons 
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in the male germline for de novo methylation resulting in their silencing (Kuramochi-
Miyagawa et al., 2008).  However, the exact mechanism by which this occurs in 
mammals is still to be deciphered.  
 
Long non-coding RNAs (lncRNAs) are greater than 200 nucleotides long but 
do not encode proteins and have been found to play key roles in many processes such 
as chromatin remodelling, post transcriptional processing, and transcription, as 
reviewed in (Mercer et al., 2009).  The lncRNA HOTAIR, Hox transcript antisense 
RNA, has the ability to direct Polycomb chromatin remodelling complexes to the 
HOXD locus, resulting in transcriptional silencing (Rinn et al., 2007). Whilst the 
lncRNAs NRON inhibits the transportation of NFAT to the nucleus via the binding 
of specific nucleocytoplasmic machinery (Willingham et al., 2005). While the 
functions of lncRNAs are many and diverse, few have been characterised to date, 
indeed future research may uncover more roles for lncRNAs.  
 
1.1.6  Correlation between epigenetic marks 
Recently it has been found epigenetic modifications do not act independently, 
rather they are able to work together and/ or cross regulate each other.  Many studies 
have focused on the unique relationship between DNA methylation and histone 
methylation.  The histone methyltransferase Ehmt2 (euchromatic histone lysine N-
methyltransferase 2) has been found to be responsible for catalysing mono- and 
dimethylation of H3K9 in embryonic stem cells (ESC), and loss of Ehmt2 results in 
the loss of DNA methylation at CpG rich loci (Ikegami et al., 2007; Tachibana et al., 
2008). In contrast, loss of the three DNA methyltransferases 
(DNMT1/DNMT3a/Dnmt3b) in ES cells has no impact upon H3K9 methylation with 
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cells retaining the ability to maintain an undifferentiated state (Tsumura et al., 2006). 
Whilst the mechanism through which many independent epigenetic modifiers has 
been studied in detail, there is still much to be learnt as to how the presence of 
different epigenetic marks influence one another.  
 
1.2 EPIGENETIC PHENOMENA     
  
The study of epigenetic regulation of gene expression has been investigated 
utilising different model systems including Drosophila, C. elegans and mammalian 
models. This review will focus on dosage compensation, parental imprinting and 
transgene silencing in mammals.  
 
1.2.1  Dosage compensation 
Female mammals have two X-chromosomes, whilst males have one X and one 
Y Chromosome.  Early in embryogenesis, one of the female X-chromosomes 
becomes silenced leaving the other active (Lyon, 1961).  Transcriptional output on 
this active X-chromosome is then increased to be equal to expression of autosomal 
genes, (Lin et al., 2007; Nguyen & Disteche, 2006).  Interestingly, mammalian X-
linked gene transcripts have been shown to be less susceptible to decay compared to 
autosomal gene transcripts and this may contribute to their greater abundance (Yin et 
al., 2009).  Only cells that contain two or more X-chromosomes are able to undergo 
this process of X inactivation.  The Xic locus (X-chromosome inactivation centre) 
located on the X-chromosome and which produces the non-coding RNA Xist, has 
been shown to play a role in ensuring only one X remains active (Kay et al., 1993; 
Penny et al., 1996).  Xist RNA is expressed from the allele on the inactive X and 
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mediates gene repression in a chromosome wide manner (Brockdorff et al., 1992; 
Brown et al., 1992). Recent studies have identified further factors that are required 
for chromosomal repression by Xist. One example is Spen (Spen family 
transcriptional repressor), which is recruited by Xist and subsequently recruits Hdac3 
followed by Polycomb repressive complex 1 accompanied by H3K27me (Chu et al., 
2015; McHugh et al., 2015; Monfort et al., 2015). This is then followed by 
recruitment of Polycomb repressor complex 1 and Dnmt1 leading to the repression of 
the X chromosome (Cao et al., 2002).  
 
1.2.2  Genomic imprinting 
Whilst the majority of genes in the human genome are expressed equally when 
inherited from either parent, a small minority (~100 in mammals) are not, as 
reviewed in (Bartolomei & Ferguson-Smith, 2011).  These genes undergo genomic 
imprinting, whereby expression is restricted to one of the two parental alleles in 
diploid cells (reviewed in Bartolomei et al., 2011).  Studies investigating nuclear 
transplantation were the first to suggest genomic imprinting. These studies found 
embryos reconstructed from either two maternal or two paternal pronuclei failed to 
survive, when compared to embryos reconstructed from one maternal and one 
paternal pronuclei (McGrath & Solter, 1984; Surani et al., 1986).  Interestingly, the 
small number of paternal imprinted genes identified are implicated in growth 
promotion, whilst maternal imprinted genes have functions in growth retardation.  
One example of this is the paternally expressed insulin like growth factor 2 gene, 
Igf2, and its maternally expressed receptor Igf2r (Barlow et al., 1991; Latham et al., 
1994).  Studies investigating knockout mice for both of these genes found mice null 
for paternally expressed Igf2 were growth retarded, whilst those null for maternally 
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expressed Igf2r exhibited overgrowth (Lau et al., 1994).  Many imprinted genes are 
found in clusters and are under the control of cis-acting loci called imprinting control 
regions which are differentially methylated in the germline (Kurukuti et al., 2006; 
Shin et al., 2008).  This difference in methylation may be acquired either during 
gametogenesis or following fertilisation (Lewis & Reik, 2006). 
 
1.2.3  Silencing of foreign DNA, including transgenes 
 
Studies investigating the insertion of transgenes and foreign DNA into host 
genomes have found them to often be silenced via epigenetic mechanisms (Garrick et 
al., 1996; Martin & Whitelaw, 1996).  Alterations in methylation at both the site of 
integration as well as at sites further away have been identified. Indeed the insertion 
of foreign DNA into the hamster genome has been shown to lead to marked 
alterations in certain cellular DNA segments, which is thought to be due to changes 
in chromatin structure (Remus et al., 1999). Transgenes have also been shown to be 
expressed in a variegated manner, whereby they are expressed in some, but not all, 
cells and this is thought to be influenced by their insertion site (Martin et al., 1996).  
Furthermore, studies in mice have shown differences in transgene copy number alter 
transgene expression (Garrick et al., 1998). Mice containing ~200 copies of a murine 
transgene showed a marked increase in silencing versus those carrying ~5-8 copies 
of the same transgene (Kearns et al., 2001).  
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1.3 EPIGENETIC REPROGRAMMING    
  
Once the epigenetic state of an organism has been established, it is relatively 
stable and is maintained throughout the organisms’ life (Morgan & Whitelaw, 2008).  
Epigenetic state is rarely passed on to the next generation, instead epigenetic 
reprogramming serves to erase epigenetic marks that have accumulated in the parent, 
so that the next generation has a ‘clean slate’ with which to initiate development 
(Dean et al., 2003; Hajkova et al., 2002).  Genome-wide demethylation occurs 
immediately following fertilization of the zygote and also during establishment of the 
primordial germ cells, Figure 1.2 (Gregoretti et al., 2004).  In the zygote the genome 
contributed by each parent undergoes independent epigenetic remodelling.  The 
paternal genome is actively demethylated before the first cell division is completed, 
and there has been recent evidence of paternal 5mC being actively converted to 
5hmC and removed over subsequent cleavages (Inoue et al., 2011; Inoue & Zhang, 
2011; Oswald et al., 2000), whilst the maternal genome is passively demethylated 
over successive cleavage divisions due to the exclusion of DNMT1 from the nucleus 
(Howlett & Reik, 1991).  Daughter cells of the zygote therefore inherit a lowly 
methylated reprogrammed genome (Gregoretti et al., 2004).  However, research has 
begun to look for evidence that this “clearing” of marks may not always be complete 
resulting in transgenerational epigenetic inheritance (Morgan & Whitelaw, 2008).  
This incomplete clearing is thought to provide a chance to adapt to environmental 
changes faster than genetic inheritance (Cerone et al., 1997). 
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Figure 1.2: DNA methylation reprogramming in mammalian embryos.  
Following fertilisation DNA methylation marks are erased in two waves. Firstly, the paternal genome (blue) undergoes rapid demethylation, 
followed by passive loss of methyl marks in the maternal genome (red). Re-establishment of DNA methylation is observed after the morula 
stage.  The second wave occurs in primordial germ cells (PGCs) in which paternal and maternal marks are erased, followed by the re-
establishment of imprinted genes in PGCs.  Adapted from Cell, Vol 157, Issue 1, (Heard & Martienssen, 2014), Transgenerational Epigenetic 
Inheritance: Myths and Mechanisms, Pages No. 95-109, Copyright (2014), with permission from Elsevier; review. (Appendix XII). 
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1.4 TRANSGENERATIONAL INHERITANCE   
 
Transgenerational epigenetic effect refers to the transfer of non-genetic 
physical and behavioural information across generations.  Transgenic epigenetic 
inheritance, however, refers to the transfer of chromosomal modifications to the next 
generation via the gametes, as reviewed in (Youngson & Whitelaw, 2008).  To date 
there have been numerous studies investigating transgenerational epigenetic 
inheritance in plants, with many studies focusing on how changes to the environment 
can induce changes in the epigenome that are consequently inherited and expressed 
by progeny not exposed to the parental stressor (Norouzitallab et al., 2014; Zheng et 
al., 2013).  Studies in C. elegans have also found epigenetic marks can be transmitted 
from on generation to the next. For example, loss of the histone demethylase lsd1 
leads to an accumulation of histone methylation in the subsequent generation (Katz 
et al., 2009). Although there is some evidence for transgenerational epigenetic 
inheritance in mammals, the field remains highly controversial.  In humans the study 
of transgenerational epigenetics is complex due to the inability to exclude genetic or 
societal reasons for the transmission of a phenotype across generations (Morgan & 
Whitelaw, 2008).  This makes the utilisation of inbred genetically identical mouse 
colonies suitable models for studying transgenerational epigenetic inheritance.  
 
1.4.1  Avy metastable epiallele 
Metastable epialleles, loci at which activity is dependent on the epigenetic 
state, provide molecular evidence for transgenerational epigenetic inheritance in the 
mouse (Youngson & Whitelaw, 2008).  One such example is the agouti viable yellow 
(Avy) allele, which can undergo stochastic gene silencing associated with variegation 
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similar to transgenes (Bultman et al., 1992; Rakyan et al., 2002).  The agouti alleles 
are responsible for the production of black and yellow pigment in the hair follicles 
(Wolff et al., 1998). The Avy metastable epiallele is the result of insertion of an 
intracisternal A particle (IAP) upstream of the agouti gene transcription start site, 
Figure 1.3A (Morgan et al., 1999).  Mouse coat colour correlates with methylation 
state of a cryptic promoter in the 3’ long terminal repeat (LTR) of the 
retrotransposon (Morgan et al., 1999).  Isogenic mice carrying the Avy allele can be 
yellow, mottled or pseudoagouti (dark brown), Figure 1.3B (Bultman et al., 1992).  
Hypomethylation of the cryptic promoter is associated with a yellow coat colour and 
hypermethylation is associated with silencing and a pseudoagouti coat. The presence 
of mottled mice illustrates that the allele is expressed in a variegated manner 
(Morgan et al., 1999).   
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Figure 1.3: Schematic diagram of Avy allele and mice carrying the Avy. 
A. Avy allele carries an IAP retrotransposon inserted upstream of agouti gene.           
B. Isogenic C57BL/6 Avy/mice showing phenotypes ranging from completely yellow 
(left), through degrees of yellow/agouti mottling, to completely pseudoagouti (right). 
Adapted by Permission from Macmillan Publishers Ltd: Nature Genetics (Morgan et 
al., 1999), copyright (1999). (Appendix XIII). 
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1.4.2  Evidence for transgenerational inheritance in mice 
Early studies of the Avy locus found a transgenerational effect on coat colour 
when inherited from the dam but not the sire, as pseudoagouti dams produced more 
pseudoagouti offspring than mottled and yellow dams (Wolff et al., 1998). This was 
further supported by Morgan et al., 1999 who identified the cause being due to 
incomplete clearing of the epigenetic state in the female germline rather than being 
environmentally induced.  More recent studies have utilised the Avy allele to 
investigate the effect of methyl supplemented diet on transgenerational inheritance 
with conflicting results.  
 
One study by Cropley et al., 2006, showed in utero exposure of Avy mice to 
folate can shift coat colour of not only those mice, but also their offspring (Cropley 
et al., 2006).  In this study pregnant pseudoagouti dams were fed a supplemented diet 
from E8.5 – E15.5.  At which time the gametes of F1 offspring are being formed that 
will produce F2 offspring. The shift in coat colour of F2 offspring may have been 
influenced by the ‘presence’ of F2 gametes during F0 diet supplementation (Cropley 
et al., 2006). A more recent study by this group using the same supplementation 
method found this had no impact on methylation at the Avy allele in either F1 or F2 
offspring (Cropley et al., 2010). A separate study by Waterland et al., 2007, found no 
cumulative effect when investigating the effect of methyl rich diets across multiple 
generations (Waterland et al., 2007).  This study was designed as a three generation 
cumulative exposure study, in which slightly yellow mottled dams (F0) were fed a 
supplemented diet throughout pregnancy and lactation and F1 and F2 females 
weaned onto the same diet as their mothers. The supplemented diet group consisted 
of more heavily mottled mice than the control group in each of the generations, 
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however no cumulative increase in the number of heavily mottled mice was 
observed. Waterland et al., 2007, results suggest diet induced changes are actively 
erased between each of the generations versus those of Cropley et al., 2006, which 
suggest environmental influences may allow for maintenance of epigenetic state in 
the germ line rather than the accumulation of new epigenetic marks (Waterland et al., 
2007).  Whether environmentally induced epigenetic changes can lead to 
transgenerational epigenetic inheritance is still poorly understood.    
 
Whilst the majority of studies to date have investigated the retention or loss of 
epigenetic marks across generations, studies investigating the disruption of 
epigenetic reprogramming in the future may be more beneficial.  
 
1.4.3  Evidence for transgenerational inheritance in humans 
There are few studies investigating transgenerational epigenetic inheritance in 
humans. One study investigated the availability of food supply to grandparents with 
the mortality risk ratio of their grandchildren.  This study of the Överkalix, northern 
Sweden cohort, found the grandfathers food supply was linked only to the mortality 
risk of grandsons, whilst the grandmothers was linked only with the risk ratio of 
granddaughters (Pembrey et al., 2005).  However, a pitfall of this study, and most 
human studies investigating this phenomenon, is that transgenerational epigenetic 
inheritance is not the only possible explanation.  It is complex to rule out genetic or 
societal reasons for observing the transmission of a particular phenotype across 
multiple generations in humans (Morgan & Whitelaw, 2008). In this context inbred 
mouse colonies offer a chance to study transgenerational epigenetic inheritance in a 
setting where each mouse is genetically identical. 
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1.5 DISEASES RESULTING FROM ABERRANT EPIGENETIC STATE 
The mutation or inactivation of a number of epigenetic modifiers have been 
implicated in the development and/or progression of a wide variety of diseases in 
humans. The introduction of next generation sequencing has enabled the 
identification of causative mutations within epigenetic modifiers to be associated 
with diseases they had not previously been associated with.  
 
1.5.1  Diseases related to aberrant control of imprinted regions 
A number of disorders arise due to disruptions in imprinted genes/regions.  
Two well characterised but distinct disorders are Angelman syndrome (AS) and 
Prader-Willi syndrome (PWS), both of which arise from a deletion within an 
imprinted control region on chromosome 15 (Kishino et al., 1997; Ledbetter et al., 
1981).  Loss of the maternally expressed UBE3A, ubiquitin protein ligase E3A, a 
gene required for brain development results in AS (Kishino et al., 1997).  Deletion of 
the maternal chromosome 15q11-13 region has been linked to a more severe 
phenotype than point mutations within this gene (Gentile et al., 2010).  A number of 
paternally expressed genes within this same region have been linked with PWS.  
Unlike AS, where deficiency in a single gene has been linked to phenotype severity, 
it is thought deficiency in a number of genes in PWS results in a more severe 
phenotype (Angulo et al., 2015; Kanber et al., 2008).  Interestingly, both PWS and 
AS can arise due to uniparental disomy, whereby the child may inherit two copies of 
the maternal allele (PWS) or paternal allele (AS) resulting in no active allele being 
present and manifestation of these disorders (Malcolm et al., 1991).  
 
 50 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 
1.5.2  Disorders related to DNA methylation defects 
Mutations in DNMT3B have been associated with Immunodeficiency, 
Centromeric region instability and Facial anomalies syndrome (Okano et al., 1999; 
Xu et al., 1999). Mutations in the C-terminal portion of both alleles of DNMT3B are 
commonly identified in patients with ICF (Hansen et al., 1999; Wijmenga et al., 
2000). It has been predicted complete loss of DNMT3B is likely to be embryonic 
lethal, as observed in the mouse, and as such it is thought the mutations observed in 
DNMT3B cause a reduction in activity, rather than a loss of function (Jin et al., 
2008; Okano et al., 1999). Another feature of ICF syndrome is hypomethylation of 
DNA satellites that are normally highly methylated, in lymphocytes this is combined 
with chromosomal instability suggesting DNMT3B function is of particular 
importance in this cell type (Kondo et al., 2000; Xu et al., 1999).   
 
1.5.3  Disorders related to histone modifying enzymes 
Loss of function of a number of histone modifying enzymes results in different 
disorders in humans.  One example is Kabuki syndrome, in which patients display 
intellectual disability, distinct facial features and developmental delay (Niikawa et 
al., 1981).  The majority of patients present with mutations in the histone 
methyltransferase KMT2D, lysine (K)-specific methyltransferase 2D, while a small 
number present with mutations in KDM6A, lysine (K)-specific demethylase 6A 
(Hannibal et al., 2011; Lederer et al., 2012; Ng et al., 2010).  Another group of 
patients displaying classical Kabuki phenotype were found to have no mutations in 
either of these genes.  As both KDM6A and KMT2D are associated with the same 
large protein complex, mutations in other proteins within this complex may be 
suitable candidate genes (Van Laarhoven et al., 2015).  Interestingly, KDM6A 
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functions in removing the silencing histone mark H3K27me3, while KMT2D 
functions in removing the activating histone mark H3K4me3 suggesting the 
maintenance of histone methylation is critical for normal development. (Hübner et 
al., 2013).  
 
1.5.4  Disorders related to chromatin remodelers   
Chromatin remodelers have been shown to be critical for normal development 
and mutations in different complex subunits can lead to disease.  One disorder is 
Coffin-Siris syndrome characterised by mental retardation, developmental delay and 
phalange defects (Santen et al., 2012; Tsurusaki et al., 2012).  The majority of 
Coffin-Siris patients carry one or more mutations in both catalytic and non-catalytic 
subunits of the SWI/SNF complex (Santen et al., 2012; Tsurusaki et al., 2012).  
Regardless of the different mutations identified patients with Coffin Siris syndrome 
present with similar phenotypes, suggesting alterations to any of the SWI/SNF 
subunits can result in aberrant gene regulation (Tsurusaki et al., 2012). This is further 
supported by studies investigating Nicolaides–Baraitser syndrome, which is caused 
by mutations within the subunit SMARCA2 that are not found in patients with 
Coffin-Siris syndrome (Sousa et al., 2009).  
 
1.6 A SCREEN FOR EPIGENETIC MODIFIERS IN THE MOUSE 
 
Screens investigating genes that affect variegated expression have been undertaken 
in Drosophilia and the mouse (Schotta et al., 2003). Past screens in the mouse were 
utilised to identify genes implicated in parental imprinting and X-inactivation 
(Percec et al., 2002; Tsai et al., 2002). The Whitelaw laboratory was the first to 
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design a screen for identifying genes involved in establishing and maintaining 
epigenetic state in the mouse (Blewitt et al., 2005).  
 
1.6.1 Modifiers of murine metastable epialleles 
An N-ethyl-N-nitroso urea (ENU) random mutagenesis screen was established 
by Professor Whitelaw and colleagues to identify novel epigenetic modifiers in the 
mouse (Blewitt et al., 2005).  The mice used in this study carry a multi-copy green 
fluorescent protein (GFP) transgene array linked to an erythroid specific α-globin 
promoter and a HS40 enhancer (Preis et al., 2003).  Multi-copy transgenes have been 
shown to undergo silencing due to the formation of repressive chromatin 
environments via epigenetic mechanisms that are locus specific (Garrick et al., 
1998).  This results in variegated expression of GFP in the red blood cells, i.e. only 
55% of red blood cells express GFP, as it is silenced in 45% of cells, Figure 1.4.  
Alleles that variegate in this way are known as metastable epialleles (Rakyan et al., 
2002).  A male mouse was injected with the chemical mutagen ENU and mated to 
females carrying the transgene (Blewitt et al., 2005).  Mutation of an epigenetic 
modifier is expected to lead to a shift in the percentage of red blood cells expressing 
GFP, and offspring in which the percentage of GFP expression has been significantly 
altered are identified and named a MommeD (Modifier of murine metastable epiallele 
Dominant) (Blewitt et al., 2005).  
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Figure 1.4: Variegated expression of GFP in erythrocytes. 
GFP is expressed in 55% of erythrocytes in wild-type mice, while it is silenced in the 
remaining 45%. Adapted from Daxinger et al., 2013. 
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Over 60 mutant mouse lines were identified from the Momme screen. 
Causative genes included known epigenetic modifiers such as Dnmt1, validating the 
screen (Ashe et al., 2008; Chong et al., 2007; Daxinger et al., 2013).  Novel 
epigenetic modifiers have also been identified, for example structural maintenance of 
chromosomes hinge domain containing 1 (Smchd1), encodes a formerly 
uncharacterised protein that was found to play a critical role in X inactivation 
(Blewitt et al., 2008). Rlf is a second novel epigenetic modifier identified from the 
Momme screen (Daxinger et al., 2013). 
 
1.6.2  The first mouse mutants of Rearranged L-Myc Fusion 
 
Three mouse lines from the screen were found to have mutations in Rlf, Figure 
1.5A.  MommeD8 has a mutation changing a cysteine to a phenylalanine in the last 
predicted zinc finger in exon 8 of Rlf (Daxinger et al., 2013).  MommeD28 was found 
to have an adenine → guanine mutation at the 3’ splice site of intron 4,  and a point 
mutation changing a cysteine to a stop codon was detected in MommeD34 (Daxinger 
et al., 2013).  A decrease in GFP expression was observed in all three lines compared 
to wild-type mice, showing Rlf to be an enhancer of variegation (Daxinger et al., 
2013).  Western blotting revealed a ~280 kDa band in protein lysates made from 
E12.5 wild-type embryo heads, Figure 1.5B.  The band was absent in                      
Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 heads, suggesting presence of a null 
allele, and reduced in Rlf MommeD8/MommeD8 heads, suggesting a hypomorphic allele 
(Daxinger et al., 2013).  Currently little is known about how Rlf acts as an epigenetic 
modifier. 
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Figure 1.5: Schematic diagram of Momme mutations in Rlf, and expression of Rlf in Momme mutants. 
A. Location of ENU point mutations in Rlf for the MommeD8, MommeD28 and MommeD34 mouse lines. B. Western blotting of Rlf in embryo 
head lysates from E12.5 Rlf +/+, Rlf MommeD28/MommeD28, Rlf D34/34 (both no protein expression) and Rlf MommeD8/MommeD8 embryos (some protein 
expression), using commercially available polyclonal Rlf antibody (Abcam, Ab115011) and monoclonal Rlf antibody (Abnova, M05, clone2G2) 
(Daxinger et al., 2013). 
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1.6.3 Rlf is a novel epigenetic modifier 
 
Alterations in DNA methylation at the transgene were investigated utilising 
bisulphite sequencing of wild-type and MommeD8, MommeD28 and MommeD34 
homozygous mutant mice.  Bisulphite sequencing allows the methylation status of 
single cytosines to be determined, since addition of bisulphite converts unmethylated 
cytosines to uracil, whilst methylated cytosines remain unchanged (Clark et al., 
1994; Frommer et al., 1992; Hyatsu et al., 1970).  Analysis of the enhancer of the 
GFP transgene revealed an increase in methylation in all three Rlf mutant lines 
compared to wild-type littermates (Daxinger et al., 2013).  
 
Haploinsufficiency for modifiers of epigenetic reprogramming have been shown to 
alter the ratio of coat colours in mice carrying the Avy allele (Blewitt et al., 2005; 
Chong et al., 2007; Gaudet et al., 2004). The effect of haploinsufficiency for Rlf on 
the endogenous Avy allele has also been investigated. MommeD8 heterozygous mice 
were mated to pseudoagouti mice carrying the Avy allele and the offspring scored for 
coat colour.  It was found that offspring that inherited the MommeD8 allele were 
more likely to be pseudoagouti than their wild-type littermates, indicating that 
haploinsufficiency for Rlf increases the probability of silencing at the Avy locus 
(Daxinger et al., 2013).  This result is consistent with the initial observation that Rlf 
acts as an enhancer of variegation.  
 
Taken together the above experiments provide substantial evidence for the 
involvement of Rlf in regulating epigenetic state. However, the mechanism via which 
this occurs is still unclear and no previous studies have investigated the 
consequences of loss of Rlf in the mouse.   
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1.7 REARRANGED L-MYC FUSION   
    
RLF was first identified as part of a gene fusion in human small cell lung 
cancer (SCLC), and more recently has been identified as a putative binding partner 
with other chromatin interacting proteins (Eberl et al., 2013; Makela et al., 1991b; 
Nozawa et al., 2010). These key papers will be summarised here.  
 
1.7.1  Gene fusion in small cell lung cancer 
 
A recurrent RLF-MYCL1 (v-Myc avian myelocytomatosis viral oncogene lung 
carcinoma derived homolog) gene fusion has been detected in multiple studies in 
human SCLC cell lines and primary tumours (Makela et al., 1995; Makela et al., 
1991a; Makela et al., 1992; Rudin et al., 2012).  This fusion protein consists of the 
first 79 amino acids of RLF joined to three MYCL1 noncoding amino acids and the 
second and third exons of MYCL1, although this was found to differ slightly 
between cell lines (Makela et al., 1991b).  Although previous studies have 
investigated the function of the RLF-MYCL1 fusion protein, the function of RLF 
itself has not been investigated. 
 
1.7.2  Interaction of RLF with chromatin 
 
Recently, two independent studies using human cell lines and mouse tissue 
have utilised proteomics to identify proteins that bind to H3K9me3.  Whilst human 
and mouse Rlf were not found to directly interact with this histone mark they do bind 
to HP1α (Heterochromatin protein 1α), a protein that localizes to heterochromatin 
and is thought to be critical for initiating and maintaining heterochromatin 
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conformation (Cheung & Lau, 2005; Nozawa et al., 2010).  HP1α contains a 
chromodomain (CD) and a chromoshadow domain (CSD) separated by a hinge 
region (Tahiliani et al., 2009).  The CD recognizes methylated H3K9, while the CSD 
is responsible for dimerisation of HP1α creating a hydrophobic surface that binds to 
HP1α binding proteins containing a PxVxL motif (Eden et al., 1998; Hashimshony et 
al., 2003; Tsukada et al., 2006).   
 
The first study found human RLF bound to a full-length flag tagged HP1α, as 
well as two mutants with deletions in the CSD, and histone binding domains.  A 
mutant carrying a single amino acid substitution in HP1α’s PxVxL binding domain 
was found to not bind RLF (Nozawa et al., 2010).  Preliminary analysis of both 
human and mouse Rlf protein coding sequence reveals a PxVxL (PVVVL) motif 
approximately 30 amino acids from the carboxyl end (L. Bourke, unpublished). This 
motif may interact directly with HP1α, however this has not been tested.  The second 
study linked mouse Rlf with HP1α in histone peptide H3K9me3 pull-downs with 
quantitative mass spectrometry in mouse brain and liver tissue (Eberl et al., 2013).  
While Rlf was identified as a putative interacting protein in both of these proteomics 
studies, no further validation of the Rlf interaction was performed.  
 
1.7.3  HP1ɑ interacting proteins 
 
Analysis of the primary amino acid sequence of Rlf revealed 15 putative 
Cys2His2 zinc fingers domains, and also a putative PxVxL motif (Makela et al., 1995) 
(Bourke, unpublished).  Proteins containing either a Cys2His2 zinc finger domain or 
PxVxL motif have been found to bind to HP1α.  In both studies that identified Rlf as 
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a potential binding partner of HP1α, a large number of zinc finger containing 
proteins were also pulled down.  Some of these may destabilise HP1α binding or 
they may enable the localisation of HP1α by facilitating heterochromatin formation.  
One example of this is ZFP462 (Zinc finger protein 462) where loss of this protein 
disrupted heterochromatin resulting in cell death due to HP1α mislocalisation 
(Tamaru & Selker, 2001).  Another protein whose association with HP1α has been 
studied in depth is POGZ (Pogo transposable element with ZNF domain).  POGZ 
was found to bind to HP1α through a Cys2His2 zinc finger like motif.  This binding 
region competes with HP1α binding partners containing PxVxL sequence and 
destabilises the interaction of HP1α with chromatin (Nozawa et al., 2010).  However 
both of these mechanisms of action suggest HP1α binding partners are associated 
with gene repression, this is in disagreement with the Momme screen where Rlf has 
been linked with gene activation.  
 
Although small amounts of information about the role of Rlf can be gathered 
from these global approaches. More direct studies into the function of Rlf are 
required to gain a better understanding. 
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1.8 AIMS OF THIS THESIS     
Currently little is known about how Rlf acts as an epigenetic modifier. This 
project will utilise the first mouse mutants of Rlf to understand the effects of loss of 
Rlf on phenotype, and to gain a clearer understanding as to the molecular 
consequences of loss of Rlf in the mouse.  
 
The hypothesis of this thesis is: 
Rearranged L-Myc Fusion, Rlf, is a novel epigenetic modifier of critical importance 
in development and disease in the mouse. 
 
The major aims of this thesis are: 
Aim 1:  To analyse the effect of loss of Rlf in E14.5 fetal mouse liver 
Previous work by the Whitelaw laboratory showed loss of Rlf results in an 
increase in methylation at the GFP transgene (Daxinger et al., 2013). The fetal liver 
was chosen for this study as at E14.5 it is the hematopoietic organ of the embryo and 
the Momme screen assesses transgene variegation in red blood cells. This thesis will 
investigate how loss of Rlf affects methylation across the genome, analyse the 
transcriptome to identify genes that are directly and indirectly regulated by Rlf, and 
identify putative Rlf binding sites in the fetal liver. 
 
Aim 2:  To determine the consequence of loss of Rlf on mouse development  
Previous studies by the Whitelaw laboratory have shown mice homozygous 
null for Rlf are not viable at three weeks of age (Daxinger et al., 2013), and 
heterozygous null Rlf offspring show a reduction in weight compared to wild-type 
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mice (Ashe et al., 2008; Daxinger et al., 2013). However no further investigations 
into the loss of Rlf on phenotype have been undertaken. I have chosen to investigate 
the impact of loss of Rlf on embryonic development, and also the impact of reduced 
Rlf expression on ageing.  
 
Aim 3:  To investigate the consequence of reduced Rlf expression in adult mice  
Epigenetic reprogramming resets the epigenetic marks accumulated in the 
parent so that the next generation has a ‘clean slate’ to initiate development from 
(Dean et al., 2003; Hajkova et al., 2002). Incomplete clearing of these epigenetic 
marks is referred to as transgenerational epigenetic inheritance (Morgan & Whitelaw, 
2008). In this thesis I will assess whether reduced Rlf expression alters epigenetic 
reprogramming across multiple generations by assessing effects on litter size, weight, 
and methylation of the GFP transgene and at an endogenous locus.  
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Chapter 2: Materials and Methods 
2.1 MATERIALS  
2.1.1 Chemicals and reagents 
Following is a list of all the major chemicals and reagents, in alphabetical 
order, used while conducting this project, along with the suppliers they were 
purchased from.  
All chemicals are molecular biology grade, unless otherwise stated.  
 
 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, Applichem 
Agar (bacteriological grade), Sigma-Aldrich 
Agarose (for electrophoresis), Sigma-Aldrich 
Albumin from bovine serum lyophilised powder, Sigma-Aldrich 
Ampicillin salt, Progen Industries 
Chloroform:Isoamylalcohol 24:1, Sigma-Aldrich 
Deoxyribosenucleoside triphosphates  
               (dATP, dCTP, dGTP, dTTP), Bioline 
Diethylpyrocarbonate, Sigma-Aldrich 
Dithiothreitol (DTT), Bio-Rad 
Ethanol, Ajax Finechem 
Ethidium Bromide, Sigma-Aldrich 
Ethylenediaminetetra acetic acid disodium dehydrate (EDTA), Sigma-Aldrich 
Glacial Acetic Acid, Ajax Finechem 
Glycerol, ChemSupply 
Glycine, Ajax Finechem 
 64 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 
Glycogen, Life Technologies/Invitrogen 
Isoflurane, Abbott Australasia 
Isopropanol, Ajax Finechem 
Isopropyl β-D-1-thiogalactopyranoside, Applichem 
Methanol, Ajax Finechem 
Osmosol, POCD Healthcare 
Paraformaldehyde, Sigma-Aldrich 
Phenol (pH 7.9), Amresco 
Phenylmethylsulfonyl fluoride, Sigma-Aldrich 
Phosphate buffered saline tablets, Sigma-Aldrich 
Protease Inhibitor Cocktail tablets, Roche 
Sodium chloride, Sigma-Aldrich 
Sodium dodecyl sulphate, Sigma-Aldrich 
Tris-HCl, Sigma-Aldrich 
Tween-20, Sigma-Aldrich 
Urea, Sigma-Aldrich 
β-mercaptoethanol, Sigma-Aldrich 
Dimethylformamide, Ajax Finechem 
 
2.1.2  Enzymes 
All enzymes were used as per their manufacturer’s instructions.  
HpyCH4Vrestriction endonuclease, New England Biolabs Inc.  
Proteinase K from Tritirachium album, Astral Scientific. 
RNase A (from bovine pancreas), Roche Molecular Biochemicals 
 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 65 
2.1.3 Buffers and solutions 
All solutions and buffers, alongside of their formulas and concentrations, are 
listed below. Milli-Q water was used as a diluents for all buffers and solutions.  
 
10 X PBS 1.45 M NaCl, 10 mM Na2HPO4, 3 mM KH2PO4 
10 x Transfer Buffer 10 mM Tris, 100 mM glycine, 10% methanol,            
0.005% SDS 
100mM PMSF Made in 100% isopropanol 
4% PFA solution 20 g PFA, in 1 X PBS,  
pH adjusted with 1 M NaOH to 7.0 
4 X Loading dye 12.5 ml 4 X TrisCl/SDS (pH 6.8),  10 ml gycerol,             
2 g SDS, 1.55 g DTT 
4 X TrisCl/SDS (pH 6.8) 0.5 M TrisCl, 0.4% SDS,  
pH adjusted with 1 M HCl to 6.8 
5 X Running Buffer 25 mM Tris, 0.1% SDS, 200 mM glycine 
50 X TAE 0.2 M Tris-acetate, 5 mM EDTA (pH 8.0), 10% Glacial 
acetic acid 
Blocking Solution 5% Skim milk, 1% BSA, PBS-Tween20 
DNA lysis buffer 50 mM Tris, 10 mM EDTA, 100 mM NaCl, 1% SDS 
IPTG 100 mU (23.8 mg/ml IPTG powder), diluted in H2O 
PBS-Tween 20 PBS, plus 0.1% (v/v) Tween20 
Urea lysis buffer 8 M urea, 1/10 vol glycerol, 1/20 vol 20% SDS,1/200 vol 
1 M DTT, 1/100 vol 1 M Tris (pH 6.8) 
X-gal 20 mg/ml X-gal powder in DMF 
TFB I 30 mM KC2H3O2, 50 mM MnCl2, 100 mM KCl,             
10 mM CaCl2, 15% (v/v) glycerol titrated to pH 5.8 with 
0.2 M acetic acid 
TFB II 10 mM MOPS (pH 7.0) 75 mM CaCl2, 10 mM KCl,       
15% (w/v) glycerol 
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2.1.4  Bacterial strains and microbial media 
The bacterial strain used for all plasmid manipulations was Escherichia coli 
DH5α [supE44 DlacU169 (f80lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 
relA1], Bethesda Research Laboratories (Gaithersburg, MD, USA).  
 
Bacteriological culture media was dissolved in Milli-Q water and sterilised by 
autoclaving.  
 
LB broth  10 g/L Bacto® tryptone peptone digest (Amyl Media Pty. Ltd.), 5 g/L 
Bacto® yeast extract (Amyl Media Pty. Ltd.) 10 g/L NaCl. The 
medium was stored at 4 °C and ampicillin (from a filter sterilised 
stock) was added to a concentration of 100 µg/ml prior to inoculation.  
LB agar LB broth supplemented with 15 g/L bacteriological agar (Amyl Media 
Pty. Ltd.). After the medium had cooled to 55 °C, ampicillin (from a 
filter sterilised stock) was added to a concentration of 100 µg/ml.  
SOB broth  20 g/L Bacto® tryptone peptone digest (Amyl Pty. Ltd.), 5 g/L 
Bacto® yeast extract (Amyl Pty. Ltd.),10 mM NaCl, 10 mM KCl,    
10 mM MgSO4, 10 mMMgCl2. SOB medium was prepared by adding 
tryptone, yeast extract and NaCl to Milli-Q water, adjusting the pH to 
7.0, autoclaving, and adding filter sterilised stocks of MgSO4 and 
MgCl2. 
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2.1.5  Commercial kits 
All commercial kits, and their suppliers, used throughout this project are listed 
below in alphabetical order.  
 
AllPrep DNA/RNA Mini and Micro Kit, Qiagen 
Big Dye Terminator kit v3.1, Applied Biosystems 
Bradfords Reagent, Thermo Fisher Scientific Inc. 
Clarity™ Western ECL blotting substrate, Bio-Rad 
EpiTect Bisulphite Kit, Qiagen 
GeneRuler™ DNA ladder mix, Thermo Fisher Scientific Inc.  
iScript™ Reverse Transcription Supermix for qRTPCR, Bio-Rad 
MangoTaq™ DNA Polymerase, which contains Taq DNA polymerase from 
Thermus aquaticus, Bioline 
NucleoSpin Gel and PCR Clean-up, Macherey-Nagel 
pGEM®-T Easy Vector, Promega 
Platinum® SYBR® Green qPCR SuperMix-UDG, Invitrogen 
Precision Plus Protein™ Kaleidoscope™ Standard, Bio-Rad 
 
2.1.6  Primer sequences 
All primers used in this project, along with PCR conditions, oligo sequences 
and electrophoresis protocols are shown in Appendix I. All primers were purchased 
from Integrated DNA Technologies.  
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2.1.7  Mouse strains and housing conditions 
Ethical approval for the use of transgenic mice in this project was provided by 
the Animal Ethics Committee at QIMR Berghofer Medical Research Institute 
(QIMRB) (P2037 A081207) and QUT Animal Ethics Committee (1200000388). 
The following Mus musculus strains were used: 
1. Line3 transgenic line, produced in FVB/NJ mice by Dr J. Priest in the 
Whitelaw laboratory (Preis et al., 2003).  
2. FVB/NJ mice carrying the Rlf MommeD8 allele from Prof E. Whitelaw of the 
Whitelaw laboratory.   
3. FVB/NJ mice carrying the Rlf MommeD28 allele from Prof E. Whitelaw of the 
Whitelaw laboratory.  
4. FVB/NJ mice carrying the Rlf MommeD34 allele from Prof E. Whitelaw of the 
Whitelaw laboratory.  
5. FVB/NJ mice carrying the Rlf MommeD8 and Rlf MommeD34 alleles from Prof E. 
Whitelaw of the Whitelaw laboratory.  
 
All mice were housed at a temperature between 21 and 23 °C with a light/dark 
cycle of 12 hours. The mice had unlimited access to food and water. Male and female 
mice were placed in separate cages, unless they were being used for breeding 
experiments. Mice were weaned 21 days after birth.  
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2.2 GENERAL METHODS 
2.2.1  Isolation of genomic DNA 
Phenol: Chloroform method 
Genomic DNA was isolated from adult tail, embryonic tail/limb or yolk sac 
tissue. Adult tail biopsies were collected from mice anesthetised with isoflurane 
(Abbott Australasia) using an anesthetising machine until sedated and a 0.2 cm 
section of tail removed. Embryo and yolk sac tissue were obtained by sacrificing 
pregnant dams at specified time-points after the observation of a copulation plug, 
noted as E0.5, and dissecting embryos in PBS. Proteolytic digestion was achieved by 
the addition of 300 µl of DNA lysis buffer containing proteinase K (Astral Scientific) 
at 1 mg/ml and incubating at 55 °C overnight. Organic extractions were sequentially 
performed in equal volumes of phenol (Amresco) and chloroform:isoamyl alcohol 
(Sigma) (total volume of 300 µl each), by vigorous shaking at room temperature 
followed by centrifugation (1,300 rpm, RT) for 5 min each. The organic phase was 
discarded after each extraction. High molecular weight chromosomal DNA was 
precipitated by adding 2 volumes of absolute ethanol (600 µl) to the final aqueous 
phase and mixed by inversion. The sample was centrifuged (1,300 rpm, 5 min RT), 
liquid removed and precipitated DNA washed with 70% ethanol. The ethanol was 
removed and the DNA pellet left to air-dry. DNA was then resuspended in ~100 µl of 
Milli-Q water. Concentration of the DNA extracted was determined 
spectrophotometrically with a NanoDrop 1000 Spectrophotometer (Thermo Fisher 
Scientific), assuming that an A260 nm of 1.0 corresponds to 50 µg/ml of dsDNA 
(Sambrook & Russell, 2001).  
 
 70 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 
2.2.2  Genotyping by Polymerase Chain Reaction (PCR) 
MommeD8, Momme28 and MommeD34 genotyping 
Genotyping for the MommeD8, MommeD28 and MommeD34 alleles was 
performed using PCR followed by restriction enzyme digest (MommeD8) or Sanger 
sequencing (MommeD28, MommeD34).  PCR was carried out in a Bio-Rad S1000 
Thermal Cycler. Each reaction consisted of approximately 20 ng/µl of template 
gDNA, 0.1 U of MangoTaq™ DNA polymerase (Bioline), 200 µM of dNTPs 
(dATP, dCTP, dGTP, dTTP), 1.5 mM of MgCl2, 500 nM each of forward and 
reverse primer for each allele, and 5X MangoTaq™  PCR reaction buffer. Primer 
sequences for each of the Momme alleles are shown in Table 2.1. The PCR reaction 
for all Momme alleles was 2 min of initial denaturation at 94 °C, then 35 cycles of 
denaturation (94 °C, 30 s), annealing (56 °C, 30 s) and extension (72 °C, 1 min), with 
final extension for 5 min at 72 °C. MommeD8 allele primers produced a 500 bp 
product, MommeD28 primers a 400 bp product and MommeD34 primers a 500 bp 
product. These products were resolved on a 1.5% TAE (w/v) agarose gel.  
 
2.2.3 Gel electrophoresis and purification of DNA fragments 
PCR reactions were subject to gel electrophoresis on a 1.5% agarose (Sigma) 
gel in 1X TAE. Agarose gels contained ethidium bromide at 0.5 µg/ml. From each 
sample, 3-5 µl of PCR product was loaded on agarose gels, adjacent to one lane 
containing the DNA ladder GeneRuler™ marker (Thermo Fisher Scientific).  
Electrophoresis was carried out at 1-8 V/cm until the dye front had migrated an 
appropriate distance. Visualisation of agarose gels was performed by ultraviolet 
transillumination and photographed using a Bio-Rad Gel Imaging System. Following 
visualisation of a band at the appropriate size PCR products from MommeD28 and 
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MommeD34 mice were purified using the NucleoSpin Gel and PCR Cleanup Kit 
according to manufacturer’s instructions.  
 
2.2.4  Restriction endonuclease digestion of DNA 
Restriction endonuclease digestion of MommeD8 PCR products was 
undertaken using HpyCH4V (New England Biolabs Inc). PCR product was digested 
with 0.1 U of restriction enzyme and 1X NEB Buffer 4 at 37 °C overnight and 
digested products resolved on a 1.5% TAE (w/v) agarose gel. Rlf +/+ mice produced 
two bands of 300 and 200 bp each, Rlf MommeD8/+ mice three bands of 500, 300 and 
200 bp, and Rlf MommeD8/MommeD8 mice one band at 500 bp.  
 
2.2.5  PCR sequencing 
Recovered PCR products were cleaned using the NucleoSpin Gel and PCR 
Cleanup kit (Macherey-Nagel) according to manufacturer’s instructions and 
resuspended in 20 µl of Elution buffer (from Kit). Concentration of recovered 
product was determined with a NanoDrop 1000 Spectrophotometer. Approximately 
1-2 ng per 100 bp PCR product was used in ABI Big Dye 3.1 sequencing reactions 
with 800 nM of forward or reverse primer, 0.6 µl Dye Terminator and 4.2 µl  5X 
reaction buffer in a final volume of 12 µl. Sequencing reactions underwent thermo 
cycling in a Bio-Rad S1000 Thermo Cycler with the following conditions: 96 °C for 
1 in, followed by 25 cycles of 96 °C for 10 s, 50 °C for 5 s, 60 °C for 3min. 
Sequencing products were then cleaned by adding 72 µl 70% isopropanol followed 
by vortexing and incubating for 15 min at RT. Samples were then centrifuged for    
30 min at maximum speed at 4 °C, supernatant removed and pellet rinsed in 200 – 
300 µl 70% isopropanol and re-spun for 5-10 min. Again all liquid was removed and 
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samples air-dried at room temperature, before precipitated pellet was sent to QIMRB 
Sequencing Facility for capillary sequencing.  
 
2.2.6  Western blotting 
Protein extraction  
Protein was extracted from tissue using urea lysis buffer. Adult tissue was 
homogenised using a handheld homogeniser (IKA) and embryonic tissue by passing 
tissue through a 19-guage needle with syringe until single cell was suspension 
observed. Samples were sonicated (3 x 10 s) using a Branson Sonifier 450A 
(Consonic), centrifuged at 13,000 g for 10 min at 4 °C and the supernatant collected 
for Western blot analysis. Protein concentration was measured using BCA protein 
assay reagent (Thermo Fisher Scientific), using 5 µl of sample and 200 µl of reagent 
as per the manufacturer’s instructions. Protein yield was quantified by comparing to 
a standard curve of 1 – 10 µg/µl BSA.  All samples were read at 595 nm on a 
VersaMax microplate reader (Molecular Devices). 
 
SDS-PAGE 
Protein (25 – 30 µg) was heated to 98 °C for 10 min in urea lysis buffer and 6X 
loading dye. Samples were then loaded onto a 4 – 15% Mini-PROTEAN® TGX™ 
Precast gel (Bio-Rad), and electrophoresed for approximately 120 min at 130 V in 
1X Running buffer. The Precision Plus Protein™ Kaleidoscope™ pre-stained protein 
standards molecular weight marker was used to enable protein size estimation.  
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Western blot protein transfer 
PVDF membrane (Merck Millipore) was activated in 100% methanol for 15 s 
and immersed in Milli-Q water for at least 2 min. The foam pads and filter paper 
were also pre-soaked in 1X Transfer buffer for 5 min. Separated proteins were then 
transferred to a membrane for 1 – 2 hours at 130 V and 4 °C in 1x Transfer buffer.  
 
Membrane blocking and antibody incubations 
The membrane was blocked for 30 min in blocking solution, and incubated 
with primary antibody overnight at 4 °C; antibodies were used at 1:100 – 1:1000 
dilutions. The membrane was washed 3 times in PBS-Tween for 5 min each. 
Followed by an hour incubation at room temperature with secondary horseradish 
peroxidise antibody diluted in blocking solution (1:5000). The membrane was then 
washed 5 times in PBS-Tween, 5 min each. The following primary antibodies were 
used: RLF (Ab115011, Abcam), custom designed Rlf (Ab1, Ab2, Ab3, GenScript) 
and γ-tubulin (SAB4503045, Sigma-Aldrich).  Secondary antibodies used were 
polyclonal goat anti-rabbit immunoglobulins/HRP (Dako) and polyclonal goat anti-
mouse immunoglobulins/HRP (Dako). 
 
 
Chemiluminescent detection  
Clarity™ Western ECL substrate (Bio-Rad) was mixed according to 
manufacturers’ instructions. Excess wash buffer was drained from membrane and 
ECL detection substrate pipetted onto the membrane surface and incubated for 5 min. 
The membrane was then visualised using MF-ChemiBis 3.2 (DKSH) or ImageQuant 
LAS 500 (GE Healthcare). 
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2.2.7  Quantitative reverse transcription Real-time PCR 
RNA extraction  
Total RNA was extracted using either an AllPrep Mini kit (Qiagen) (adult 
tissue, fetal liver) or AllPrep Micro kit (Qiagen) (fetal hearts) according to 
manufacturer’s instructions. Fresh tissue (< 30 mg for AllPrep Mini kit or < 5 mg 
AllPrep Micro kit) was homogenised in RLT Plus buffer supplemented with β-
mercaptoethanol using a needle and syringe.  RNA was eluted in 30 µl of RNase free 
water (Sigma), and the eluate re-run through the column a second time to increase 
final RNA concentration. Samples were stored at -80 °C until required.  
 
cDNA synthesis 
cDNA was synthesised from total RNA using iScript™ Reverse Transcription 
Supermix for qRT-PCR (Bio-Rad), according to manufacturers’ instructions. Total 
RNA concentration was quantified using a NanoDrop 1000 Spectrophotometer and 1 
µg of total RNA was mixed with 4 µl of iScript RT Supermix and RNase free water 
to a total reaction volume of 20 µl. Samples were incubated in a Bio-Rad S1000 
Thermal Cycler for 5 min at 25 °C, 30 min at 42 °C and 5 min at 85 °C. cDNA was 
then stored at -20 °C prior to use.  
 
qRT-PCR 
qRT-PCR was performed with Platinum® SYBR® Green qPCR SuperMix 
UDG (Life Technologies), following manufacturers’ instructions. SYBR Green mix 
(including 3mM MgCl2), 200 nM forward and reverse primers (Appendix I) and 10 
ng cDNA were mixed together. The reaction was run on a Corbett Rotorgene™ 6000 
using the following conditions: 95 °C for 10 min, followed by 40 cycles of      95 °C 
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for 15 s and 60 °C for 30 s, a melt curve of 95 °C for 15 s and 60 °C for 30 s, and a 
ramp of 62 °C, to 95 °C, adding 1 °C per 5 s. Primers were designed to span 
exon/intron boundaries to eliminate the risk of gDNA contamination. All samples 
were run in triplicate alongside no template and β-actin controls for each sample in 
the same reaction. Data from each run were analysed separately, and triplicates of 
less than 0.5 cycle thresholds (Ct) apart were tolerated. Transcript relative levels 
were calculated using the comparative Ct (ΔΔCt) method (Livak & Schmittgen, 
2001): 
1. Calculate the first ΔCt: gene of interest (Ct) minus reference gene (Ct) for 
each sample.  
2. Calculate the ΔΔCt: subtract each ΔCt with the biggest ΔCt (will become 
calibrator from step 1.  
3. Calculate the relative copy number by 2-(ΔΔCt). One value becomes ‘1’ 
(calibrator).  
 
2.3  EMBRYO DISSECTIONS AND HISTOLOGY 
 
Timed matings were performed by pairing male and female mice of the desired 
genotypes overnight, and the detection of a vaginal plug designated as embryonic 
day 0.5 (E0.5). Nine to 18 days after vaginal plug detection (E9.5 – E18.5), pregnant 
dams were anesthetised and sacrificed by cervical dislocation. Uterine horns were 
removed and washed in PBS. Embryos were removed from the uterus and 
photographs taken with the Leica DFC320 camera, followed by decapitation (as per 
ethical guidelines).  
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2.3.1 Embryo fixation for histology purposes 
Embryos and placentas to be used for haematoxylin and eosin staining (H&E) 
and periodic acid-Schiff staining (PAS) were fixed in 4% paraformaldehyde (PFA) 
overnight at 4 °C, and then washed twice in PBS and stored in 70% ethanol at RT.  
Genotyping of yolk sacs was undertaken by myself and whole embryos and bisected 
placentas were sent to either QIMRB histopathology services, or Dr G. Del Monte 
Nieto, Victor Chang Cardiac Research Institute, for embedding, sectioning and 
staining.  
 
2.3.2   Cardiac morphology quantification  
ImageJ quantification 
Histology slides were scanned to create digital images using an Aperio AT 
Turbo slide scanner (Leica) at 40X magnification. Left and right ventricle field 
images were acquired in ImageScope (v12.1.0.5029) and saved as individual files. 
These files were then imported into ImageJ (v1.50c4) bundled with Java v1.8.0_60 
for quantification. Ventricle wall thickness was measured towards the apex of the 
heart, with a minimum of 5 measurements taken from three serial sections per 
embryo, all hearts were analysed blind to genotype. The mean thickness for each 
placenta was plotted using GraphPad Prism 6.  
 
2.4 BISULPHITE SEQUENCING 
2.4.1  Bisulphite conversion of DNA 
Genomic DNA was purified using the AllPrep Mini kit (Qiagen) (adult tissue, 
fetal liver) or AllPrep Micro kit (Qiagen) (fetal hearts) according to manufacturer’s 
instructions. Fresh tissue (< 30 mg for AllPrep Mini kit or < 5 mg AllPrep Micro kit) 
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was homogenised in RLT Plus buffer supplemented with β-mercaptoethanol using a 
needle and syringe.  DNA was eluted in 20 µl Milli-Q water, and the eluate re-run 
through the column a second time to increase final DNA concentration. Sample 
concentration was measured spectrophotometrically using a NanoDrop 1000 
(Thermo Fisher Scientific), and 1 µg of DNA bisulphite converted using the EpiTect 
Bisulphite conversion kit (Qiagen), as per manufacturer’s instructions. Converted 
DNA was eluted in 20 µl of Milli-Q water, the eluate re-run through the column a 
second time to increase final DNA concentration and stored at – 20 °C.  
 
2.4.2  PCR amplification of bisulphite treated DNA 
PCR was carried out in a Bio-Rad S1000 Thermal Cycler. Each reaction 
consisted of approximately 20 ng/µl of template gDNA, 0.1 U of MangoTaq™ DNA 
polymerase (Bioline), 200 µM of dNTPs (dATP, dCTP, dGTP, dTTP), 1.5 mM of 
MgCl2, 500 nM each of forward and reverse primer for each methylated region, and 
5X MangoTaq™  PCR reaction buffer. The primary PCR reaction for each of the 
methylated regions was 2 min of initial denaturation at 95 °C, then 35 cycles of 
denaturation (95 °C, 30 sec), annealing (various temperatures, refer Appendix I, 30 
sec) and extension (72 °C, 45 sec), with final extension for 5 min at 72 °C. Primary 
PCR was performed for each region, and PCR product purified using the NucleoSpin 
Gel and PCR Cleanup Kit according to manufacturer’s instructions, followed by 
secondary PCR performed using the same conditions as described for primary PCR. 
PCR products were then resolved on a 1.5% TAE (w/v) agarose gel.  
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2.4.3  Ligation of nested PCR product  
All ligations were performed using the pGEM®-T Easy Vector (Promega) 
according to manufacturer’s instructions. Briefly, each ligation reaction contained 
purified PCR product (purified as in Section 2.2.3) and 5 ng of vector at a molar 
ratio of 3:1. Ligation reactions were performed using the T4 DNA ligase supplied 
with the kit and undertaken at 4 °C for 16 hrs in a Bio-Rad S1000 thermal cycler, in 
preparation for transformation and colony screening (below).   
 
2.4.4  Transformation of competent bacterial cells 
All transformation steps were carried out using aseptic techniques. 10 µl of 
ligation reaction was added to 100 µl competent cells and gently mixed, cells were 
then left on ice for 30 min. Cells were then heat shocked at 42 °C for 45 s and 
returned to ice for 2 min.  LB broth (500 µl) was then added to the cells and 
incubated at 37 °C and shaken at 220 rpm for 90 min to allow for recovery and 
expression of the ampicillin resistance gene by the transformants. Cells were then 
centrifuged at 1,000 rpm for 10 min and 500 µl of supernatant removed. The 
remaining 100 µl was resuspended and plated onto LB agar/ampicillin (100 µg/ml) 
plates with IPTG and X-gal solution added just prior to plating out transformed cells 
(discussed below) and incubated at 37 °C overnight.  
2.4.5  Blue/White colony screening 
The pGEM®-T Easy Vector (Promega) contains the coding sequence of the 
lacZ gene which can be used to detect the presence of an insert.  A vector that has re-
ligated with no insert present will express β-galactosidase in the presence of IPTG; 
β-galactosidase converts X-gal into a blue product, turning colonies with no insert 
present blue. The presence of an insert disrupts this expression resulting in white 
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colonies. IPTG (50 µl of 100 mU) and X-gal (20 mg/ml) were plated onto LB 
agar/ampicillin (100 µg) plates. White colonies were then selected to undergo 
sequence analysis.  
 
2.4.6  PCR and sequencing of bacterial colonies  
PCR was carried out in a Bio-Rad S1000 Thermal Cycler. Each reaction 
consisted one white colony, 0.1 U of MangoTaq™ DNA polymerase (Bioline), 200 
µM of dNTPs (dATP, dCTP, dGTP, dTTP), 1.5 mM of MgCl2, 500 nM each of T7 
and Sp6 primer, and 5X MangoTaq™  PCR reaction buffer. Primer sequences are 
shown in Table 2.1. The PCR reaction was 2 min of initial denaturation at 94 °C, 
then 35 cycles of denaturation (94 °C, 30 sec), annealing (55 °C, 30 sec) and 
extension (72 °C, 1 min), with final extension for 5 min at 72 °C. PCR products were 
resolved on a 1.5% TAE (w/v) agarose gel and products of the correct size then 
underwent Sanger sequencing as described in Section 2.2.5.   
 
2.4.7  Bisulphite sequencing analysis 
Analysis of bisulphite sequencing data was undertaken using the BiQ Analyser 
(Max Planck Institute) (Bock et al., 2005). Sequences were excluded that had a 
conversion rate of less than 90% and less than 80% homology to the unconverted 
sequence. For multiple sequences that resembled the same clone, only one sequence 
was included in analysis. Results from BiQ Analyser program were saved as .html 
files and methylated and unmethylated CpGs calculated for each biological replicate.  
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2.4.8  Preparation of competent bacterial cells 
All subcloning was performed using competent E. coli DH5-α cells. Batches of 
competent cells were prepared at one time-point and aliquots stored at – 80 °C prior 
to use. Each of the following steps was undertaken using aseptic techniques and all 
solutions sterilised prior to use. Cultures of 100 ml of SOB broth were inoculated 
with 0.5 ml of an overnight culture of E. Coli DH5-α and incubated at 37 °C with 
vigorous aeration until an optical density at 550 nm of 0.3 had been attained. 
Cultures were rapidly cooled on ice and the remaining steps performed at 4 °C.  
Bacterial cells were pelleted by centrifugation at 2,000 rpm for 10 min and the 
supernatant medium decanted. Cells were then gently washed and resuspended in 10 
ml TFB I solution and left on ice for 15 min. Cells were then centrifuged as above, 
and supernatant decanted and the cells gently resuspended in 4 ml TFB II solution. 
Aliquots of 100 µl of competent cells were stored at – 80 °C.  
 
2.5 FLOW CYTOMETRY ANALYSIS OF TAIL BLOOD 
 
For the collection of blood for flow cytometry, 3 week old mice were 
anesthetised with isoflurane and 0.2 cm tail biopsied for genotyping. A drop of blood 
from the tail was also collected in 1 ml of Osmosol (POCD) and mixed by inversion. 
A Guava® easyCyte™ HT flow cytometer (Millipore) was used to detect and 
quantify levels of cellular fluorescence. Two channels were used: 488 nm to detect 
fluorescence from the transgene, and 550 nm used when required to gauge the 
autofluorescence of cells. The use of two channels allows for a greater accuracy in 
distinguishing GFP-expressing and non-expressing cell populations (Rasko et al., 
1999). Flow cytometry data were analysed using Cell Quest Pro software (Becton 
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Dickinson) using conservative gates set to exclude 99.9% of wild-type 
autofluorescing erythrocytes.  
 
2.6 RNA SEQUENCING ANALYSIS 
 
Total RNA was extracted using the AllPrep Mini and Micro kits (Qiagen) as 
described in Section 2.2.7. RNA purity was checked on a Nanodrop 1000 
spectrophotometer (Thermo Fisher scientific), and quality tested using the Agilent 
Bioanalyser RNA 6000 Nano kit (Agilent Technologies).  
 
2.6.1  Library Preparation and Sequencing 
Library preparation and Illumina sequencing was performed by the Australian 
Genome Research Facility (AGRF). Four Rlf +/+, four Rlf MommeD28/MommeD28 and three 
Rlf MommeD28/+ fetal hearts were sequenced on an Illumina HiSeq 2000 with 50 bp 
single end reads, and sequenced on two lanes. The Illumina CASAVA1.8 pipeline 
was used to generate sequencing data.  
 
2.6.2  RNA-seq read mapping and differential expression testing 
RNA-seq read mapping for E14.5 liver samples was undertaken by Dr H. Oey. 
All RNA-seq mapping for E13.5 heart samples was undertaken by myself using the 
open-web based platform Galaxy (www.galaxy-qld.genome.edu.au) (Blankenberg et 
al., 2001; Giardine et al., 2005; Goecks et al., 2010). All sequenced reads were 
aligned to the mouse genome (NCBIM37/mm9) using Tophat (Trapnell et al., 2009), 
a program that aligns RNA-seq reads to the genome using the short read aligner 
BowTie, v0.6, and analyses the mapped results to identify splice junctions. The 
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following Tophat, v0.9, parameters were used --  maximum intron length between 
donor/acceptor site must be less than 100,000 bp -- coverage search disabled -- read 
alignments with > 2 mismatches discarded -- library type is unstranded 
 
Aligned reads were then used for differential gene expression testing using 
default parameters in each of the following programs: CuffDiff, v2.2.1.2 (Trapnell et 
al., 2012), DESeq, v3.3 (Anders & Huber, 2010) and EdgeR, v2.4.6 (Robinson et al., 
2010). Read counts for mRNA transcripts were extracted from the mapped reads 
using htseq-count (Anders & Huber, 2010) using the parameters --not from a strand 
specific assay --model for counting reads over the supplied gene model set to 
intersection strict 
 
Differential expression analysis in EdgeR and DESeq was assessed using the 
htseq-count matrix as the input matrix and gene annotations from Ensembl 
(www.ensembl.org, release 67). Default parameters for both programs. Differential 
expression analysis in CuffDiff was undertaken utilising the reference transcriptome 
to aggregate read counts per gene, and default parameters used in analysis.   
 
2.6.3 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) integrates gene expression data with 
biological information derived from published literature and public databases to 
predict functional linkages. E14.5 liver differentially expressed genes with an 
adjusted p value >0.05 and minimum fold change of 1.2 were analysed for their 
direct relationship to a network.  
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The network score (p score) is the probability of finding n number of focus 
genes in a set of a random gene set from the Global Molecular Network, and is 
calculated with the right-tailed Fishers exact test. The p score = -log10 (p value).  
 
E13.5 heart genes identified as differentially expressed (> 1.5 fold change, p ≤ 
0.05) were uploaded to IPA and a core biological pathway analysis performed to 
identify molecular networks and upstream regulators. GOplot was used in order to 
better visualise the connections between the genes and the canonical pathways 
highlighted in the Ingenuity pathway and upstream regulator analysis (Walter et al., 
2015). 
 
2.7 WHOLE GENOME BISULPHITE SEQUENCING 
2.7.1 Sample preparation 
Fetal liver was collected from two Rlf +/+ and two RlfMommeD2/MommeD28 E14.5 
embryos derived from the same litter. Tissue was then sent to the Centro National de 
Analisis Genomico (CNAG, Spain) for bisulphite conversion and sequencing.  
 
2.7.2 Library preparation and sequencing 
Genomic DNA samples were spiked with λ DNA and sheared by sonication. 
Libraries were prepared using the TruSeq Sample Prep Kit (Illumina) and underwent 
two rounds of sodium bisulphite conversion using the EpiTect Bisulphite Kit 
(Qiagen). 100 bp paired end sequencing was performed on the Illumina HiSeq 2000. 
Sequencing reads were trimmed for poor quality at their 3’ ends using the program 
trim_seq (www.biopieces.org) with the options -l 3 -m 3.  
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2.7.3 Mapping and methylation calling 
Reads were mapped to mouse genome (NCBI37/mm9) after first converting 
known FVB SNPs to the FVB state using the tool FastaAlternateReferenceMaker 
from the GATK package (McKenna et al., 2010). The SNP positions were obtained 
from Sanger (rsIDdbSNPv137) and coordinates converted from the NCBI38/mm10 
to NCBI37/mm9 using the LiftOver tool from UCSC (Kent et al., 2002). Only 
nucleotide substitutions were to maintain genome length. The lambda genome 
sequence and the sequence for the GFP transgene (Preis et al., 2003) were added to 
the genome sequence as separate chromosomes. Sequencing reads were mapped to 
the new genome using the program Bismark, version 0.7.12, (Krueger & Andrews, 
2011) combined with Bowtie2, version 2-2.1.0 (Langmead & Salzberg, 2012), using 
the options -N 1 -D 30. The resulting files were filtered for PCR duplicates using the 
program deduplicate_bismark_alignment_output.pl  and CpG methylation values 
were then extracted using the program bismark_methylation_extractor with the 
options --ignore_r2 2 --counts  --bedGraph --paired-end --no_overlap --
comprehensive --merge_non_CpG (Krueger & Andrews, 2011). The CpG 
methylation calls (one for each strand) were merged to a single methylation call for 
each CpG using custom scripts. 
 
Differentially methylated regions were identified using the R package bsseq 
(Hansen et al., 2012). The smoothing was carried out with the options ns=20, h=250, 
maxGap=100,000,000. Loci with coverage ≥8 in at least one biological replicate for 
wild-type and mutant were retained and Rlf-DMRs were identified using t-statistic 
quantile cut-offs of 0.01 and 0.99, requiring >10 CpGs per Rlf-DMR and a mean 
methylation change >15%. 
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Methylation values used for hierarchical clustering were the weighted averages 
of CpG methylation within each genomic coordinate. Only coordinates containing at 
least 8 CpGs with coverage of at least 6 reads across all samples, were used. 
 
2.8 ENRICHMENT OF HISTONE MARKS 
To calculate enrichment of histones at Rlf-DMRs the ENCODE sequencing 
reads (Shen et al., 2012) for both biological replicates, and for the input, for each 
tissue and histone modification considered (E14.5 liver, E14.5 heart and E14.5 
brain), were obtained from the UCSC Genome Browser (Rosenbloom et al., 2013a). 
Datasets with longer reads were 3’ trimmed such that all datasets contained reads of 
equal length. The reads were subsequently mapped to the mouse reference genome 
(NCBI37/mm9) using the program Bowtie2 with the options --trim5 6 --local -L 22 -
N 1 retaining only uniquely mapped reads. Reads likely to be PCR duplicates were 
identified and removed using the program MarkDuplicates Picard 
(http://picard.sourceforge.net). Enrichment of histone modifications were calculated 
as described in (Hon et al., 2013b), requiring >2-fold enrichment over input for both 
replicates. 
 
2.9 GENE ONTOLOGY ANALYSES, DNA SEQUENCE MOTIF SEARCH 
AND CONSERVATION SCORES 
Gene ontology analyses of genes proximal to Rlf-DMRs were carried out using 
the GREAT tool (McLean et al., 2010). The Homer tool, version 4.6 (Heinz et al., 
2010), was used to investigate for enrichment of known and novel transcription 
factor binding motifs at Rlf-DMRs using the options -size given –cpg, and otherwise 
default parameters. PhastCons conservation scores (Siepel et al., 2005) for placental 
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mammals, obtained from the UCSC Genome Browser (Karolchik et al., 2014), were 
used to get average conservation scores for Rlf-DMRs. 
 
2.10 CHROMATIN IMMUNOPRECIPITATION SEQUENCING ANALYSIS 
Fetal liver was collected from eight Rlf +/+ E14.5 embryos that were then 
divided into four replicates, consisting of two livers in each replicate. Tissue was 
then sent to ActiveMotif for chromatin extraction and immunoprecipitation using 
either the commercial Abcam Rlf antibody (AB115011) or a custom designed Rlf 
antibody.  
2.10.1  Library Preparation and Sequencing 
Sequencing of Abcam samples and their input control was undertaken on an 
Illumina HiSeq 2000 with 50 nt reads, whilst the Ab1 samples and their input 
(unprecipitated DNA) control were sequenced in the Illumina NextSeq 500 with 75 
nt reads.  
 
2.10.2  ChIPseq read mapping and peak calling 
All reads were mapped to the mouse genome (NCBI37/mm9) using the 
Burrows-Wheeler Aligner (BWA) algorithm with default settings (Li & Durbin, 
2009). Reads passing Illuminas purity filter, aligned with no more than 2 mismatches 
and map uniquely to the genome were used in subsequent analyses. Samples from 
each experiment were normalised alongside of their respective input controls to the 
same number of unique alignments following the removal of duplicate reads. Peaks 
were then identified using the MACS v1.4.2 peak finding algorithm (Zhang et al., 
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2008). Different p value cut offs were used for each experiment (p = 1e-7 Ab1, and p 
= 1e-5 Abcam).  
 
2.10.3 ChIPseq enrichment visualisation 
For visualisation of putative Rlf binding sites ChIPseq data was loaded onto the 
UCSC genome browser (www.genome.ucsc.edu.au). MACs generates a peaks.bed 
file with peak locations that is suitable for uploading into the UCSC genome browser 
as a custom track. Putative Rlf binding sites were visualised on the mus musculus 
NCBI37/mm9 assembly.  
 
2.11 PAVIS CHIPSEQ ANNOTATION 
PAVIS is a tool that enables the annotation of ChIPseq data to genomic regions 
(http://manticore.niehs.nih.gov/pavis2/). Location of the 200 ChIPseq peaks 
identified in experiments using two independent Rlf antibodies was input into PAVIS 
as a .bed file and the parameters: mouse/mm9 refGene set, upstream length 2500 and 
downstream length 2500 used. Peak enrichment was calculated by PAVIS using 
binomial testing to compare relative peak enrichment in different genomic regions. 
With the binomial p value equalling the probability of having peaks in a particular 
genomic region (Huang et al., 2013).  
 
2.12 STATISTICAL ANALYSIS 
2.12.1 Standard Student’s t-test 
The Standard Student’s t-test assessed whether the means of two groups are 
statistically different from each other. A p-value of 0.05 implies that there is only a 
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5% probability that the two groups have statistically different means by chance when 
they are in fact the same. If the p-value is 0.05 or less one can consider that the two 
groups have been drawn from two populations with statistically significantly 
different means. Unless otherwise stated, all statistics used in this thesis are two-
tailed t-tests with unequal variance, and results are presented as mean ± standard 
error of the mean (SEM).  
 
2.12.2 F-test 
The F-test assesses whether the variances observed in two sets of data are 
statistically different from each other. A p-value of 0.05 implies that there is only a 5% 
probability that the two groups have statistically different variances by chance when they 
are in fact the same. If the p-value is 0.05 or less one can consider that the two groups 
have been drawn from two populations with statistically significantly different variances. 
This is taken into account when calculating the T-test statistic. 
 
2.12.3 Statistical analysis of clonal bisulphite sequencing date 
The odds ratio Chi-squared test was used to measure the significance of methylation 
between genotypes. When conditions for the Chi-squared test were not met (less than 5 
replicates) Fisher's exact test was used.   
 
2.12.4 Pearson correlation testing 
Relationships between qRT-PCR and RNA-seq, and litter size and pup weight, were 
determined by Pearson correlation analysis using GraphPad Prism6. R2 values were 
considered significant when a two tailed p value was ≤ 0.05.  
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Chapter 3: Analysing the effect of loss of 
RLF in E14.5 fetal liver 
3.1 INTRODUCTION 
Previous work by the Whitelaw laboratory has shown that loss of Rlf results in 
a decrease in the number of erythrocytes expressing the GFP reporter transgene, an 
increase in methylation at the transgene, and haploinsufficiency for Rlf increased the 
probability of silencing at the Avy allele (Daxinger et al., 2013).  To gain insight into 
how loss of Rlf impacts upon transcription and methylation across the whole genome 
RNA-seq and whole genome bisulphite sequencing were undertaken1.  The 
identification of direct and indirect endogenous targets of Rlf may suggest cellular 
pathways and functions that are regulated by Rlf.  The identification of differentially 
methylated regions in the genome of Rlf homozygous mutants will identify regions in 
the genome that require Rlf for maintenance of methylation.  Additionally, some but 
not all, of the zinc fingers present in Rlf have been found to be capable of directly 
binding DNA (Harten et al., 2015). ChIPseq was undertaken to identify putative Rlf 
binding sites in the genome using two independent Rlf antibodies. Fetal liver was 
chosen for this study as at E14.5 this is the hematopoietic organ for the embryo and 
the ENU mutagenesis screen, from which Rlf was identified, assesses transgene 
variegation in red blood cells.  Encyclopedia of DNA elements (ENCODE) data of 
many functional elements is also publicly available for comparison of these data sets 
to our own.  
 
                                                
 
1 A significant portion of results from this chapter have been published in Harten et al., 2015.  
 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 90 
3.2 RESULTS 
3.2.1 Loss of Rlf has no impact on fetal liver morphology 
 
 
Previous experiments have shown Rlf to be expressed in the fetal liver, 
although no further experiments investigating the impact of loss of Rlf on the liver 
have been undertaken (Harten et al., 2015).  To determine whether loss of Rlf alters 
cell morphology in fetal livers I undertook histological analysis from fixed whole  
Rlf +/+ and Rlf MommeD28/MommeD28 E14.5 embryos (n = 5 per genotype).  No overt 
differences in cell morphology were observed when comparing Rlf +/+ and               
Rlf MommeD28/MommeD28 fetal livers following haematoxylin and eosin (H&E) staining, 
Figure 3.1A.  Western blot analysis of Rlf using the custom designed antibody (refer 
Section 4.2.1), Ab1, in Rlf +/+ and Rlf MommeD28/MommeD28 E14.5 fetal livers also showed 
Rlf is expressed in wild-type but not homozygous livers, Figure 3.1B.  This confirms 
the liver as a suitable tissue to investigate the effect of loss of Rlf on gene expression 
and methylation. 
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Figure 3.1: Rlf is expressed in the fetal liver and has no impact on morphology.  
A. Haematoxylin and eosin staining of E14.5 Rlf +/+ and Rlf MommeD28/MommeD28 fetal 
liver. Whole embryos were fixed in 4% PFA and embedded in paraffin. Sections 
were cut and stained by QIMR Berghofer Histotechnology facility, representative 
sections are shown. n = 5 per genotype. Scale bars, 300 µm (top) and 60 µm 
(bottom) respectively. B. Western blotting for Rlf in protein extracted from E14.5   
Rlf +/+ and Rlf MommeD28/MommeD28 fetal livers. Each lane represents an individual 
embryo and littermates were used for analysis. Rlf was detected at 250 kDa and γ-
tubulin used as a loading control.  
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3.2.2 Rlf regulates endogenous gene expression in the fetal liver 
 
Previous studies by the Whitelaw laboratory have shown loss of Rlf alters 
expression of the GFP transgene in mutant mice (Daxinger et al., 2013). The effect 
of loss of Rlf on endogenous gene expression has not previously been undertaken. 
Thus I chose to undertake RNA sequencing (RNA-seq) to investigate the effect of 
loss of Rlf on the fetal liver transcriptome. The identification of genes whose 
expression is altered in Rlf mutants may suggest cellular pathways and functions that 
are regulated by Rlf, which in turn may point towards how Rlf acts as an epigenetic 
modifier. RNA-seq analysis of E14.5 liver extracted from Rlf +/+,   Rlf MommeD28/+ and 
Rlf MommeD28/MommeD28 littermates (n = 3 per genotype).  Briefly, mRNA-seq library 
preparation and Illumina HiSeq 2000 sequencing with 50 bp single end reads was 
performed by Australian Genome Research Facility (AGRF). Each fetal liver 
underwent sequencing and alignment to the mouse genome (NCBI37/mm9) 
individually. Read counts were then extracted from the mapped reads for each 
sample using HTSeq-count and a matrix file of read counts for all samples generated 
for differential expression testing (Anders et al., 2015). Analysis of differentially 
expressed genes was then undertaken in DEseq, using default parameters and all p 
values are adjusted for multiple testing using the Benjamini Hochberg method 
(Anders & Huber, 2010; Benjamini & Hochberg, 1995).  
 
Using an adjusted p value cut off of p < 0.05 and fold change of > 1.2, 184 
genes were found to be differentially expressed in Rlf MommeD8/MommeD28  compared to 
Rlf +/+ E14.5 liver (97 up-regulated and 87 down-regulated). The top 20 up- and 
down-regulated genes in Rlf MommeD28/MommeD28 fetal liver, based on fold change, are 
shown in Table 3.1 and Table 3.2, and Appendix II lists all of the RNA-seq data 
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comparing Rlf +/+ and Rlf MommeD28/MommeD28 genotypes. Analysis of genes whose 
expression was altered greater than two fold in Rlf MommeD28/MommeD28 fetal liver found 
approximately four times as many genes were down-regulated (n = 31) than up-
regulated (n = 7),  
Table 3.3.  This correlates with previous finding of Rlf being required for gene 
activation (Daxinger et al., 2013). Rlf was not found to be differentially expressed 
following RNA-seq analysis. Further investigation of RNA-seq mapped data found 
reads mapped to intron 2 as well as no reads mapping to the beginning of exon 3 
potentially due to alternate splicing. A representative               Rlf MommeD28/MommeD28 
sample illustrating this mapping is provided in Figure 3.2. That we see no Rlf 
protein expression in the fetal liver (Figure 3.1) suggests the RNA product may 
undergo degradation, for example via nonsense mediated decay.   
 
Comparison of Rlf +/+ and Rlf MommeD28/+ RNA-seq data found no genes to be 
significantly differentially expressed between the two genotypes following correction 
for multiple testing, Appendix III.  Although no genes were identified as being 
statistically differentially expressed, investigation of gene expression in                  
Rlf MommeD28/+ and Rlf MommeD28/MommeD28 livers compared to wild-type revealed read 
counts for genes in Rlf MommeD28/+ were altered in the same direction as those observed 
in Rlf MommeD28/MommeD28, Table 3.4.  
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Table 3.1: Top 20 down-regulated genes in Rlf MommeD28/MommeD28 fetal liver. 
Symbol Gene Name Fold Change Adjusted P value  
Hpd 4-hydroxyphenylpyruvate dioxygenase 0.011 1.90E-19 
Cyp2d37-ps Cytochrome P450, family 2, subfamily d, polypeptide 37, pseudogene 0.024 5.68E-05 
Tcfl5 Transcription factor-like 5 (basic helix-loop-helix) 0.097 4.32E-02 
Hormad2 HORMA domain containing 2 0.100 5.96E-03 
Mc2r Melanocortin 2 receptor 0.193 7.05E-04 
Prss50 Protease, Serine, 50 0.211 4.16E-20 
Atp2b2 ATPase, Ca++ transporting, plasma membrane 2 0.263 8.82E-04 
Upb1 Ureidopropionase, beta 0.272 1.14E-20 
Pnliprp2 Pancreatic lipase-related protein 2 0.273 3.21E-02 
Timd2 T-cell immunoglobulin and mucin domain containing 2 0.279 4.95E-33 
Apoc1 Apolipoprotein C-I 0.281 1.96E-14 
Psma8 Proteasome subunit alpha type 8 0.283 5.68E-05 
Cyp2d9 Cytochrome P450, family 2, subfamily d, polypeptide 9 0.295 5.13E-02 
Zfp783 Zinc finger protein 783 0.313 1.42E-05 
Dnajb3 DnaJ (Hsp40) homolog, subfamily B, member 3 0.316 8.78E-06 
Crispld2 Cysteine-rich secretory protein LCCL domain containing 2 0.332 3.72E-03 
Dnahc8 Dynein, axonemal, heavy chain 8 0.350 2.08E-02 
Sycp1 Synaptonemal complex protein 1 0.354 5.13E-03 
Haao 3-hydroxyanthranilate 3,4-dioxygenase 0.355 7.01E-08 
Liph Lipase, member H 0.359 1.84E-02 
Table 3.1: Top 20 down-regulated genes in Rlf MommeD28/MommeD28 fetal liver compared to wild-type, ordered by fold change, following RNA-seq 
analysis.  Fetal liver was collected from three individual E14.5 embryos for each genotype; all embryos were from the same litter.  RNA-seq was 
performed by AGRF on the Illumina HiSeq 2000 and bioinformatic analysis in DESeq provided by Dr H. Oey.  Adjusted p value controls for 
false discovery rate through the use of the Benjamini-Hochberg procedure. (Full data Appendix II).  
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Table 3.2: Top 20 up-regulated genes in Rlf MommeD28/MommeD28 fetal liver. 
Symbol Gene Name Fold Change Adjusted P value 
Mgam Maltase-glucoamylase 3.497 3.80E-18 
Myo5c Myosin VC 3.224 2.15E-03 
Nupr1 Nuclear protein transcription regulator 1 2.827 3.60E-02 
Sox9 SRY (sex determining region Y)-box 9 2.597 3.02E-04 
Nefh Neurofilament, heavy polypeptide 2.310 1.84E-02 
Clic6 Chloride intracellular channel 6 2.20 9.80E-03 
Aldh1a7 Aldehyde dehydrogenase family 1, subfamily A7 1.995 2.04E-05 
Igsf11 Immunoglobulin superfamily, member 11 1.984 5.68E-05 
Myof Myoferlin 1.931 3.39E-02 
Vldlr Very low density lipoprotein receptor 1.788 5.68E-03 
Akr1c12 Aldo-keto reductase family 1, member C12 1.782 2.11E-05 
Pcdh7 Protocadherin 7 1.781 6.79E-03 
Zbtb20 Zinc finger and BTB domain containing 20 1.741 2.15E-02 
Eml5 Echinoderm microtubule associated protein like 5 1.720 2.19E-02 
Dak Dihydroxyacetone kinase 2 homolog (yeast) 1.683 4.56E-09 
Card6 Caspase recruitment domain family, member 6 1.652 3.72E-03 
Ppm1e Protein phosphatase 1E (PP2C domain containing) 1.644 6.92E-04 
Tnfsf14 Tumor necrosis factor (ligand) superfamily, member 14 1.642 3.14E-02 
Kcnj5 Potassium inwardly-rectifying channel, subfamily J, member 5 1.639 6.54E-06 
Scai Suppressor of cancer cell invasion 1.611 5.68E-05 
Table 3.2: Top 20 up-regulated genes in Rlf MommeD28/MommeD28 fetal liver compared to wild-type, ordered by fold change, following RNA-seq 
analysis.  Fetal liver was collected from three individual E14.5 embryos for each genotype; all embryos were from the same litter.  RNA-seq was 
performed by AGRF on the Illumina HiSeq 2000 and bioinformatic analysis in DESeq provided by Dr H. Oey.  Adjusted p value controls for 
false discovery rate through the use of the Benjamini-Hochberg procedure. (Full data Appendix II).  
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Table 3.3: More genes are down-regulated in Rlf MommeD28/MommeD28 fetal liver than up-regulated. 
 
 
 
 
 
Table 3.3: The number of genes significantly (p < 0.05) differentially expressed in Rlf MommeD28/MommeD28 E14.5 livers relative to Rlf +/+ controls at 
various fold-change cut-offs, shows more are down-regulated than up-regulated. ↑ and ↓ indicates increased or reduced expression in Rlf 
mutants. 
 
 
Figure 3.2: RNA-seq mapped reads in a representative Rlf MommeD28/MommeD28 sample. 
Representative RNA-seq mapping of a Rlf MommeD28/MommeD28 replicate, showing a large number of reads mapped to intron 2 of Rlf and no reads 
mapped to the beginning of Exon 3 where the MommeD28 mutation is located.  
Fold Change Differentially regulated genes in Rlf MommeD28/MommeD28 fetal liver (n) 
≥ 4 ↑ 0 ↓ 2 
≥ 3 ↑ 2 ↓ 10 
≥ 2 ↑ 7 ↓ 31 
≥ 1.5 ↑ 31 ↓ 59 
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Table 3.4: Gene expression in Rlf MommeD28/+fetal liver is in the same direction as Rlf MommeD28/MommeD28 fetal liver.  
 
Table 3.4: Gene expression in Rlf MommeD28/+ samples is in the same direction as Rlf MommeD28/MommeD28 gene expression. Significance of changes in 
expression in Rlf MommeD28/+ samples before (P value) and after (adjusted P value) correction for multiple testing. (Full data Appendix III).  
 
Symbol Gene Name ↑ or ↓in 
MommeD28/MommeD28 
↑ or ↓in 
MommeD28/+ 
P value in 
MommeD28/+ 
Adjusted P value in 
MommeD28/+ 
Timd2  T-cell immunoglobulin and mucin domain containing 2 Ô Ô 3.47E-05 0.270011 
Itga6 Integrin alpha 6, full insert sequence Ó Ó 3.53E-05 0.270011 
Pgp Phosphoglycolate phosphatase Ô Ô 3.91E-05 0.270011 
Ipcef1 Interactor protein for cytohesin exchange Ô Ô 4.92E-05 0.270011 
Psma8 Proteasome subunit alpha type-7-like Ô Ô 1.56E-04 0.554285 
Itga2b Integrin alpha-IIb Ó Ô 1.67E-04 0.554285 
BC100530 Stefin A-like protein Ô Ô 1.95E-04 0.554285 
Tubb1 Tubulin, beta 1 Ó Ó 2.02E-04 0.554285 
Nr2f6 Nuclear receptor subfamily 2, group F, member 6 Ô Ô 2.69E-04 0.655303 
Dak Bifunctional ATP-dependent dihydroxyacetone Ó Ó 3.11E-04 0.662043 
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Given this finding I chose to use RNA extracted from wild-type, heterozygous 
and homozygous MommeD34 mice, an independent line, for validation.  A selection 
of genes whose expression had a fold change greater than three and were 
significantly (p < 0.005)  up- or down-regulated in Rlf MommeD28/MommeD28 fetal liver 
were chosen for quantitative real-time RT-PCR validation (qRT-PCR), Figure 3.A-
B. mRNA expression was normalised to the housekeeping gene β-actin as expression 
values were found to not vary between genotypes. qRT-PCR validation found each 
gene to also be significantly differentially expressed in Rlf MommeD34/MommeD34 fetal 
liver. These results indicate that the differential expression of these genes is due to 
loss of Rlf, although which genes are direct versus indirect targets is still unclear.  
Significant differences in mRNA expression comparing Rlf MommeD34/+ and Rlf +/+ 
fetal livers were also observed, unlike in the RNA-seq data.  A number of factors 
may contribute to the differences observed between the RNA-seq and qRT-PCR 
methods. These include bias introduced during library preparation, variability 
between replicates, or correction for multiple testing.   
 
To investigate this further I examined the p value and adjusted p value from 
RNA-seq data comparing Rlf +/+ and Rlf MommeD28/+ E14.5 liver. While no genes were 
found to be significant following correction testing (adjusted p value), 414 genes 
were found to be significantly differentially expressed according to their non-
adjusted p value (p < 0.05), the top 10 of which are shown in Table 3.4 (Appendix 
III). Analysis of the fold change values from the RNA-seq and qRT-PCR datasets 
showed they correlated well with each other (R = 0.8133), Figure 3.3, suggesting the 
correction for multiple testing is the reason for discrepancy between the two 
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methods. Confirmation of our findings in tissue from an independent Rlf mutant line 
provides strong evidence that the validated genes are regulated by Rlf. 
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Figure 3.3: Validation of differentially expressed genes from RNA-seq. 
A, B. qRT-PCR analysis of differentially expressed genes identified from RNA-seq 
was performed on RNA extracted from the independent Momme34 mouse line.  
mRNA expression of the most significantly up and down-regulated genes according 
to RNA-seq results was investigated.   mRNA expression was normalised to β-actin 
and wild-type controls. Error bars represent SEM and Student’s t-test was used to 
calculate p values (*p < 0.05, **p < 0.005, ***p < 0.0005).  n = min. 4 for each 
genotype.  
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Figure 3.3: Correlation of Rlf MommeD28/+ RNA-seq and Rlf MommeD34/+ qRT-PCR 
datasets 
Rlf MommeD28/+ RNA-seq (y-axis) and Rlf MommeD34/+ qRT-PCR (x-axis) datasets 
correlated well with each other, using the fold change measure of genes chosen for 
qRT-PCR validation. Genes included in the analysis include those found to be 
significantly differentially expressed (p < 0.05) following qRT-PCR but not RNA-
seq (red), and those not significantly differentially expressed following either method 
(blue).  
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Next I investigated whether genes identified as being significantly 
differentially expressed in Rlf MommeD28/MommeD28 fetal liver were associated with the 
same biological pathways and processes. A small number of genes were found to 
have a minimum fold change of 1.5, and an adjusted p value of < 0.05 (90 genes in 
total). To increase the ability to identify biological mechanisms and pathways that 
may be altered in Rlf mutants, this gene list was expanded to include genes with a 
minimum fold change of 1.2, and an adjusted p value of < 0.05 (184 genes in total).   
 
Analysis of these 184 differentially expressed genes using QIAGEN’s 
Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, 
www.qiagen.com/ingenuity), revealed the top associated network functions to be 
lipid metabolism (p score = 19), e.g. Aldh1a7 (Aldehyde dehydrogenase family 1, 
subfamily A7), and cardiovascular system development and function (p score = 52), 
e.g. Crispld2 (Cysteine-rich secretory protein LCCL domain containing 2).  This 
analysis is consistent with the role of the liver in metabolism and fetal 
haematopoiesis (Lee et al., 2012).   
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3.2.3 Investigating Hpd and the Fetal Liver 
 
Of the genes found to be differentially expressed in Rlf mutant fetal liver I 
chose to investigate Hpd, the most highly down-regulated gene, in more detail. 
Expression of Hpd mRNA was found to be decreased almost 94 fold in homozygous 
fetal liver versus wild-type following RNA-seq analysis and validated using qRT-
PCR in an independent Momme line (Table 3.1 and Figure 3.).   
 
In both mice and humans Hpd protein is primarily expressed in the liver, but is 
also detected in the kidneys and is required for the catalysis of 4-
hydroxyphenylpyruvate to homogentisate in the tyrosine catabolism pathway, which 
is conserved between humans and mice, Figure 3.4A-B (Kent et al., 2002; Tanaka et 
al., 2006).  Loss of Hpd function results in a build up of tyrosine (Endo et al., 1991).  
Mutations in HPD in humans have been shown to lead to two disorders – 
Tyrosinemia Type III (autosome recessive/ homozygous mutation) and 
Hawkinsinuria (dominant/ heterozygous mutation) (Tomoeda et al., 2000). In both 
disorders patients present with mental retardation and show “a failure to thrive” 
(Borden et al., 1992; Cerone et al., 1997; Ellaway et al., 2001; Niederwieser et al., 
1977).   As initial observations of Rlf mutants found they weighed less than wild-
type littermates in late gestation (refer Section 4.2.6) (Daxinger et al., 2013), this 
raised the question whether Hpd deficiency in Rlf mutant mice contributes to the 
reduced weight phenotype observed.   
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A.  
	  
B.  
 
 
 
 
 
 
 
Figure 3.4: Hpd expression in the liver and tyrosine catabolism pathway. 
A. UCSC Genome Browser snapshot (http://genome.ucsc.edu.au) (NCBI37/mm9), 
showing Hpd (blue) RNA-seq ENCODE expression data in different tissues – heart 
(red), kidney (pink), and liver (yellow), at different time-points – adult (8 weeks) and 
embryo (E14.5). B. Tyrosine catabolism pathway, enzymes that catabolise each step 
are shown on the right and diseases occurring due to deficiency in an enzyme shown 
on the left. Hpd identified as being down-regulated in Rlf mutant livers is 
highlighted.  Adapted from Tanaka et. al., 2006. 
(Appendix XIV).  
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Mice lacking Hpd have been found to have increased tyrosine levels in the 
blood (Endo et al., 1991). As RNA-seq and qRT-PCR validation in MommeD28 and 
MommeD34 Rlf mutants showed a significant decrease in Hpd expression (94 fold 
(Figure 3.), and qRT-PCR of Hpd in E14.5 Rlf MommeD8/MommeD34 offspring also 
showed a reduction in Hpd mRNA in mice with reduced Rlf expression (results 
presented and discussed in Chapter 5,Figure 5.3). I asked whether loss of Rlf affects 
tyrosine levels in the blood of Rlf mutant mice.  To study this I utilised hypomorphic 
compound heterozygous adult mice (Rlf MommeD8/MommeD34) and age matched wild-type 
mice (n = 5 per genotype), and also E18.5 Rlf MommeD34/MommeD34 and Rlf +/+ littermates 
(n = minimum 3 per genotype). Compound heterozygous mice were chosen for the 
adult portion of this study as homozygous MommeD28 and MommeD34 mice die 
shortly after birth, making it unfeasible to perform the study in adult mice from these 
lines (refer Sections 4.2.5 and 4.2.6) (Daxinger et al., 2013). Compound 
heterozygous mice have also been found to display a reduced weight phenotype 
similar to the null Rlf MommeD28 and MommeD34 lines (refer Figure 5.4). I 
collected whole blood from adult mice via cardiac puncture following euthanasia 
with CO2, and from embryos following decapitation. Blood was allowed to clot at 
room temperature and centrifuged at 10,000 rpm for 5 minutes; serum was removed 
and sent for tyrosine analysis to Dr. B. McWhinney, Queensland Health.  
 
No significant difference (p = 0.325) in tyrosine levels in the blood was 
observed in adult compound heterozygote mice compared to wild-type mice, Figure 
3.5. Comparison of the raw data collected from both Rlf +/+ and Rlf MommeD8/MommeD34 
adult mice (63 -120 µmol/L, Table 3.5) to previously published data by other groups 
found our results to be similar to that of wild-type mice in other studies (50 – 120 
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µmol/L), whilst Hpd-/- mice had an approximate 10 fold increase in tyrosine in the 
blood (Endo et al., 1991). This suggests that even though there is reduced mRNA 
expression of Hpd in these mice a minimal amount of Hpd protein may enable the 
tyrosine pathway to function effectively. Western blotting for Hpd using the Aviva 
Systems Biology antibody (OAAB05183), was unable to detect any signal in either 
wild-type or mutant liver (data not shown), making it difficult to determine how Hpd 
protein levels are affected in these mice.  
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Figure 3.5: Analysis of serum tyrosine levels in adult Momme mice. 
Analysis of tyrosine levels in serum in adult Rlf MommeD8/MommeD34 compound 
heterozygous and wild-type age matched mice.  Blood was collected from adults via 
cardiac puncture and left to clot before centrifuging and removing serum.  Tyrosine 
amino acid assay was performed by Dr B. McWhinney at Qld Health.  Tyrosine 
levels were normalised to the average tyrosine level of wild-type littermates.  Error 
bars represent SEM and Student’s t-test was used to calculate p values. n = 5 per 
genotype.   
 
Table 3.5: Adult Mouse Tyrosine values.     
 
 
 
 
 
 
Table 3.5: Raw tyrosine values (µmol/L) of adult mice shows no difference in 
tyrosine levels between genotypes. 
Genotype Tyrosine Level (µmol/L) 
Rlf +/+ 71 
Rlf +/+ 79 
Rlf +/+ 96 
Rlf +/+ 73 
Rlf +/+ 63 
Rlf MommeD8/MommeD34 87 
Rlf MommeD8/MommeD34 120 
Rlf MommeD8/MommeD34 64 
Rlf MommeD8/MommeD34 87 
Rlf MommeD8/MommeD34 80 
A 
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At E18.5 a small but significant (p = 0.0087) decrease in tyrosine in                        
Rlf MommeD34/MommeD34 embryos compared to Rlf +/+ was observed, Figure 3.6 and 
Table 3.6. This is in contrast to the anticipated increase in tyrosine in mice lacking 
Hpd expression. During this PhD I have found Rlf MommeD34/MommeD34 embryos weigh 
approximately 30% less at E18.5 than their wild-type littermates (refer Section 4.2.6. 
This difference in size between the two genotypes could be the cause of the reduced 
tyrosine levels observed, with smaller embryos either not requiring or producing 
tyrosine at the same concentration as larger Rlf +/+ embryos, this will be further 
discussed in Section 3.3. Due to the observation that this difference in size between 
genotypes occurs early in development (refer Figure 4.9), it would be unfeasible to 
examine tyrosine levels at earlier time-points in embryos which have a reduced blood 
supply compared to the E18.5 embryos examined here.  
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Figure 3.6: Analysis of serum tyrosine levels in embryo Momme mice. 
Analysis of tyrosine levels in serum in E18.5 Rlf +/+ and Rlf MommeD34/MommeD34 
embryos.  Blood was collected from embryos via decapitation and left to clot before 
centrifuging and removing serum.  Tyrosine amino acid assay was performed by Dr 
B. McWhinney at Qld Health.  Tyrosine levels were normalised to the average 
tyrosine level of wild-type littermates.  Error bars represent SEM and Student’s t-test 
was used to calculate p values (**p < 0.01). n = minimum of 3 per genotype. 
 
Table 3.6: Mouse Embryo Tyrosine value. 
	  
	  
 
 
 
 
 
 
 
 
Table 3.6: Raw tyrosine values (µmol/L) of embryos shows a slight reduction in 
tyrosine levels in MommeD34 homozygous mice.  
Genotype Tyrosine Level (µmol/L) 
Rlf +/+ 180 
Rlf +/+ 171 
Rlf +/+ 161 
Rlf +/+ 160 
Rlf MommeD34/MommeD34 125 
Rlf MommeD34/MommeD34 148 
Rlf MommeD34/MommeD34 128 
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3.2.4 Analysis of the Effect of Loss of Rlf on the Fetal Liver Methylome 
 
Following the observation of changes in transcription in our mouse modes, I 
next asked how loss of Rlf impacts methylation in these mice. Loss of Rlf has been 
shown to increase methylation at the GFP transgene in each of the three Rlf mutant 
mouse lines (Daxinger et al., 2013), however, the effect of Rlf on methylation across 
the genome is unknown. As a result I decided to utilise genome-wide bisulphite 
sequencing (GWBS) to investigate methylation across the genome in the 
MommeD28 mouse line.  GWBS allows for genome-wide analysis of methylation 
patterns, whilst other methods such as methylated DNA immunoprecipitation and 
reduced representation bisulphite sequencing are sufficient for analysis of 
methylation at CpG islands and promoter regions (Meissner et al., 2005; Tost & Gut, 
2007; Weber et al., 2005). As it is unknown where, or at which regions, in the 
genome loss of Rlf may alter methylation we chose to use a genome-wide analysis 
method. GWBS is a more expensive method, however its reproducibility and 
accurate results allow for a smaller number of replicates to be studied with the same 
outcome as using more replicates and an alternate methylation analysis method (Tost 
& Gut, 2007).   
 
Of the nine samples sent for RNA-seq, two Rlf MommeD28/MommeD28 and two Rlf +/+ 
littermates from this group were also sent for GWBS.  Sequencing was completed for 
this sample set by Centre Nacional d’Analisi Genomica (CNAG), Spain.  Initially, 
this dataset was used to determine how loss of Rlf impacts methylation across the 
genome.  
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Key questions I was interested in addressing from this data were: 
1. Does loss of Rlf alter methylation at specific regions across the genome? 
2. Do sites identified as Rlf differentially methylated regions (Rlf-DMRs) 
correlate with genes identified as differentially expressed in the fetal liver? 
3. Are the Rlf-DMRs present in Rlf MommeD28/MommeD28 mice also present in           
Rlf MommeD34/MommeD34 mice? 
 
Subsequently bioinformatic analysis to address these questions was carried out 
by Professor I. Gut, CNAG, and Dr H. Oey, La Trobe University. These findings 
were reported in Harten et al., 2015, alongside of complementary studies outside of 
the scope of my thesis, investigating the effect of Rlf on the methylome at different 
time-points. 
 
Whilst GWBS analysis pipelines were being established by Dr H. Oey, I firstly 
asked whether I could identify differential methylation at putative regulatory regions 
that overlapped with genes identified as being differentially expressed in our RNA-
seq analysis, and secondly whether this could be validated using bisulphite PCR.  
DNA from the independent mouse line, MommeD34, was bisulphite converted and 
Sanger sequenced according to standard protocols (refer Section 2.4).  Two 
candidate genes that showed significant differences in mRNA expression, Hpd and 
Prss50 (Protease, Serine, 50), down-regulated ~93 and ~5 fold, respectively (Table 
3.1), were chosen to determine whether differential expression correlated with 
differential methylation at putative regulatory regions.   
 
 112 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 
A DNase I hypersensitive site (DHS) upstream of Hpd reflecting an enhancer 
region was identified by manually viewing GWBS data alongside of E14.5 liver 
DHS produced by the ENCODE project (Rosenbloom et al., 2013b). No other 
potential differentially methylated regions were found to be proximal to Hpd. This 
region consisted of 5 CpG sites and appeared differentially methylated from GWBS 
data in Rlf MommeD28/MommeD28 (~20%) fetal liver compared to Rlf +/+ (~10%), and was 
subsequently chosen for validation, Figure 3.7A.  
 
Many recent publications investigating differential methylation classify a ten 
percent difference in methylation as being a biologically significant change with 
reduced probability of representing an artificial methylation change (Stefansson et 
al., 2015; Yuen et al., 2010; Zeller et al., 2012). In accordance with the literature I 
have classified candidate regions with a minimum methylation difference of ten 
percent as being differentially methylated. 
 
While a ten percent increase in methylation in Rlf MommeD28/MommeD28 fetal liver 
was observed in the GWBS dataset, a decrease was observed following bisulphite 
sequencing validation in Rlf MommeD34/MommeD34 (78%) compared to Rlf +/+ (87%) 
littermates, p = 0.1489, Figure 3.7B. Possible reasons for these differences in 
methylation will be discussed in Section 3.3.  Also of note is the large discrepancy in 
methylation between wild-types from the MommeD28 line (~10%) and MommeD34 
line (~87%). One possible explanation for the differences in methylation observed 
between the two methods may be due to poor read coverage occurring at this region 
in GWBS data, resulting in methylation at this region being inaccurately defined. 
Studies investigating the minimum sequencing depth in GWBS have shown short 
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regions with few CpGs, such as the 5 CpG sites analysed here, are the most 
susceptible to being missed due to reduced coverage of reads at these regions, 
resulting in the large different observed between the two methods (Ziller et al., 
2015).  
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Figure 3.7: Methylation analysis of Hpd in the fetal liver. 
A. UCSC Genome Browser tracks of GWBS results for region chosen for validation 
upstream of Hpd. The top 4 tracks display samples used in GWBS (n = 2 Rlf +/+, top, 
and 2 Rlf MommeD28/MommeD28, bottom). The DNase I hypersensitivity site (DHS) 
upstream of Hpd investigated is shown as a yellow track, produced by the University 
of Washington as part of the publicly available ENCODE mouse project. B. 
Bisulphite sequencing of this DHS revealed a small decrease in DNA methylation in 
Rlf MommeD34/MommeD34 versus Rlf +/+ fetal liver. Each column represents DNA from a 
single embryo (n = 3 per genotype), each row is the sequence from a single cell and 
each circle represents one CpG site. Black circles represent methylated CpGs and 
white circles represent unmethylated CpGs. (X2, p = 0.1489). 
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Figure 3.7: Methylation analysis of Hpd in the fetal liver. 
 
A. 
 
 
 
 
B.  
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A CpG island containing 24 CpGs across the transcription start site of Prss50 
was identified as being differentially methylated in Rlf MommeD28/MommeD28 (~37%) 
compared to Rlf +/+ (~21%) from our GWBS dataset, Figure 3.8A. A smaller change 
in methylation was observed between Rlf MommeD34/MommeD34 (~25%) and Rlf +/+        
(~20%) fetal liver following bisulphite sequencing, p = 0.4242, Figure 3.8B. 
Comparison of the methylation level in wild-type fetal liver for each of the Momme 
lines also found them to be the same (MommeD34 ~20% and MommeD28 ~21%). In 
order to be classified as a Rlf-DMR following GWBS analysis regions were required 
to have a minimum methylation difference of 15% between the two genotypes (refer 
next Section 3.2.5). Although the Prss50 region was defined as a Rlf-DMR 
following GWBS using this cut off (Appendix IV), the 15.5% change in methylation 
between genotypes observed may be attributable to a number of reasons, which will 
be discussed below. 
 
Failure to validate the Hpd and Prss50 sites may be the result of differences 
between the MommeD28 and MommeD34 lines. Each of these mouse lines was 
produced from a screen in which a chemical mutagen was used to introduce random 
point mutations (Blewitt et al., 2005). It has been estimated that the ENU induced 
mutation rate in mice generated from this screen is 1:1,000,000 bp (Daxinger et al., 
2013). Although these mouse lines were backcrossed to unmutagenised FVB/NJ 
mice, it may be possible that an independent ENU generated mutation is still present 
in one of the Momme lines resulting in differences in methylation between the 
independent Momme lines. 
 
 116 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 
Due to the high costs of performing GWBS on multiple samples, GWBS was 
only performed in the MommeD28 mouse line. Undertaking this same analysis in the 
MommeD34 mouse line may provide an overlap of differentially methylated regions 
between the two Rlf mutant strains that are less sensitive to heterogeneity between 
the two lines.  
 
Alternatively, whilst the Prss50 region was defined as a Rlf-DMR following 
GWBS analysis, the 15.5% change in methylation was close to the set cut off in 
methylation change of 15%. The observed 5% increase in methylation in                 
Rlf MommeD34/MommeD34 mice was in the same direction, but was not as large as the 15% 
increase observed in Rlf MommeD28/MommeD28 mice. As such, this change in methylation 
may be more susceptible to changes in biological variation between replicates. 
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Figure 3.8: Methylation analysis of Prss50 in the fetal liver. 
A. UCSC Genome Browser tracks of GWBS results for region chosen for validation 
at Prss50. The top 4 tracks display samples used in GWBS (n = 2 Rlf +/+, top, and 2 
Rlf MommeD28/MommeD28, bottom). At the CpG island (green bar) over the first exon of 
Prss50 (blue bar), an increase in methylation for both mutants is observed in 
comparison to the wild-type tracks. B. Bisulphite sequencing of the CpG island at the 
transcription start site of Prss50 displays no difference in methylation. Each column 
represents DNA from a single embryo (n = 3 for each genotype), each row is the 
sequence from a single cell and each circle represents one CpG site. Black circles 
represent methylated CpGs and white circles represent unmethylated CpGs. (X2, p = 
0.4242). 
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Figure 3.8: Methylation analysis of Prss50 in the fetal liver. 
 
A. 
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3.2.5 Identification of Rlf-DMRs in the fetal liver 
 
In parallel with the validation of candidate regions, unbiased identification of 
Rlf-DMRs using a bioinformatic analysis pipeline was also performed, in 
collaboration with Dr H. Oey. In these experiments regions were deemed to be 
significantly differentially methylated between the two genotypes as requiring > 10 
CpGs, each CpG must be covered by > 5 reads, and the difference in methylation 
between the two genotypes be greater than 15% (Harten et al., 2015).  These regions 
were defined as Rlf Differentially Methylated Regions (Rlf-DMRs).  1,329 regions 
were found to be significantly differentially methylated in Rlf MommeD28/MommeD28 
E14.5 fetal liver compared to Rlf +/+ following GWBS (Appendix IV).  Table 3.7 
lists the top 25 Rlf-DMRs and their closest gene/s.  
 
I then graphed the average CpG methylation in Rlf MommeD28/MommeD28 and Rlf +/+ 
littermates and found 94% of Rlf-DMRs were found to be hypermethylated in Rlf 
MommeD28/MommeD28, Figure 3.10.  This result is consistent with previous data showing 
loss of Rlf results in an increase in methylation of the GFP transgene (Daxinger et al., 
2013). No difference in the average number of CpGs per DMR was observed when 
comparing hypermethylated Rlf-DMRs (18.7 CpGs) to hypomethylated Rlf-DMRs 
(16.7 CpGs, p = 0.1650). However, hypermethylated Rlf-DMRs were found to have 
a significantly greater CpG density (0.055%) than hypomethylated Rlf-DMRs 
(0.045%, p = 0.0012). 
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Further analysis by Dr H. Oey found approximately half of the 1,329 Rlf-
DMRs overlapped with RefSeq transcripts (n=652) and half were intergenic (n=677), 
Figure 3.9A. A small proportion of the Rlf-DMRs, 255, lay within 2.5 kb of a 
transcriptional start site (TSS) and few, 200, overlapped with the 16,000 CpG islands 
annotated in the mouse genome. Together these findings suggest that a minority of 
Rlf-DMRs overlap with promoters (Harten et al., 2015). 
 
Of those Rlf-DMRs that overlapped with RefSeq transcripts, a large 
proportion, ~50%, were found to be located at exons (including the 3’UTR), Figure 
3.9B. This is significantly more than would be expected based on the proportion of 
genic sequence that is exonic (~10% of RefSeq transcripts), Figure 3.9C (Harten et 
al., 2015). 
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Figure 3.9: Rlf-DMRs overlap with regulatory regions. 
A. E14.5 Rlf-DMRs were investigated for overlap with RefSeq genes, proximity to TSS and CpG islands. B. E14.5 liver Rlf-DMRs overlapping 
RefSeq transcripts, were classified according to overlap with transcript features. The central CpG dinucleotides of each Rlf-DMR was used to 
define the overlap. Rlf-DMRs that overlapped multiple features were assigned to a single feature according to following ranking: TSS > single 
exon transcripts > 3’ exon/untranslated region (UTR) > internal exon > intron. C. The expected distribution was defined as the union of each 
feature category genome-wide, subtracting overlapping features of higher rank (1,006 Mb). 
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Figure 3.10: The majority of Rlf-DMRs are hypermethylated in 
RlfMommeD28/MommeD28 fetal liver.  
Scatterplot of average CpG methylation observed in Rlf MommeD28/MommeD28 mutants 
compared to Rlf +/+ littermates for 1,329 Rlf-DMRs identified in E14.5 liver, shows 
more Rlf-DMRs are hypermethylated in Rlf MommeD28/MommeD28 fetal liver than Rlf +/+ 
fetal liver.   
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Table 3.7: List of genes closest to the top 25 Rlf-DMRs in Rlf MommeD28/MommeD28 fetal 
liver compared to Rlf +/+ following GWBS analysis. All of these sites are 
hypermethylated in Rlf MommeD28/MommeD28. Fetal liver was collected from two 
individual E14.5 embryos for each genotype; all embryos were from the same litter. 
GWBS was performed on each sample individually by CNAG, and bioinformatic 
analysis was provided by Dr H. Oey. Rlf-DMRs were defined as requiring > 10 CpG 
sites, each CpG requiring > 5 reads and more than 15% change in methylation 
between genotypes. Rlf-DMRs are ordered by AreaStat which is equal to the sum of 
the t statistic in each CpG (area of DMR, weighted by the number of CpGs) (Full 
data Appendix IV). 
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Table 3.7:  Top 25 Rlf Differentially Methylated Regions (DMRs) in Rlf MommeD28/MommeD28 fetal liver  
Symbol Gene Name CpG sites Direction 
Mean 
Diff 
Area 
Stat 
Rbmxl2 RNA binding motif protein, X-linked-like 2 223 hyper 0.21 818.6 
Basp1 Brain abundant, membrane attached signal protein 1 100 hyper 0.38 603.5 
Begain Brain enriched guanylate kinase-associated 120 hyper 0.21 386.7 
Hspa1b Heat shock protein 1B 89 hyper 0.20 361.7 
Lrrc4b Leucine rich repeat containing 4B 98 hyper 0.18 354.0 
Irgc1 Immunity related GTPase family, cinema 1 83 hyper 0.24 332.1 
Arhgef19 Rho guanine nucleotide exchange factor (gef) 19 56 hyper 0.33 326.3 
Jph2 Junctophilin 2 91 hyper 0.19 311.9 
Dtnbp1/Mylip Dystrobrevin binding protein 1/ Myosin regulatory light chain interacting protein 50 hyper 0.35 310.4 
Ptger1 Prostaglandin E receptor 4 78 hyper 0.25 305.6 
Panx2 Pannexin 2 95 hyper 0.20 304.7 
AI854703 Expressed sequence AI854703 68 hyper 0.24 295.5 
Nrtn Neurturin 97 hyper 0.15 293.6 
Lingo1 Leucine rich repeat and Ig domain containing 1 95 hyper 0.18 292.6 
B3gnt3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 102 hyper 0.20 289.7 
Zfp575 Zinc finger protein 575 59 hyper 0.29 278.8 
Otop3 Otopetrin 3 64 hyper 0.27 266.7 
Kcnc1 Potassium voltage gated channel, Shaw-related subfamily, member 1 78 hyper 0.15 262.8 
Adra1a Adrenoreceptor alpha 1A 48 hyper 0.30 255.6 
Padi1 Peptidyl arginine deiminase, type 1 39 hyper 0.42 251.2 
Smad3/Smad6 SMAD family member 3/ SMAD family member 6 50 hyper 0.26 240.6 
Kif21a/Abcd2 Kinesin family member 21A/ ATP-binding cassette, subfamily D (ALD), member 2 38 hyper 0.36 229.6 
Mmp9 Matrix metallopeptidase 9 39 hyper 0.31 227.5 
Ado/ Zfp365 2-aminoethanethiol (cysteamine) dioxygenase/ Zinc finger protein 365 39 hyper 0.32 221.7 
Sod3 Superoxide dismutase 3, extracellular 50 hyper 0.24 221.0 
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3.2.6 Validation of differentially methylated regions in MommeD34 
 
Following the identification of these 1,329 Rlf-DMRs, I asked whether regions 
identified as significantly differentially methylated in our GWBS dataset could be 
successfully validated using bisulphite sequencing in an independent mouse line. 
Two Rlf-DMRs identified following bioinformatic analysis of GWBS data were 
chosen for bisulphite sequencing validation. The MommeD34 mutant line was used 
for validation of MommeD28 GWBS results, and DNA underwent conversion and 
sequencing as described previously (refer Section 3.2.4). The first region chosen for 
validation was located between Smad3 and Smad6 (Smad family members 3 and 6) 
on Chromosome 9. This region has been validated as an active enhancer in 
transgenic mouse assays (VISTA database, www.enhancer.lbl.gov) (Visel et al., 
2007). Visel et al., 2007, identified candidate enhancer sequences from 
evolutionarily conserved sequences or ChIPseq data and cloned these elements into a 
vector containing a lacZ reporter construct (Kothary et al., 1989). The construct was 
then injected into fertilised oocytes and embryos harvested at E11.5, and stained for 
lacZ reporter activity, and enhancers defined as positive if they showed expression in 
more than three independent embryos (Pennacchio et al., 2006; Visel et al., 2007). 
Enhancer hs660, located between Smad3 and Smad6 showed expression in the 
forebrain and neural tube, Figure 3.11 (Visel et al., 2007).  
 
GWBS analysis of 50 CpG sites in this region found a 26% increase in 
methylation in Rlf MommeD28/MommeD28 fetal livers (53%) compared to wild-type (27%), 
Figure 3.11B. Bisulphite sequencing of 16 CpG sites within this region in the 
MommeD34 line revealed a 40%, p<0.0001, increase in methylation (87% in                            
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Rlf MommeD34/MommeD34 compared to 40% in Rlf +/+), Figure 3.11C. The observed 
increase in methylation in both homozygous MommeD28 and MommeD34 mice, 
suggests this is truly due to loss of Rlf in these mice. The difference in methylation of 
wild-type controls observed in the two methods and Rlf mutant lines may be a result 
of the region chosen for validation. Primers for bisulphite sequencing validation 
could only be designed to encompass 16 of the original 50 CpG sites. The high CG 
content of this region meant specific primers could not be designed to cover the 
whole region but instead only a small portion, resulting in the 16 CpG sites analysed 
being skewed to the second half of the differentially methylated region (Figure 
3.11B).  Performing bisulphite sequencing validation of all 50 CpG sites may reveal 
the level of methylation in wild-type mice from both Momme lines to be similar 
across the whole Rlf-DMR.  
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Figure 3.11: Methylation analysis of Smad3/Smad6 region in the fetal liver.  
A. In vivo reporter assay validating enhancer activity for VISTA enhancer hs660 that 
overlaps a Rlf-DMR located between Smad3/Smad6. Expression is neural tube and 
forebrain specific, obtained from VISTA enhancer browser (Visel et al., 2007). B. 
UCSC Genome Browser tracks of GWBS results for regions chosen for validation of 
Smad3/Smad6 region. The top 4 tracks display samples used in GWBS (n = 2                   
Rlf +/+, top, and 2 Rlf MommeD28/MommeD28, bottom). An increase in methylation is 
observed in the mutant versus the wild-type tracks. The PCR region analysed in 
bisulphite sequencing validation is highlighted below the tracks in purple. C. 
Bisulphite sequencing of region between Smad3/Smad6 on Chromosome 9 reveals an 
increase in DNA methylation in Rlf MommeD34/MommeD34 compared to wild-type fetal 
liver. Each column represents DNA from a single embryo (n = 3 for each genotype), 
each row is the sequence from a single cell and each circle represents one CpG site. 
Black circles represent methylated CpGs, white circles represent unmethylated 
CpGs, and lines (-) represent an ambiguously sequenced position where a CpG exists 
in the genomic sequence. (X2, p < 0.0001). 
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Figure 3.11: Methylation analysis of Smad3/6 region in the fetal liver. 
A.    B.  
 
 
     C.
A. B. 
A. B. 
Enhancer Hs660 
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The second region chosen for validation was an intragenic region on 
Chromosome 15 located over the last exon of Basp1 (Brain abundant, membrane 
attached signal protein 1).  GWBS analysis of this region found a 38% increase in 
methylation in Rlf MommeD28/MommeD28 (55%) compared to wild-type (16%), Figure 
3.12A.  Bisulphite sequencing of 39 of the 100 CpG sites present found a 40% 
increase, p<0.0001, in methylation in Rlf MommeD34/MommeD34 (82%) fetal liver 
compared to wild-type (41%), Figure 3.12B.  This was consistent with Dr Oey’s 
bioinformatics analysis of GWBS data.  The validation of GWBS results in an 
independent Momme line confirms that the regions identified are a result of loss of 
Rlf. Furthermore, validation of these two sites gives us confidence that the 
parameters used for defining Rlf-DMRs are suitable and effective. 
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Figure 3.12: Methylation analysis of Basp1 region in the fetal liver.  
A. UCSC Genome Browser tracks of GWBS results for regions chosen for validation 
of Basp1 region. The top 4 tracks display samples used in GWBS (n = 2 Rlf +/+, top, 
and 2 Rlf MommeD28/MommeD28, bottom), an increase in methylation is observed in the 
mutant versus the wild-type tracks. The CpG island (green bar) over the last exon of 
Basp1 (blue bar) is shown below GWBS tracks, as well as the PCR region analysed 
in bisulphite sequencing validation (purple). B. Bisulphite sequencing of Basp1 
region on Chromosome 15 reveals an increase in DNA methylation in                        
Rlf MommeD34/MommeD34 compared to wild-type fetal liver. Each column represents DNA 
from a single embryo (n = 3 for each genotype), each row is the sequence from a 
single cell and each circle represents one CpG site. Black circles represent 
methylated CpGs, white circles represent unmethylated CpGs, and lines (-) 
represents an ambiguously sequenced position where a CpG exists in the genomic 
sequence. (X2, p < 0.0001). 
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Figure 3.12: Methylation analysis of Basp1 region in the fetal liver.  
 
A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
B.  
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3.2.7 Rlf-DMRs may reflect active enhancers in early development or different 
tissues 
Following the successful validation of two Rlf-DMRs in an independent mouse 
lines, and the observation that one of these overlapped a validated enhancer, I wanted 
to determine whether other Rlf-DMRs also overlapped regulatory regions in the 
genome. Initial characterisation of the 1,329 Rlf-DMRs by Dr H Oey, found them to 
be short (~ 1kb) and occurring at regions of the genome that are less methylated than 
the surrounding DNA (Harten et al., 2015). These features are reminiscent of 
recently identified tissue specific DMRs (tsDMRs) (Hon et al., 2013a). tsDMRs are 
defined as regulatory elements thought to be involved in tissue specific 
differentiation. Some tsDMRs were found to mark enhancers that are dormant in 
adult tissue but active during embryonic development. Hon et al., 2013, termed these 
‘vestigial enhancers’ and noted they were hypomethylated and lacking active histone 
marks in adult tissue, but were likely to have been active at earlier stages in 
development.  
 
Given the similarities between Rlf-DMRs and tsDMRs I asked whether any 
DMRs were consistent between the two groups (bioinformatics was performed by Dr 
H. Oey and data interpreted by myself). Fifty-nine percent of Rlf-DMRs were found 
to overlap with a tsDMR (data not shown). As some tsDMRs overlap with active 
histone marks present in early development but not in adults, I then wanted to 
determine whether Rlf-DMRs overlapped with active histone marks in the fetal liver. 
Our data was compared to publicly available ENCODE E14.5 liver ChIPseq datasets, 
to determine whether Rlf-DMRs overlapped with histone marks associated with gene 
activation (The ENCODE Project Consortium, 2012). The histone marks investigated 
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were H3K4me1 (associated with enhancers), H3K27ac (distinguishes active 
enhancers from inactive enhancers) and H3K4me3 (associated with active 
promoters). Comparison of the Rlf-DMRs to ENCODE data by Dr H. Oey found 45 
of the 1,329 Rlf-DMRs were enriched for each of the three histone marks analysed, 
Figure 3.13A. Furthermore, 287 were enriched for the H3K4me1 mark alone, 140 
for H3K27ac, and 130 for H3K4me3.  However, the majority of the fetal liver Rlf-
DMRs (973 of the 1,329) did not overlap any of these histone marks, Figure 3.13A. 
One explanation for this could be that Rlf-DMRs may be active enhancers in another 
tissue or at a different stage of development.  
 
To address this I asked whether Rlf-DMRs overlap with active histone marks 
in other tissues. Our E14.5 fetal liver data was compared to ENCODE’s H3K4me1 
ChIPseq data in E14.5 brain and heart. An additional 478 Rlf-DMRs were enriched 
for the enhancer mark H3K4me1 in one or both of these tissues, Figure 3.13B. These 
results suggest that many, if not all, of the Rlf-DMRs without active histone marks in 
E14.5 liver may display enhancer marks in other tissues, one of which will be 
analysed in Section 4.2.16. 
 
Gene ontology analysis of the genes closest to the 1,329 Rlf-DMRs did not 
identify a specific class of gene except for an enrichment of genes encoding for 
transcription factors (Dr. H Oey, personal communication) (Harten et al., 2015). 
Consensus DNA binding motifs at Rlf-DMRs were also investigated with no motifs 
found to be enriched significantly over the background (Dr. H Oey, personal 
communication)  (Harten et al., 2015). 
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Figure 3.13: Rlf-DMRs overlap with active histone marks identified in 
ENCODE E14.5 liver, heart and brain tissue.  
A. Overlap of E14.5 fetal liver Rlf-DMRs with the histone marks H3K4me1, 
H3K4me3 and H3K27ac in E14.5 liver (obtained from ENCODE). B. Overlap of 
E14.5 fetal liver Rlf-DMRs with the enhancer mark H3K4me1 in ENCODE E14.5 
liver, heart and brain tissues. ChIPseq enrichment was defined as elements with 
ChIPseq Reads Per Kilobase per Million mapped (RPKM) greater than two-fold 
enriched over input RPKM for both replicates. Figure produced by H. Oey and 
published (Harten et al., 2015). 
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3.2.8 Chromatin immunoprecipitation sequencing of Rlf fetal liver 
 
The RNA-seq and GWBS experiments undertaken in this chapter do not 
indicate whether changes observed in the methylome or transcriptome are a direct 
result of the presence of Rlf binding at these sites. Previous work by our laboratory 
has found that some, but not all of the zinc fingers present in Rlf are capable of 
directly binding DNA (Harten et al., 2015).  As a result of this I wanted to determine 
where in the genome Rlf may bind using ChIPseq, which allows for genome-wide 
identifications of putative chromatin occupancy sites (Zhang et al., 2012b).  
 
Two independent Rlf antibodies designed to different termini of Rlf were used 
for ChIPseq analysis. The use of antibodies that that recognise different regions of 
Rlf is recommended by the ENCODE consortia for characterising antibody binding 
and is expected to be beneficial in defining the specificity of the Rlf antibodies 
(Landt et al., 2012). The commercial Abcam Rlf antibody (AB115011) is designed 
against the C-terminal end of human RLF (mouse amino acid 1845 – 1918), with 
93% homology to mouse Rlf, whilst the custom designed Rlf antibody, Ab1 (please 
refer Section 4.2.1), is designed against the N-terminal end of mouse Rlf (amino acid 
265-279) (refer Figure 4.1). Making these antibodies suitable, according to 
ENCODE recommendations, for ChIPseq identification of putative Rlf binding sites.  
 
Fetal liver was collected from eight Rlf +/+ E14.5 embryos that were then 
divided into four replicates, consisting of two livers in each replicate. Fetal liver was 
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then sent to ActiveMotif for chromatin extraction and immunoprecipitation using 
either the commercial Abcam Rlf antibody custom Rlf antibody Ab1.  
 
Sequencing of Abcam samples and their input control was undertaken on an 
Illumina HiSeq 2000 with 50 nt reads, whilst the Ab1 samples and their input control 
were sequenced on an Illumina NextSeq 500 with 75 nt reads. Sequencing was 
performed by ActiveMotif and all of the following bioinformatics analysis was 
undertaken by myself. All reads were mapped to the mouse genome (NCBI37/mm9) 
using the Burrows-Wheeler Aligner (BWA) algorithm with default settings (Li & 
Durbin, 2009). Reads passing Illuminas purity filter, aligned with no more than two 
mismatches and map uniquely to the genome were used in subsequent analyses. 
Samples from each experiment were normalised alongside of their respective input 
controls to the same number of unique alignments following the removal of duplicate 
reads (Table 3.8).   
 
Peaks were identified using model based analysis for ChIPseq (MACS v1.4.2) 
(Zhang et al., 2008) peak finding algorithm with a cut off p value of p = 1e-7 (Ab1) 
and p = 1e-5 (Abcam). Following ChIPseq with the Abcam antibody a different p 
value cut off was used due to the low number of unique alignments after the removal 
of duplicate reads (6.5 million, Table 3.8). This low number of unique alignments 
indicates there was low coverage in these samples which may have been the result of 
inadequate starting material or excessive amplification in the PCR step (Bailey et al., 
2013). In comparison the number of unique reads following the removal of 
duplicates for the Ab1 analysis was approximately three times greater (18.3 million, 
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Table 3.8), indicating a much higher coverage in these samples. Additionally, 
experiments analysing ChIPseq data of histone modifiers have identified broad 
peaks, spanning larger regions, that are less enriched than control samples, making 
less stringent p value cut offs more useful in initial analysis (Feng et al., 2012). As it 
is unknown where in the genome Rlf may bind or whether it is enriched across large 
or short regions, the less stringent cut off for this experiment was chosen.  
 
Each of the replicates that underwent ChIPseq with the Abcam antibody were 
found to have over 3,800 peaks, of which a small number were found to be on the 
ENCODE Blacklist for false-positive ChIPseq peaks (~100 in each sample Table 
3.9) and were excluded from further analysis. Following the removal of these false 
positive peaks over 3,700 peaks remained in each sample, 1,681 of which were found 
in both replicates, Table 3.9 (full data Appendix V).   
 
From the replicates that underwent ChIPseq with the custom designed Rlf 
antibody, one sample (Wild 5) was found to have > 9,000 peaks, whilst only 409 
peaks were identified in the other sample (Wild 6), Table 3.9 (Full data Appendix 
VI). No peaks were found to be on the ENCODE Blacklist for false-positive peaks in 
either sample and the false discovery rate was zero. Ninety-five percent of the peaks 
identified in Wild 6 overlapped with those identified in Wild 5, resulting in 381 
peaks called in both replicates.  
 
Comparison of results from the two independent ChIPseq experiments 
identified 202 putative Rlf binding sites that were in each of the biological replicates. 
 134 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 
Enrichment at these sites was observed to be higher in the Ab1 Wild 5 replicate than 
all other replicates, from both ChIPseq experiments. This may be indicative of 
reduced DNA pulled down during immunoprecipitation for the other replicates. A 
representative Rlf ChIP peak showing differences in enrichment between the 
replicates and ChIPseq experiments is shown in Figure 3.14. 
 
 
   Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 135 
Table 3.8: Sequencing Statistics following ChIPseq with Abcam and Ab1 Rlf antibodies 
Table 3.8: Sequencing statistics showing total number of reads for each sample, number of alignments for each sample, unique alignments, and 
number of alignments following removal of duplicate reads.  
Table 3.9: Number of Peaks identified following MACS analysis of Abcam and Ab1 Rlf ChIPseq  
 Abcam Rlf Antibody Custom Rlf Antibody 
 Wild 1 Wild 2 Wild 5 Wild 6 
Paired Peaks 1,195 1,219 1,859 308 
Final MACs peaks 3,984 3,835 9,005 409 
Predicted Fragment length 346 332 270 85 
Negative peaks 4 4 0 0 
 
 
0.10% 0.10% 0.00% 0.00% 
mm9 blacklisted 108 116 0 0 
filtered 3,876 3,719 0 0 
	  
Table 3.9: Peaks identified following MACs analysis of Abcam and Ab1 Rlf ChIPseq data, showing the number of peaks in each sample and the 
final number of peaks following the removal of false-positives. (Full list of peaks and genome co-ordinates Appendix V (Abcam) and VI (Ab1)).
 Abcam Rlf Antibody Custom Rlf Antibody 
 Wild 1 Wild 2 Input Wild 5 Wild 6 Input 
Total number of reads  27,771,300 21,328,600 35,982,257 29,966,334 29,782,883 39,935,321 
Total number of alignments (mm9) 24,520,594 19,867,160 34,726,380 24,244,952 24,068,296 32,405,757 
Unique alignments (-q 25) 19,313,752 15,800,299 27,016,755 20,629,207 20,393,786 26,981,092 
Unique alignments (without duplicate 
reads) 6,523,873 8,054,275 19,495,616 18,365,494 19,080,384 24,973,129 
Normalized tags 6,523,873 6,523,873 6,523,873 18,358,881 18,358,881 18,358,881 
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Figure 3.14: Representative ChIP peak identified in all four replicates from ChIPseq experiments with two independent Rlf antibodies.  
UCSC Genome Browser tracks of putative Rlf binding site at the transcription start site of Trim24, Tripartite motif-containing 24, (blue bars). 
The top four tracks display enrichment in each of the wild-type replicates used for ChIPseq (Abcam Wild 1 and 2, and Ab1 Wild 5 and 6), and 
the ChIP peak is highlighted (green box). The respective input controls tracks for each experiment are displayed in the bottom two tracks (blue). 
Greater enrichment at the putative binding site was observed in the Ab1 Wild5 replicate compared to the other replicates.  
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Following the identification of these 202 putative Rlf binding sites, I wanted to 
annotate where in the genome these sites may occur. To do this I used the web-based 
tool Peak Annotation and Visualisation (PAVIS) to annotate the Rlf ChIP peaks 
(Huang et al., 2013). Sixty-nine Rlf ChIP peaks were found to be intronic, whilst 45 
peaks were located in a 5' untranslated region and 40 peaks within 2.5 kb of a TSS, 
Figure 3.15. The observation of these putative Rlf binding sites close to TSS 
correlates with Rlf playing a role in transcriptional activation.  
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Rlf ChIP peaks overlap regulatory regions  
ChIP peaks identified using two different Rlf antibodies are classified according to 
their overlap with transcript features, the percentage and enrichment p value as 
calculated by PAVIS are provided.  
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I then wanted to determine whether any of these peaks overlapped with genes 
previously identified as being differentially expressed within the fetal liver. One 
caveat of using these 202 peaks is that some true Rlf binding sites may have been 
removed due to low enrichment resulting, in them not being identified in one or more 
replicates as a peak by MACS peak calling software (Yang et al., 2014).  This is 
important in the case of the Wild 6 biological replicate in which a lower number of 
peaks were identified compared to all other biological replicates. This may have 
resulted in a number of ‘true/good’ peaks being discarded prior to further analysis 
(Landt et al., 2012).  By choosing to analyse these 202 peaks present in all biological 
replicates across the two ChIPseq experiments, the likelihood of including peaks that 
are irreproducible, false or representative of noise has been reduced.   
 
Twenty-seven genes that were identified as differentially expressed (p < 0.05, 
FC > 1.2) in Rlf MommeD28/MommeD28 E14.5 liver were found to have a Rlf ChIP peak 
within 50 kb of their TSS (Figure 3.16). The majority of these ChIP peaks were 
proximal to genes that were down-regulated (n = 17) rather than up-regulated (n = 
10), consistent with Rlf being required for transcriptional activation. Seven of these 
genes also had a Rlf-DMR within 50 kb, whilst an additional 50 genes had a Rlf-
DMR within 50 kb but no Rlf ChIP peak (Table 3.10, Figure 3.16).  Repeating this 
analysis to find Rlf ChIP peaks and DMRs within 1 kb of the TSS of differentially 
expressed genes identified eleven genes with a ChIP peak and an additional two 
genes with both a ChIP peak and Rlf-DMR (Dnajb3, Mesdc, data not shown). 
Investigation of a random gene list of the same size (881 genes total) identified one 
gene that had both a ChIP peak and Rlf-DMR within 50 kb of its TSS (data not 
shown). None of the random genes had a Rlf ChIP peak and Rlf-DMR within 1 kb of 
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its TSS (data not shown). This suggests significantly more differentially expressed 
genes were found to have Rlf ChIP peaks than random (Fishers exact test, p 
<0.0001), and the peaks identified are true Rlf binding sites and are not false 
positives.  
 
I then wanted to determine whether putative Rlf binding sites overlapped with 
Rlf-DMRs identified in the fetal liver. Of the 202 peaks identified from both ChIPseq 
experiments, four Rlf-DMRs were found to be within 1 kb of a putative Rlf binding 
site; whilst forty Rlf-DMRs were found to be within 50 kb of a putative Rlf binding 
site (data not shown). Repeating this analysis using the two ChIPseq experiments as 
independent datasets identified 32 Abcam ChIP peaks (out of total 1,681), and eight 
Rlf Ab1 ChIP peaks (out of total 381) within 1 kb of a Rlf-DMR (data not shown). 
As few Rlf-DMRs and putative Rlf binding sites were found to overlap this suggests 
Rlf binding is not the cause of the change in methylation observed. Instead the 
presence of Rlf binding sites proximal to TSS may suggest that Rlf is stabilising or 
facilitating an interaction with a complex, through chromatin looping, that is bound 
to the Rlf-DMR and altering methylation. This will be discussed further in Section 
3.3. 
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A subset of genes differential ly expressed in E14.5 l iver are 
proximal to Rlf ChIP peaks and Rlf-DMRs 
Figure 3.16: A subset of genes differentially expressed in E14.5 liver are 
proximal to Rlf ChIP peaks and Rlf-DMRs 
Volcano plot depicting differentially expressed genes comparing RNA-seq analysis 
of E14.5 livers from Rlf +/+ and Rlf MommeD28/MommeD28 mice (n = 3 per genotype). 
Significantly differentially expressed genes, with an adjusted p value < 0.05, and fold 
change > 1.2, are presented as red, blue, green or purple data points. Genes that have 
either an Rlf-DMR or an Rlf-dependent ChIP peak within 50 kb of their TSS are 
highlighted by purple and blue diamonds, respectively. Green diamonds highlight 
genes with a change in both DNA methylation and an Rlf-dependent ChIP peak.  
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Table 3.10: Differentially expressed genes that have both a putative Rlf binding site and an Rlf DMR within 50 kb of their TSS. 
 
Table 3.10: Seven genes identified as being differentially expressed in E14.5 liver following RNA-seq analysis were found to have an Rlf ChIP 
peak and Rlf-DMR within 50 kb. The chromosome co-ordinates from both the ChIP peak and Rlf-DMR analysis are listed alongside of the genes 
fold change in expression (in Rlf MommeD28/MommeD28 mice) and adjusted p value determined by RNA-seq analysis.  
  
Gene Symbol 
 
Rlf ChIP peak  
co-ordinates 
Rlf-DMR 
Co-ordinates 
RNA seq statistics 
Chr Start End Start End 
Log 2  
Fold Change 
Adjusted P 
value 
Dnajb3 1 90,051,665 90,115,572 90,101,665 90,102,005 3.162 8.76E-06 
Ppapcd3 2 31,951,048 31,966,340 31,951,068 31,951,529 1.63 2.24E-07 
0610031J06Rik 3 88,128,945 88,135,235 88,169,691 88,170,207 0.80 4.77E-01 
Txn1 4 57,956,245 57,969,283 58,047,491 58,047,890 1.21 3.33E-01 
Atf7ip 6 136,467,372 136,518,358 136,503,640 136,504,622 1.20 1.97E-01 
Slc27a5 7 13,573,695 13,583,541 13,534,577 13,535,644 2.04 5.19E-04 
Mesdc 7 91,029,005 91,032,851 91,030,912 91,031,416 1.22 1.64E-01 
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While a number of putative Rlf binding sites have been identified here, it is 
important to note the technical limitations that can impact upon ChIPseq results. 
Antibody quality has been noted as an important factor in the literature. Studies have 
shown that whilst the majority of antibodies are suitable for ChIPseq, approximately 
25% have problems with their specificity (Elgin et al., 2011). Western blotting for 
Rlf using each of the independent Rlf antibodies investigated here, has found only 
one band to be present at the expected size for Rlf in the fetal liver (Figure 3.1 and 
Harten et al., 2015).  However, multiple bands in other tissue types have been 
observed with these antibodies, and this in turn may impact upon the sensitivity and 
specificity of these Rlf antibodies in ChIPseq experiments.   
 
Another limitation is the use of suitable controls in ChIPseq analysis. The 
analysis undertaken here utilised DNA input controls in the absence of Rlf null fetal 
liver DNA. The use of total sheared DNA as an input control is common in ChIPseq 
experiments and is recommended as by the ENCODE consortia (Landt et al., 2012). 
Repeating ChIPseq analysis or undertaking validation using ChIP-qPCR with Rlf null 
fetal liver controls would provide confirmation that the putative sites identified here 
are not due to non-specific antibody binding and are true Rlf binding sites.  
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3.3 DISCUSSION  
 
In this chapter I have shown for the first time that loss of Rlf alters the 
transcriptome and methylome in the mouse fetal liver.  Previous studies have 
suggested that Rlf is an enhancer of variegation and the data presented here 
correlates with these previous findings (Daxinger et al., 2013).  In this study I 
undertook RNA-seq in the MommeD28 mouse line and validated results using the 
independent mouse line, MommeD34. More genes were found to be down-regulated 
(n = 51) than up-regulated (n = 31) (Figure 3.A) and also the majority of DMRs 
were hypermethylated (Table 3.7) in Rlf MommeD28MommeD28 mice, consistent with Rlf 
being required for transcriptional activation.  
 
One of the genes identified as being markedly reduced in Rlf mutant livers was 
Hpd, which plays a key role in the tyrosine catabolism pathway (Figure 3.4B) 
(Tanaka et al., 2006).  Published studies show mutant mice null for Hpd resulting in 
no protein being produced have elevated tyrosine levels in the blood and no liver 
damage (Endo et al., 1991).  Histological analysis of Rlf mutant compared to wild-
type mice also showed no liver damage was present (Figure 3.1A).  However, we 
did not observe any increases in blood tyrosine levels in adult Rlf mutant mice 
(Figure 3.5A).  Interestingly the blood tyrosine levels observed in our adult 
compound heterozygous mice (63 - 120 µmol/L) were similar to that observed in 
control mice (50 – 150 µmol/L) in Endo et al., 1991, whilst Hpd-/- mice had 
approximately 10 fold increase in blood tyrosine (717 – 1,052 µmol/L).  As             
Rlf MommeD8/MommeD34 mice still express some Rlf protein, unlike Rlf MommeD34/MommeD34 
and Rlf MommeD28/MommeD28 which produce no Rlf protein (Daxinger et al., 2013), it is 
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likely that the amount of Hpd produced in our compound heterozygous adult mice          
(Rlf MommeD8/MommeD34) is sufficient for catalysing 4-hydroxyphenylpyruvate to 
homogentisate.  
 
The impact of loss of Rlf on tyrosine in the embryo was also investigated. 
During human fetal development the accumulation of available tyrosine decreases, 
late gestation babies were found to have decreased tyrosine accumulation compared 
with early gestational babies (Polin et al., 2004). This decrease in tyrosine 
accumulation correlates with independent studies showing the activity of Hpd 
increases towards late stage gestation (Fellman et al., 1972).  Here I have analysed 
tyrosine serum levels using embryos from the MommeD34 mouse line. Due to a 
marked decrease in Hpd mRNA expression (Figure 3.) an increase in tyrosine was 
anticipated. A confounding factor in this analysis is Rlf MommeD34/MommeD34 pups are 
smaller in size (Daxinger et al., 2013), as potential delays in development may also 
result in higher tyrosine concentration in mutant mice. However, a decrease in 
tyrosine was observed in homozygous offspring (Figure 3.6B).  A possible 
explanation for our results could be that fetal uptake of tyrosine from the maternal 
supply is low. Whilst the mothers primary tyrosine source is dietary based, the 
embryo may instead rely upon endogenous production of tyrosine and the small size 
of our mutant embryos results in less tyrosine production (Chien, 1991). 
Additionally, an alternate pathway resulting in the degradation of tyrosine may also 
be responsible. Further studies would be required to reveal the underlying 
mechanism in Rlf mutant mice. 
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Previously, the Whitelaw laboratory has shown an increase in methylation of 
the GFP transgene in mice homozygous for each of the Rlf mutant alleles MommeD8, 
MommeD28 and MommeD34, consistent with a decrease in the number of GFP 
expressing cells in mutant mice. As changes in transcription can also correlate with 
changes in methylation we decided to analyse methylation at two genes, Hpd and 
Prss50, which were found to be differentially expressed in MommeD28 mutant mice. 
A DHS site upstream of Hpd (Figure 3.7A) was analysed as these sites commonly 
mark enhancers, which can regulate genes that are both proximal and distal to the 
DHS (Heintzman et al., 2009; Li et al., 2012; Zhang et al., 2012a). Once cut offs 
were assigned the change in methylation at the Hpd region chosen was not 
considered to be substantial enough to be classified as an Rlf-DMR. As Rlf-DMRs 
were found to overlap with enhancer marks, which can act over long ranges, a region 
distal to Hpd may be controlling the mRNA expression of this gene. Making the 
investigation of this DHS site unsuitable for determining whether there is a 
correlation between methylation and gene expression of Hpd.  
 
Unlike the DHS site upstream of Hpd, which was not classified as an Rlf-
DMR, Rlf-DMRs were identified at CpG islands at the promoters of Prss50 and 
Basp1. The majority of promoters (72%) have been found to have a high CpG 
content, while 28% have CpG content that more closely resembles the overall 
genome CpG content. Genes that have CpG islands across their promoters have also 
been shown to be expressed in a number of different tissues (Saxonov et al., 2006). 
Interestingly, these promoters are mostly free of methylation, this correlates with our 
observation of low methylation of the CpG islands at the promoters of Prss50 and 
Basp1 (Figure 3.8 and Figure 3.12). GWBS revealed an increase in methylation 
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across both the Prss50 and Basp1 promoters, 15% and 40% respectively, and both 
were classified as a Rlf-DMR following GWBS analysis in the MommeD28 line. 
However, only the Basp1 region was successfully validated using bisulphite 
sequencing in the MommeD34 line. To be identified as a differentially methylated 
region Rlf-DMRs were required to have a greater than 15% change in methylation 
between the two genotypes. The Prss50 Rlf-DMR identified in GWBS was only just 
above this cut off with a 15.5% difference in methylation identified. As our GWBS 
was undertaken with two replicates per genotype, changes in methylation that are 
close to the fixed cut off may be difficult to validate successfully. For example, 
differences in biological variation between two replicates can have a greater 
influence on the efficiency of statistical testing, than if additional replicates are 
analysed. Making large changes such as those observed at Basp1 easier to validate. 
Alternatively, undertaking validation of the Prss50 site in the MommeD28 line, the 
same mouse line in which GWBS was completed, may uncover this change in 
methylation as being specific to the MommeD28 mutation and not the MommeD34 
mutation.  
 
Recent studies investigating differential methylation in different tissues in both 
mice and humans have found that tsDMRs overlap transcription factor binding sites 
and histone marks associated with active enhancers (H3K4me1 and H3K27ac) in at 
least one of the tissues or time-points studied. Hon et al., 2013, found that in late 
gestation and adult tissue some of these regions lacked active histone marks that 
were present early in gestation but retained a hypomethylated state. This suggests 
these hypomethylated regions represent regions that were active earlier in 
development. The Rlf-DMR we identified and validated between Smad3 and Smad6 
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in the fetal liver is an example of an Rlf-DMR without active histone marks (Figure 
3.11B). Interestingly, this region showed reproducible expression in the neural tube 
and forebrain (Figure 3.11A), and was defined as a positive enhancer at E11.5 (Visel 
et al., 2007). This could suggest that while some of the Rlf-DMRs were not enriched 
for active histone marks in the fetal liver, they may retain epigenetic memory from a 
different developmental time-point or tissue.  
 
No previous work has investigated where in the genome Rlf may bind and 
whether there is a correlation between Rlf binding, transcription and methylation. 
Here I have used two independent Rlf antibodies, designed to different termini of 
Rlf, to determine where in the fetal liver genome Rlf may bind. 202 putative Rlf 
binding sites were identified and the majority of these were found to be enriched 
proximal to gene transcription start sites (Figure 3.15). A small subset of these Rlf 
binding sites were also found to be proximal to differentially expressed genes and 
Rlf-DMRs in the fetal liver. Recent studies have shown DNA binding factors, such 
as CTCF and REST, can influence DNA methylation; for example, the binding of 
REST to methylated CpG poor regions leads to demethylation (Feldmann et al., 
2013; Stadler et al., 2011). Whilst we do not observe Rlf binding at the majority of 
Rlf-DMRS the binding of Rlf to the TSS of a gene may be facilitating an interaction 
with a complex (i.e. factor X) that binds to the Rlf-DMR/distal enhancer leading to 
demethylation. This may occur through chromatin looping bringing the distal 
enhancer into contact with the TSS allowing for Rlf to interact with factor X and 
stabilise its binding, Figure 3.16. By stabilising this binding the presence of Rlf may 
be influencing the loss of methylation at the distal site. In cells in which Rlf is 
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absent, this interaction and stabilisation cannot occur resulting in the distal region 
remaining methylated.  
 
Other possibilities as to why we did not observe Rlf binding at the majority of 
DMRs may include that these DMRs have been falsely identified as Rlf-DMRs, such 
as the case with the Rlf-DMR identified at Prss50, Figure 3.8, which was found to 
not be differentially methylated following clonal bisulphite sequencing.  Some of 
these differentially methylated regions may also be downstream effects occurring 
due to loss of Rlf, or that they are false positive DMRs.  For example, loss of UHRF1 
has been found to lead to decreases in DNA methylation as it is no longer able to 
recruit DNMT1 (Bostick et al., 2007). Loss of Rlf may lead to alterations in DNA 
methylation in a similar manner; however the mechanism through which this may 
occur is unclear. 
 
Recent work by our group has also identified fifty percent of Rlf-DMRs 
overlap with exons, significantly more than would be expected, ten percent, Figure 
3.9 (Harten et al., 2015). This is consistent with studies revealing many exons act as 
enhancers, having the ability to influence transcription either at the gene in which 
they reside or a neighbouring gene (Birnbaum et al., 2012). Fifteen percent of our 
putative Rlf ChIP peaks were also found to overlap with exons, Figure 3.15. Whilst 
these ChIP peaks did not overlap with DMRs the high stringency cut-offs in defining 
a ChIP peak from the two independent experiments used here may have removed 
ChIP peaks that did. Further investigations of putative Rlf binding sites throughout 
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the genome with an antibody of appropriate quality may allow for the mechanism 
through which Rlf is acting to be elucidated.  
 
These results support previous findings by or laboratory that Rlf is required for 
transcriptional activation, however there may be other factors in addition to Rlf that 
are required for transcription to be affected. As Rlf-DMRs are thought to represent 
active enhancers in other tissues or from earlier stages in development, future 
experiments investigating the impact of Rlf on chromosome conformation in 
different tissues and/or developmental time-points may reveal how Rlf acts as an 
epigenetic modifier.  
 
 
 
 
 
 
Figure 3.17: Proposed mechanism of Rlf 
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Proposed mechanism by which Rlf alters transcription. Rlf binding of TSS stabilises 
an interaction with a complex (factor X) that binds to distal enhancer and leads to 
demethylation of the distal enhancers.   
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3.4 FUTURE DIRECTIONS  
 
As a large number of epigenetic modifiers act within complexes, and Rlf-
DMRs have been found to overlap regions with active histone marks undertaking 
chromosome conformation capture would be helpful in determining the target genes 
of these enhancers. This may in turn identify interactions between genes with Rlf 
bound at the TSS and Rlf-DMRs.   
 
One caveat to this experiment is that the interactions that may occur within the 
cell are transient or only present at distinct times in development and not in all 
tissues/cell types.  Also epigenetic modifiers can work together and/ or cross regulate 
each other differently in different cell types. Thus selecting the correct cell type in 
addition to developmental time-point is critical for ensuring accurate information is 
generated.  As no previous studies have investigated the importance of Rlf in 
development and/or disease progression, the identification of a role for Rlf in a 
specific pathway or disease would greatly influence how future experiments are 
designed. For example, a putative role for Rlf in cardiac development has been 
identified in this PhD (refer Chapter 4), undertaking chromatin chromosome 
conformation capture in a cardiac cell type (e.g. cardiomyocytes or epicardial cells), 
may reveal interactions that occur in cardiac cells that are required for cardiac 
development. The ability to obtain sufficient amounts of tissue/DNA from early 
developmental time-points sets limitations on being able to validly perform these 
experiments. 
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Chapter 4: Investigating the consequence of 
loss of Rlf on development 
4.1 INTRODUCTION 
Mutations in many epigenetic modifiers have been associated with embryonic 
lethality and/or developmental delay (Daxinger et al., 2013; Okano et al., 1999). 
Preliminary studies by the Whitelaw laboratory have found Rlf mutants to weigh less 
than their wild-type littermates and are present in reduced numbers at weaning, 
however no further analysis of phenotype was undertaken (Ashe et al., 2008; 
Daxinger et al., 2013). Cardiovascular defects are a potential cause of perinatal 
lethality and several epigenetic modifiers identified in the Momme screen have been 
found to play critical roles in cardiac development (Conway et al., 2003; Hang et al., 
2010; Montgomery et al., 2007). The role of Rlf in the developing heart will be of 
particular focus in this chapter. 
  
4.1.1 Epigenetics and heart development 
 
The heart is the first functional organ formed in the developing embryo, and 
consists of various cell types such as cardiomyocytes, fibroblasts, epicardial and 
smooth muscle cells (Banerjee et al., 2007).  Loss of epigenetic modifiers, such as 
Hdac1, Hdac2 and Lsd1 (lysine specific demethylase 1), have been shown to result 
in heart defects and perinatal lethality (Montgomery et al., 2007; Nicholson et al., 
2013). Global deletion of Hdac2 results in cardiac defects and perinatal lethality, 
whilst global deletion of Hdac1 results in embryonic lethality before E9.5 
(Montgomery et al., 2007). Additionally, conditional deletion of both Hdac1 and 
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Hdac2 in cardiomyocytes resulted in perinatal lethality due to left ventricle dilation 
and cardiac stress (Montgomery et al., 2007).  Other studies have shown reduced 
Lsd1 expression in mice also results in perinatal lethality and ventricular septal 
defects (Nicholson et al., 2013). Both Hdac1 and Hdac2 have been shown to bind the 
Lsd1-CoREST complex, which plays a role in transcriptional repression (You et al., 
2001).  Investigations by our lab have also identified members of the Lsd1-CoREST 
(rest co-repressor 1) complex to be putative binding partners of Rlf in-vitro (Harten 
et al., 2015). Taking these findings into account it is plausible that Rlf may also play 
a role in cardiac development. 
 
4.1.2 The placenta and cardiovascular development 
 
The placenta also plays an important role in the regulation and development of 
the cardiovascular system (Thornburg et al., 2010). In some cases abnormal placental 
development is the underlying cause of abnormal cardiac development and 
congenital heart disease. For example, mice deficient in Pparγ (peroxisome 
proliferator-activated receptor γ) were found to have placental and cardiac defects 
(Barak et al., 1999). When Pparγ null embryos were aggregated with wild-type 
placentas the cardiac defect was corrected (Barak et al., 1999). However placental 
defects are not always the cause of observed cardiac defects. Pbrm1 (Polybromo 1) is 
a subunit unique to the Polybromo Associated Factor (PBAF) chromatin remodelling 
complex, and is expressed in many tissues including the heart and placenta (Wang et 
al., 2004). The left side of the heart in Pbrm1 deficient mice was found to be 
underdeveloped compared to wild-type mice, and an accumulation of trophoblast 
cells in the placenta was also observed (Wang et al., 2004). It was thought this could 
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compromise fetal-maternal exchange. When diploid Pbrm1 null embryos were 
aggregated with wild-type embryonic stem cells, which contributed to the embryo 
but not the placenta, the embryonic heart defect was rescued (Wang et al., 2004). 
These results suggest the defects occurring due to depletion of Pbrm1 in the heart 
and placenta are independent of one another, and while a placental defect may be 
present it may not be the driver of the cardiac defect observed. In this chapter 
preliminary investigations of the placenta in Rlf mutant mice will also be reported.  
 
This chapter will determine whether Rlf is critical for development in the 
mouse using the Rlf null mouse line MommeD28.  
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4.2 RESULTS 
4.2.1 Designing custom antibodies for Rlf  
 
Currently very little is known about Rlf and in which tissues it is expressed. A 
good quality antibody is important for being able to accurately define in which tissue 
and/or cell types a protein is expressed, using methods such as Western blotting and 
immunohistochemistry.  
 
There are two commercial antibodies for Rlf; however each of these has 
limitations. The first antibody from Atlas (HPA057300) is a polyclonal antibody 
designed against human RLF that aligns to the middle of the mouse Rlf protein 
sequence but with poor homology (~63%), Figure 4.1. This antibody has been 
previously tested by other members of the laboratory and has been found to be 
unsuitable for use in mouse tissue (data not shown). The second commercial 
antibody from Abcam (AB115011) is also a polyclonal antibody designed against the 
C-terminal end of human RLF, Figure 4.1. The antigen sequence for this antibody 
also has strong homology to the mouse Rlf protein sequence (~93%).  
 
Western blotting with the Abcam antibody in Rlf tissue has identified multiple 
bands at both the expected size for Rlf and also at lower molecular weight sizes (data 
not shown). Additionally, at the beginning of this PhD Abcam began to supply a new 
lot number for this Rlf antibody which, on testing, was found to be less sensitive and 
specific than the previously supplied lot number. For these reasons we aimed to 
design our own mouse Rlf specific antibody to reduce variability and maintain a 
consistent supply. Three antigen sequences against mouse Rlf were chosen using 
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GenScript’s OptimumAntigen™ design tool to ensure they would be strongly 
antigenic. The peptide antigens were produced by GenScript, who injected them into 
rabbits for production of polyclonal antibodies. Antibody containing serum was 
collected from the rabbits and designated Ab1, Ab2 and Ab3, shown in Figure 4.1.   
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Figure 4.1:  Mouse Rlf protein coding sequence.   
Alternate exons are identified in blue and black text and the location for each of the Rlf mutations, MommeD28, MommeD34 and MommeD8 are 
indicated by red arrows and green text, and the 16 putative zinc finger domains highlighted in orange. The two commercial antibodies are 
outlined by a pink text box and the three custom designed antibodies highlighted in black (Ab1), blue (Ab2) and green (Ab3). 
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4.2.2 Testing unpurified custom designed antibodies for Rlf 
 
Each of the new custom antibodies was first tested unpurified alongside of the 
Abcam polyclonal Rlf antibody using adult wild-type heart and brain tissue, Figure 
4.2. Brain tissue was chosen as this has previously been used to validate Rlf 
expression in wild-type and homozygous fetal mouse tissue (Daxinger et al., 2013).  
The heart was chosen as an independent tissue that has previously shown high Rlf 
expression using the Abcam antibody (data not shown). 
 
Initial testing was carried out using adult wild-type tissue due to its ready 
availability. A single heart and brain tissue sample from one male adult mouse was 
used for testing of each of the antibodies, to reduce potential variability between 
samples. The unpurified antibodies were each found to have a higher sensitivity for 
Rlf (~250 kDa) in the heart than the Abcam antibody which required a longer 
exposure. No bands were observed in the adult brain samples, suggesting Rlf is not 
expressed in the adult brain and use of this tissue for validation is not appropriate.  
Lower molecular weight bands not at the expected size for Rlf were also observed in 
the heart, ~150 kDa, and brain, ~100 kDa, following blotting with the Abcam 
antibody, Figure 4.2.  These lower molecular weight bands were also observed 
following blotting with each of the unpurified antibodies.   
 
Investigation of annotated Rlf transcripts in the publicly available database 
Ensembl, Release 83, reveals three potential transcripts for Rlf (Zerbino et al., 2015). 
These isoforms are predicted to produce Rlf protein of 12, 206, and 217 kDa in size, 
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suggesting the lower molecular weight bands observed (100 and 150 kDa), may be 
non-specific bands. Unpurified Ab2 was found to have the most bands present that 
were not at the expected size for Rlf and it was decided to not continue validation for 
this antibody, Figure 4.2. From these Western blots unpurified Ab1 and Ab3 were 
chosen for further analysis.  
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Figure 4.2: Testing of unpurified custom Rlf antibodies. 
Western blot of Rlf +/+ adult heart (H) and brain (B) tissue comparing Abcam 
polyclonal antibody and unpurified custom antibodies, Ab1, Ab2 and Ab3. Bands at 
the expected size for Rlf (u) and not expected size (w) are indicated. 
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4.2.3 Testing of purified custom designed antibodies for Rlf  
 
Ab1 and Ab3 were purified according to the GenScript protocol and eluted as 
either a single fraction (Ab1) or eleven separate fractions (Ab3). The single Ab1 
fraction was then tested using Rlf +/+, Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 
fetal brain tissue as had been used in the past (Daxinger et al., 2013). One band at the 
expected size for Rlf was observed in wild-type but not homozygous tissue, Figure 
4.3, suggesting this is the correct band for Rlf. No bands at other sizes were observed 
in these samples for Ab1.  
 
Each of the eleven purified fractions for Ab3 were also tested using wild-type 
fetal head tissue, Figure 4.4. Following purification sensitivity of the antibody 
appeared to be reduced compared to previous Western blots. Of the eleven fractions 
faint bands at both the expected size for Rlf (~250 kDa) were observed and also 
bands lower molecular weight than the expected size for Rlf (~100, 90, 75 and 40 
kDa each). Fractions 4, 5, 8 and 9 were each found to have a faint a band at the 
expected size for Rlf, Figure 4.4. No bands at the expected size for Rlf or at other 
sizes were observed in either purified Ab3 fraction 1 or 2, Figure 4.4. It was decided 
to use fractions 4 and 8 for further validation as these fractions were in the middle of 
the two groups of fractions found to have bands at the expected size for Rlf present. 
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Figure 4.3: Testing of purified custom designed Ab1 for Rlf. 
Western blot of purified Ab1 single fraction of Rlf +/+, Rlf MommeD34/MommeD34 and       
Rlf MommeD28/MommeD28 fetal head showing Rlf protein expression in wild-type but not 
homozygous tissue.    
 
 
Figure 4.4: Testing of purified custom designed Ab3 for Rlf. 
Western blot of 11 fractions purified from Ab3 using Rlf +/+ fetal head showing Rlf 
protein expression in wild-type tissue.  u Indicates bands at the expected size for 
Rlf, w indicates bands not at the expected size for Rlf.  
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Ab3 fractions 4 and 8 (Ab3.4 and Ab3.8, respectively) were tested alongside 
purified Ab1 and the Abcam antibody to determine which antibody would be the best 
for use in future experiments. Rlf +/+ and Rlf MommeD28/MommeD28 fetal head tissue was 
used to determine which bands are specific to Rlf. A band at the expected size for Rlf 
was observed following Western blotting with Ab1, Ab3.4 and the Abcam antibody, 
but not Ab3.8 in Rlf +/+ tissue, Figure 4.5. In each case this band was not present in 
Rlf MommeD28/MommeD28, confirming that these antibodies detect Rlf. The antibodies 
were also found to detect additional bands at lower molecular weights, which were 
present in both wild-type and homozygous tissue, Figure 4.5, consistent with these 
bands being non-specific. Of the antibodies tested Ab1 was found to have the 
greatest sensitivity to Rlf, as such it was decided to use this antibody for future 
experimentation. However, the presence of multiple bands not at the expected size 
for Rlf prevents this from being a suitable antibody for immunohistochemistry 
analysis. 
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Figure 4.5: Further validation of custom designed antibodies. 
Western blot testing of purified Ab1, purified Ab3 fractions 4 (Ab3.4) and 8 (Ab3.8) 
and polyclonal Abcam antibody using MommeD28 wild-type and homozygous fetal 
head tissue, shows Ab1 has the greatest sensitivity for Rlf and no Rlf expression in 
mutant tissue. u Indicates bands at the expected size for Rlf, w indicates bands not 
at the expected size for Rlf. 
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4.2.4 Rlf is expressed across a range of different tissue 
 
Analysis of human RLF mRNA in adult and fetal tissue by Makela et al., 1995, 
found RLF is expressed in both adult and fetal heart, brain, spleen, liver, and muscle 
as well as fetal lung but not adult lung.  No studies have analysed the protein 
expression of human RLF or mouse Rlf.  I used the custom designed Rlf antibody, 
Ab1, for Western blot analysis of a number of fetal, postnatal and adult tissues, as 
this was found to have a greater sensitivity and specificity than other Rlf antibodies.  
 
Analysis of Rlf expression in four independent eight week old mice found Rlf 
to be expressed across a range of tissues including brain, heart and liver. 
Representative blots from two of the mice are shown in Figure 4.6. Lower molecular 
weight bands were also present in heart and muscle tissue (~150 and 100 kDa), but 
were not observed in any of the other tissues tested. Also of note is weaker bands at 
the expected size for Rlf were observed in the brain of two mice (Figure 4.6A, and 
data not shown) but not the other two mice studied (Figure 4.6B, and data not 
shown). This suggests Rlf expression in these tissues is near to the lower detection 
limit of Ab1.  
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Figure 4.6: Western blotting shows Rlf is widely expressed adult mouse tissue. 
Western blot of two independent wild-type adult mice showing Rlf protein 
expression in different tissues. u Indicates bands at the expected size for Rlf, w 
indicates bands not at the expected size for Rlf. γ-tubulin was used as a loading 
control for all Western blots.   
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Next I asked whether Rlf was expressed in a subset of these tissues at other 
stages in development. Analysis of whole E10.5 embryos as well as brain, heart, liver 
(E14.5 and E18.5), and lung and kidney (E18.5 only), also showed Rlf to be widely 
expressed at these time-points, Figure 4.7A.   
 
The lower molecular weight bands previously observed in adult heart tissue 
were also observed in fetal heart (~150 kDa but not ~100 kDa) and E10.5 whole 
embryo and fetal brain (~100 kDa each), Figure 4.7A. To investigate whether these 
lower molecular weight bands represented different Rlf isoforms I performed 
Western blots using Rlf +/+, Rlf MommeD28/+ and Rlf MommeD28/MommeD28 tissue. Postnatal 
day 0 (P0) brain and heart tissue from the MommeD28 line were used as positive and 
negative controls. A reduction in the 250 kDa Rlf band was observed in 
heterozygous tissue and not present in homozygous tissue as expected, Figure 4.7B.  
No change was observed between the genotypes of the lower molecular weight 150 
kDa (heart) and 120 kDa (brain) bands, Figure 4.7B.   
 
These results suggest that the 150 kDa and 100 kDa bands are non-specific to 
Rlf, rather than alternative Rlf isoforms. Taken together these Western blots show 
that Rlf is widely expressed from an early developmental time-point and is expressed 
in multiple tissues throughout development and adulthood.  
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Figure 4.7: Western blotting shows Rlf is widely expressed in fetal mouse tissue. 
A. Western blotting shows Rlf protein expression in a number of fetal and postnatal 
(P0) tissues. B. Western blotting of P0 Rlf +/+, Rlf MommeD28/+ and Rlf MommeD28/MommeD28 
heart and brain tissue shows a reduction in expression of Rlf in mutant mice.            
γ-tubulin was used as a loading control for all Western blots.   
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4.2.5 Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 mice are viable in late 
gestation 
 
Previous research in the Whitelaw Laboratory found the number of live 
homozygous MommeD34 and MommeD28 mice to be significantly reduced at three 
weeks (Daxinger et al., 2013).  To determine whether these mice were dying before 
or after birth, I established intercrosses for each of the Momme null lines.  As dams 
have been found to give birth at E19.5, embryos were analysed at E18.5 to determine 
whether Rlf mutants are viable at late gestation.  Expected Mendelian ratios were 
observed for both the MommeD28 and MommeD34 lines at E18.5 and E14.5, Table 
4.1. This data, in combination with data collected by other lab members and myself 
at three weeks (Daxinger et al., 2013), suggests Rlf MommeD28/MommeD28 and                  
Rlf MommeD34/MommeD34 embryos are viable just prior to birth and death is occurring 
between E18.5 and weaning. 
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Table 4.1: Offspring from heterozygous intercrosses of Rlf mutant mice.  
 
 
 
 
 
 
 
 
Table 4.1: Offspring at 3 weeks, E18.5 and E14.5 from Rlf Momme intercrosses. Tabulated data shows the number of observed mice and (% of 
total), 3 week data (grey) collected by myself and S. Harten (Daxinger et al., 2013), E18.5 and E14.5 (white) data collected by myself.  
 
Line Age +/+ -/+ -/- Chi-Test Reference 
Rlf MommeD8/+ 3 weeks 185 (31) 329 (55) 86 (14) <0.0001 (Daxinger et al., 2013), this study 
Rlf MommeD28/+ 3 weeks 69 (36) 119 (63) 1 (1) <0.0001 (Daxinger et al., 2013), this study 
Rlf MommeD34/+ 3 weeks 46 (32) 86 (60) 12 (8) <0.0001 (Daxinger et al., 2013), this study 
Rlf MommeD28/+ E18.5 26 (23) 68 (59) 20 (18) n.s This study (unpublished) 
Rlf MommeD34/+ E18.5 18 (31) 28 (48) 12 (21) n.s This study (unpublished) 
Rlf MommeD28/+ E14.5 47 (22) 117 (56) 45 (22) n.s This study (unpublished) 
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4.2.6 Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 mice weigh less than wild-
type littermates  
 
To determine whether there were any gross differences in development 
between genotypes in each of the Rlf null lines, the weights of E18.5 and E14.5 
embryos were measured.  Each embryo was carefully patted dry using lint free tissue 
to remove any excess liquid that may affect measurements.  
 
E18.5 Rlf MommeD28/MommeD28 embryos were found to weigh significantly less 
(0.731 g, ± 0.028) than their wild-type (1.144 g, ± 0.019) and heterozygous (1.049 g, 
± 0.020) littermates, Figure 4.8A. A similar result was also observed in the 
MommeD34 line, with Rlf MommeD34/MommeD34 embryos weighing less (0.767 g, ± 0.035) 
than both wild-type (1.059 g, ± 0.049) and heterozygous (0.965 g, ± 0.052) 
littermates, Figure 4.8B.  The difference in weight at E18.5 between wild-type and 
homozygous MommeD28, Figure 4.8C, and MommeD34 embryos (data not shown) 
was evident following the removal of embryos from the uterus prior to weighing.  
These findings are consistent with previously published data at E17.5 (MommeD34) 
and E16.5 (MommeD28) (Daxinger et al., 2013).   The observation of reduced weight 
in homozygous and heterozygous offspring from both the MommeD28 and 
MommeD34 mouse lines suggest that alterations in dosage of Rlf impact upon 
embryonic development.  
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Figure 4.8: E18.5 embryos homozygous for MommeD28 or MommeD34 weigh 
less than wild-type littermates. 
A, B. Rlf MommeD28/MommeD28 and Rlf MommeD28/+(A) and Rlf MommeD34/MommeD34 and        
Rlf MommeD34/+ (B) embryos show a significant decrease in weight versus wild-type 
littermates at E18.5.. n = 7 litters (MommeD28), and 3 litters (MommeD34). Error 
bars represent SEM and Student’s t-test was used to calculate p values (**** p < 
0.0001, **p < 0.01, *p < 0.05). Weights for each litter were normalised to the 
average weight of wild-type littermates, and only litters with more than one wild-
type embryo were included. C. Representative Rlf MommeD28/MommeD28 and Rlf +/+ E18.5 
littermates showing an observable difference in size between genotypes. Scale bar = 
1 cm. Each data point represents an individual embryo.  
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To determine whether the observed difference in weight at E18.5 was present 
at an earlier developmental time-point MommeD28 E14.5 embryos were also 
investigated.  Unlike the E18.5 embryos no overt difference in gross appearance 
between homozygous and wild-type MommeD28 E14.5 littermates was observed 
following removal from the uterus, Figure 4.9A.  Rlf MommeD28/MommeD28 embryos at 
this time-point were found to weigh significantly less (0.200 g, ± 0.007) than their 
wild-type (0.213 g, ± 0.004) and heterozygous (0.222 g, ± 0.003) littermates, Figure 
4.9B.  No difference was observed at this time-point between wild-type and 
heterozygous littermates, Figure 4.9B, suggesting reduced dosage of Rlf does not 
impact on development until later in gestation. The observation of reduced weight in 
mid-gestation homozygous embryos provides evidence that Rlf plays an important 
role earlier in embryo development.  
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Figure 4.9: E14.5 Rlf MommeD28/MommeD28 offspring weigh less than their wild-type 
littermates. 
A. No overt difference in size between Rlf MommeD28/MommeD28 and Rlf +/+ littermates is 
observed at E14.5. Scale bar = 5 mm. B. Rlf MommeD28/MommeD28 embryos at E14.5 from 
MommeD28 intercross weigh significantly less than wild-type and heterozygous 
littermates. Each data point represents an individual embryo. n = 12 litters. Error bars 
represent SEM and Student’s t-test was used to calculate p values (**p < 0.01). 
Weights for each litter were normalised to the average weight of wild-type 
littermates, and only litters with more than one wild-type embryo were included.  
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4.2.7 Identification of a heart defect in Rlf MommeD28/MommeD28 and                        
Rlf MommeD34/MommeD34 embryos 
 
A number of epigenetic modifiers identified in the Momme screen have been 
found by others to play key roles in cardiac maturation and differentiation and 
perinatal lethality is often a sign of a cardiovascular defect (Chang & Bruneau, 2012; 
Conway et al., 2003; Wang et al., 2004).  Additionally human infants that are small 
for gestational age are twice as likely to have congenital heart defects (Malik et al., 
2007).  As Rlf mutants were found to weigh less and have reduced viability (Figure 
4.9; Table 4.1), I asked whether loss of Rlf in these mice alters cardiac development 
in E14.5 mid-gestation embryos.   
 
I collected whole E14.5 embryos from the MommeD28 line for histological 
analysis (n = 12 per genotype).  A tail biopsy was collected for genotyping, heads 
were removed and bodies fixed in 4% PFA overnight.  Embryos were then washed 
twice with PBS and stored in 70% ethanol.  Rlf +/+ and Rlf MommeD28/MommeD28 matched 
littermates were taken to QIMRB histopathology services for embedding in paraffin, 
before sectioning and undergoing haematoxylin and eosin staining.  Whole embryos 
were used to reduce artefacts that could be introduced from handling of the heart, and 
to allow for trouble-free orientation, enabling accurate sections at the level of the 
tricuspid valve to be collected across the cohort.  I then analysed the slides blind to 
genotype to reduce any potential observer bias. Of the 24 embryos analysed all but 
one were successfully classified into two distinct groups that aligned with their 
genotype based upon their morphology, Table 4.2. One heart, Rlf +/+10.6, was 
similar in morphology to its Rlf MommeD28/MommeD28 littermate and also the other 
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homozygous mutant hearts analysed. This sample was re-genotyped and confirmed 
to be a true wild-type embryo, and the difference in morphology in this heart to other 
wild-types may be independent of the MommeD28 mutation. Histology images for 
all 24 hearts analysed are supplied in Appendix VII.  
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Table 4.2: E14.5 embryos used to analyse the heart in the MommeD28 line. All 
hearts except for one (10.6) separated into two distinct phenotypes that correctly 
aligned with genotype. Embryo number corresponds to litter number (first) and 
embryo number within litter (second). V, ventricle; WT, wild-type; M, mutant. 
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Table 4.2: Observed heart phenotypes in mouse cohort. 
	  
Embryo 
Number Observations 
Predicted 
Genotype Genotype 
3.1 Thin V. wall and septum with fenestration M Rlf MommeD28/MommeD28 
3.3 Well defined V wall and solid septum WT Rlf +/+ 
4.1 Thick V. walls and solid septum WT Rlf +/+ 
4.2 Thin V. walls with deep trabecular recesses M Rlf MommeD28/MommeD28 
4.4 Thin V. walls with deep trabecular recesses, also 
had fenestration at septal base 
M Rlf MommeD28/MommeD28 
4.6 Thick V. walls and solid septum WT Rlf +/+ 
5.6 Thick V. walls and solid septum WT Rlf +/+ 
5.7 Thin V. walls and septum also thin M Rlf MommeD28/MommeD28 
6.7 Thick V. walls and solid septum WT Rlf +/+ 
6.8 Thin V. walls with deep trabecular recesses M Rlf MommeD28/MommeD28 
7.4 Thick V. walls and solid septum WT Rlf +/+ 
7.7 Thin V. wall and V. oddly shaped M Rlf MommeD28/MommeD28 
7.9 Thin V. walls with deep trabecular recesses, also 
had fenestration at septum 
M Rlf MommeD28/MommeD28 
8.6 Thin V. walls with deep trabecular recesses, also 
had fenestration at septum 
M Rlf MommeD28/MommeD28 
8.7 Thick V. walls and solid septum WT Rlf +/+ 
8.8 Thick V. walls and solid septum, some gaps 
between epicardium and myocardium 
WT Rlf +/+ 
10.6 Thin V. wall, whole heart very enlarged M Rlf +/+ 
10.11 Thin V. walls and fenestrated septum M Rlf MommeD28/MommeD28 
12.1 Thin V. wall and thin septum M Rlf MommeD28/MommeD28 
12.2 Thick V. walls and solid septum WT Rlf +/+ 
14.2 Thick V. walls and solid septum WT Rlf +/+ 
14.4 Thin V. walls and fenestrated septum M Rlf MommeD28/MommeD28 
14.6 Thick V. wall, thin septal base  WT Rlf +/+ 
14.8 Thin V. walls and fenestrated septum M Rlf MommeD28/MommeD28 
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Histological analysis of MommeD28 E14.5 embryos identified a potential heart 
defect in Rlf MommeD28/MommeD28 embryos, Figure 4.10 and Appendix VII. Slides were 
analysed in collaboration with Prof R. Harvey, VCCRI, an international expert in 
cardiac development, and Rlf MommeD28/MommeD28 hearts were found to display a thin 
compact layer and over abundance of trabeculae, a subset also displayed fenestrated 
interventricular septums, Figure 4.10 i-ii. These features are similar to ventricular 
non-compaction phenotypes observed in humans (Prof. R. Harvey, personal 
communication).  
 
As these hearts displayed a thin compact layer I wanted to determine whether 
there was a difference in ventricle thickness between the two genotypes. Ventricle 
wall thickness was measured towards the apex of the fetal heart, as is commonly 
reported in the literature (Vicente-Steijn et al., 2015; Yang et al., 2012). A minimum 
of five measurements were taken from three serial sections of each embryo and 
analysed blind to genotype. A significant difference in ventricle wall thickness was 
observed in both the left and ventricles of Rlf MommeD28/MommeD28 hearts, supporting the 
observed differences in morphology, Figure 4.11A-B. 
 
 
 
 
 
 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 179 
                                                 
Figure 4.10: Rlf MommeD28/MommeD28 mutant mice display ventricular and septal 
defects in the heart at E14.5. 
Histological analysis of E14.5 Rlf +/+and Rlf MommeD28/MommeD28 embryos. Whole 
embryos were fixed and sectioned transversely at the tricuspid valve of the heart. i-ii, 
are high magnification images Rlf MommeD28/MommeD28 of mutant hearts indicating thin 
compact layer (arrow), and fenestrated septum (arrowhead). RA, right atria; RV, 
right ventricle; LV, left ventricle; IVS, interventricular septum; CL, compact layer. n 
= minimum 12 per genotype, scale bar = 500 µm, and 200 µm (i-ii). (Histology of all 
embryos investigated supplied in Appendix VII). 
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A.      B. 
 
Figure 4.11: Rlf MommeD28/MommeD28 hearts have thin ventricle walls. 
Quantification of ventricle thickness in Rlf MommeD28/MommeD28 and Rlf +/+ hearts, 
showing both the left (A) and right (B) ventricles are thinner in Rlf mutants. n = 12 
per genotype. Error bars represent SEM and Student’s t-test was used to calculate p 
values (**p < 0.01, ****p < 0.0001).  
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To confirm whether the defects observed could be attributable to loss of Rlf, I 
also investigated E14.5 Rlf +/+ and Rlf MommeD34/MommeD34 embryos (n = 6 per 
genotype). Homozygous MommeD34 embryos were found to display a similar 
phenotype to that observed in Rlf MommeD28/MommeD28 embryos, Figure 4.12 and 
Appendix VII. Again the ventricle walls of Rlf MommeD34/MommeD34 hearts were found 
to be significantly thinner than Rlf +/+ hearts, Figure 4.13A-B.  The occurrence of the 
same phenotype in an independent Rlf mutant line suggests that it is loss of Rlf that 
is underlying the cardiac defect observed. However, it is currently unknown whether 
this is a heart specific phenotype or the result of developmental delay. Development 
of a cardiac specific Rlf knockout mouse, or undertaking a time-course analysis to 
determine whether the defect observed precedes signs of developmental delay, may 
help to address this in the future.  
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Figure 4.12: Rlf MommeD34/MommeD34 mutant mice display ventricular and septal 
defects in the heart at E14.5. 
Histological analysis of E14.5 Rlf +/+and Rlf MommeD34/MommeD34 embryos. Whole 
embryos were fixed and sectioned transversely at the tricuspid valve of the heart. i-ii, 
are high magnification images Rlf MommeD34/MommeD34 of mutant hearts indicating thin 
compact layer (arrow), and fenestrated septum (arrowhead). RA, right atria; RV, 
right ventricle; LV, left ventricle; IVS, interventricular septum; CL, compact layer. n 
= minimum 6 per genotype, scale bar = 500 µm, and 200 µm (i-ii). 
(Histology of all embryos investigated supplied in Appendix VII). 
 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 183 
A.      B. 
 
Figure 4.13: Rlf MommeD34/MommeD34 hearts have thin ventricle walls. 
Quantification of ventricle thickness in Rlf MommeD34/MommeD34 and Rlf +/+ hearts, 
showing both the left (A) and right (B) ventricles are thinner in Rlf mutants. n = 6 
per genotype. Error bars represent SEM and Student’s t-test was used to calculate p 
values (*p < 0.05). 
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4.2.8 Analysis of E14.5 placentas reveals no differences in morphology between 
MommeD28 genotypes 
 
The placenta has been found to be important in regulating cardiovascular 
development and fetal growth (Sibley et al., 2005; Thornburg et al., 2010).  
Additionally, publically available ENCODE data shows Rlf mRNA is expressed in 
the placenta (data not shown). Following the identification of a potential heart defect 
I then asked whether loss of Rlf also impacts upon placental morphology.  In the 
mouse the placenta is made up of three layers or zones – the labyrinth zone, 
junctional zone and maternal decidua, in which the maternal and fetal vasculature is 
closely intertwined, Figure 4.14 (Adamson et al., 2002; Rossant & Cross, 2001).   
 
 
A.    B.    C. 
Figure 4.14: Schematic diagrams of zones, maternal and fetal circulation within 
the murine placenta.  
A. Diagram of murine placental layers, indicating the maternal decidua (Dec), 
spongiotrophoblast layer (Sp) and labyrinth zone (Lab). B, C. Diagram of maternal 
and fetal circulation respectively, shows the direction of blood flow. Red represents 
highly oxygenated blood and black least oxygenated blood. Reprinted from 
Developmental Biology, Vol 250, Issue 2, S.L. Adamson, et al., Interactions between 
trophoblast cells and the maternal and fetal circulation in the mouse placenta, p. 369, 
Copyright 2002, with permission from Elsevier. (Appendix XV). 
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Histology was undertaken on MommeD28 wild-type and mutant placentas (n = 
min. 5 per genotype) to determine whether there were differences in cellular 
morphology between the two genotypes. Placentas were fixed in 4% PFA as 
described previously, and bisected perpendicular to the flat fetal surface prior to 
embedding and staining.  Placental sections were stained with either H&E or 
Periodic acid Schiff staining (PAS), used to determine the localisation of glycogen 
containing trophoblast cells, for histology analysis. 
 
Analysis of placentas stained with both H&E and PAS, identified subtle 
changes in vasculature morphology in placentas from wild-type versus                    
Rlf MommeD28/MommeD28 embryos, Figure 4.15 and Figure 4.16. In the mouse maternal 
vessels can be identified by their trophoblast cell lining and enucleated red blood 
cells, whilst fetal vessels have a thinner endothelial cell lining and contain nucleated 
fetal blood cells (Watson & Cross, 2005). No difference in maternal vasculature was 
observed between the two genotypes, Figure 4.15 and Figure 4.16. However, subtle 
differences in fetal vasculature were observed, with fetal vessels in                          
Rlf MommeD28/MommeD28 derived placentas displaying a more collapsed and disorganised 
appearance, Figure 4.15 and Figure 4.16 (Prof. D. Simmons, personal 
communication). The placentas collected here were sectioned for preliminary 
phenotyping analysis. However, they were not sectioned appropriately for 
performing stereology to accurately quantify the phenotype observed. Future work 
investigating a larger cohort will utilise stereology to accurately quantify these 
preliminary findings and will be undertaken in collaboration with Prof D. Simmons, 
University of Queensland, who has expertise in sectioning and fixing placentas for 
histological analysis.  
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These preliminary findings in the placenta alongside of the observed reduced 
weight of Rlf mutant embryos, suggest loss of Rlf in the fetal placenta may impact 
upon embryonic growth due to insufficient circulation. The development of 
conditional knockout mouse lines would be required to definitively separate the 
placental defects from the cardiac defects observed this will be discussed further in 
Section 4.3. 
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Figure 4.15: H&E analysis of placentas reveals subtle differences in fetal 
vasculature 
Haematoxylin and eosin staining of E14.5 Rlf +/ and Rlf MommeD28/MommeD28 placentas. 
Boxed regions are shown at higher magnification below genotypes (Ai-Di). Fetal 
vessels, arrows, appear more collapsed and disorganised in Rlf MommeD28/MommeD28 
placentas than wild-type. No difference in maternal vessels, arrowheads, was 
observed. n = min. 5 per genotype. Scale bar = 800 µm (A-D) and 50 µm (Ai-Di). 
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Figure 4.16: PAS staining of placentas reveals subtle differences in fetal 
vasculature 
PAS staining of E14.5 Rlf +/ and Rlf MommeD28/MommeD28 placentas. Boxed regions are 
shown at higher magnification below genotypes (Ai-Di). Fetal vessels, arrows, appear 
more collapsed and disorganised in Rlf MommeD28/MommeD28 placentas than wild-type. No 
difference in maternal vessels, arrowheads, was observed. n = min. 5 per genotype. 
Scale bar = 800 µm (A-D) and 50 µm (Ai-Di).  
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4.2.9 Subtle differences in cardiac morphology are observed in  
 Rlf MommeD28/MommeD28 embryos at E11.5 
 
Recent studies from our collaborator, Dr G Del Monte Nieto, VCCRI, have 
found Rlf mRNA is expressed in the epicardium and endocardium as early as E8.0 
(Dr G Del Monte Nieto, personal communication). Following these findings I asked 
whether the heart defect observed at E14.5 arises from earlier in development.  
 
I established timed matings of heterozygous MommeD28 mice to generate 
embryos at E9.5 and E11.5. As ages of embryos within and between litters can vary 
dependent on time of implantation, the number of somites was counted for early 
stage embryos as a measure of developmental age.  I removed embryos from the 
uterus in RNase free cold phosphate buffered saline supplemented with 0.1% Tween 
(PBT) and counted the number of somites for each embryo.  They were then fixed in 
PFA (made in PBT) overnight at 4 °C, followed by washing in PBT and dehydrated 
in 50% and 70% ethanol all at 4 °C (all reagents used were RNase free).   The yolk 
sac for each embryo was also collected for genotyping. Following genotyping of 
embryos, E9.5 and E11.5 Rlf +/+ and Rlf MommeD28/MommeD28 embryos were sent to Dr G. 
Del Monte Nieto, Victor Chang Cardiac Research Institute (VCCRI), who has 
established technical experience investigating early cardiac development for 
embedding, sectioning and staining. 
 
Analysis of Rlf +/+ and Rlf MommeD28/MommeD28 embryos revealed no difference in 
morphology at E9.5 – E10.0 (n = min. 13 per genotype) (data not shown, Appendix 
VII).  At E11.5 (n = min. 8 per genotype) subtle differences begin to appear in 
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ventricular morphology between the two genotypes. The left ventricle of                  
Rlf MommeD28/MommeD28 hearts is more triangular in shape, like a normal right ventricle, 
making the left and right ventricles appear symmetrical in these hearts, Figure 4.17 
and Appendix VII. This finding was consistent amongst homozygous mutant 
embryos.  Another consistent, but subtle, finding in Rlf MommeD28/MommeD28 hearts is the 
observation of a less compacted interventricular septum when compared to Rlf +/+ 
hearts, Figure 4.17. These results suggest the phenotype observed at E14.5 may 
begin to arise at E11.5 in the developing heart.  
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Figure 4.17: Subtle differences in heart morphology are observed as early as E11.5 in Rlf mutants. 
Rlf MommeD28/MommeD28 hearts display less compacted interventricular septum (arrowhead) and symmetrical left ventricle morphology (arrow) (n = 
min. 8 per genotype analysed). (Histology of all embryos analysed supplied in Appendix VII).  
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4.2.10 Determining the correct samples for differential gene analysis in the 
heart 
 
After identifying a potential cardiac defect in E14.5 hearts we decided to 
undertake RNA-seq analysis on whole fetal hearts to identify genes that may be 
regulated by Rlf in the heart.  Our intention was to investigate the fetal heart prior to 
the observation of the heart defect at E14.5, to enable alterations in gene expression 
that may be causing the changes in morphology to be identified. Preliminary studies 
in E13.5 embryos found no major defect to be observed at this time-point (data not 
shown). As such whole E13.5 fetal hearts from the MommeD28 line were chosen for 
RNA-seq analysis. However, following the completion RNA-seq analysis in these 
E13.5 hearts, subtle defects in the heart were observed as early as E11.5 which may 
impact upon the results reported here. This will be discussed further later in this 
chapter.  
 
Many papers have addressed the importance of appropriate experimental 
design when undertaking RNA-seq analysis (Auer & Doerge, 2010; Fang & Cui, 
2011; Hansen et al., 2011; Liu et al., 2014). Two considerations when designing this 
RNA-seq experiment were: 
 
1. Whether to use biological replicates from the same litter regardless of sex, 
removing the potential of sex specific effects on gene expression being identified 
2. To use biological replicates of the same sex, but from different litters 
 
Based on experience from other RNA-seq studies conducted by our laboratory, 
I decided to use whole E13.5 fetal hearts dissected from littermates. The litter chosen 
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for RNA-seq consisted of four wild-type, four homozygous and two heterozygous 
MommeD28 embryos from the same litter. A third heterozygote from a separate litter 
was also included and processed alongside of these samples. No gross differences in 
heart morphology were observed comparing hearts from each genotype, Figure 4.18.  
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Figure 4.18: No gross differences in heart morphology is observed in Rlf mutant hearts at E13.5. 
E13.5 whole hearts extracted from Rlf +/+, Rlf MommeD28/+ and Rlf MommeD28/MommeD28 littermates and used for RNA-seq analysis. No overt 
differences in morphology were observed between genotypes. Embryos were removed from the uterus in cold PBS, and hearts removed from 
body under dissecting microscope, images were then taken with a Leica DFC320 camera. Scale bar = 1 mm.  
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4.2.11 RNA extraction and quality validation 
 
I extracted RNA from whole fetal hearts using the AllPrep Micro Kit (Qiagen) 
as this kit allows for high yields of RNA from small samples. Previous analysis of 
RNA extracted from whole fetal hearts at this time-point and using this kit found 
RNA to be of high quality and concentrations to be within the range of 50 – 100 ng/ 
µl. As a result of this RNA extracted from this cohort was sent directly to the 
Australian Genome Research Facility (AGRF) for sequencing without calculating the 
concentration and quality of these samples. As all samples were eluted in a small 
volume (11 µl) it was decided calculating concentration and quality of these samples 
by myself and also AGRF could result in excess sample being used leading to 
reduced DNA being available for sequencing.   
 
Quality control was undertaken by AGRF using the Agilent Bioanalyser RNA 
6000 Nano kit, and all samples were found to be of high quality, Figure 4.19. The 
RNA integrity number (RIN) for each sample was > 9.7, where a RIN of 10 is best 
quality, intact RNA, and a RIN of 1 is totally degraded RNA. The high RIN number 
for each of these samples makes these appropriate for RNA-seq analysis.  
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Figure 4.19: Quality of RNA extracted from fetal hearts. 
Agilent bioanalyser traces of RNA extracted from whole fetal hearts showing each 
contains high quality RNA for sequencing.  
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4.2.12 RNA sequencing and mapping 
 
mRNA library preparation and Illumina HiSeq 2000 sequencing, on 
polyadenylated RNA, with 50 bp single end reads was performed by the AGRF. 
Each sample was run on two lanes for sequencing and all were found to meet AGRF 
quality standards, the data yield for each sample and lane is detailed in Table 4.3.  
Following sequencing I undertook quality control checks on this raw data using 
FastQC (Andrews, 2010). FastQC reports on the following measurements: per base 
sequence quality, per sequence quality scores, per base sequence content, per base 
GC content, per base N content, sequence length distribution, sequence duplication 
levels, overrepresented sequences and Kmer content. All sequencing files 
successfully passed FastQC analysis.  
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Table 4.3: RNA sequencing data yield.  
 
Lane Sample Name Genotype Single Reads Data Yield (bp) 
6 
Herc_59-1_RNA Rlf +/+ 14,873,339 0.74 Gb 
Herc_59-2_RNA Rlf +/+ 17,398,715 0.87 Gb 
Herc_59-3_RNA Rlf MommeD28/MommeD28 17,307,986 0.87 Gb 
Herc_59-4_RNA Rlf MommeD28/MommeD28 16,505,467 0.83 Gb 
Herc_59-5_RNA Rlf +/+ 18,269,620 0.91 Gb 
Herc_59-6_RNA Rlf MommeD28/MommeD28 17,831,375 0.89 Gb 
Herc_59-7_RNA Rlf +/+ 18,148,076 0.91 Gb 
Herc_59-8_RNA Rlf MommeD28/MommeD28 18,175,123 0.91 Gb 
Herc_59-9_RNA Rlf MommeD28/+ 18,182,655 0.91 Gb 
Herc_59-10_RNA Rlf MommeD28/+ 15,840,263 0.79 Gb 
Herc_57-3_RNA Rlf MommeD28/+ 15,052,975 0.75 Gb 
7 
Herc_59-1_RNA Rlf +/+ 14,861,472 0.74 Gb 
Herc_59-2_RNA Rlf +/+ 17,410,231 0.87 Gb 
Herc_59-3_RNA Rlf MommeD28/MommeD28 17,251,411 0.86 Gb 
Herc_59-4_RNA Rlf MommeD28/MommeD28 16,476,072 0.82 Gb 
Herc_59-5_RNA Rlf +/+ 18,231,528 0.91 Gb 
Herc_59-6_RNA Rlf MommeD28/MommeD28 17,840,737 0.89 Gb 
Herc_59-7_RNA Rlf +/+ 18,141,441 0.91 Gb 
Herc_59-8_RNA Rlf MommeD28/MommeD28 18,070,558 0.90 Gb 
Herc_59-9_RNA Rlf MommeD28/+ 18,200,960 0.91 Gb 
Herc_59-10_RNA Rlf MommeD28/+ 15,824,463 0.79 Gb 
Herc_57-3_RNA Rlf MommeD28/+ 15,048,856 0.75 Gb 
Total  374,943,323 18.73 Gb 
 
Table 4.3: Data sequencing yield for each replicate in two lanes showing no bias in 
reads towards any particular replicate.  
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All of the following bioinformatics analysis was undertaken by myself using 
the open-web based platform Galaxy (www.galaxy-qld.genome.edu.au) 
(Blankenberg et al., 2001; Giardine et al., 2005; Goecks et al., 2010). Reads were 
aligned using Tophat (Trapnell et al., 2009), a program that aligns RNA-seq reads to 
the genome using the short read aligner BowTie, and analyses the mapped results to 
identify splice junctions. The following Tophat parameters were used: maximum 
intron length between donor/acceptor site must be less than 100,000 bp; coverage 
search disabled; read alignments with > 2 mismatches discarded; library type is 
unstranded 
 
Read counts for mRNA transcripts were then extracted using HTSeq count 
matrix (Anders & Huber, 2010). This tabulates mapped files into a matrix form for 
use in differential gene expression tools. The following HTSeq count parameters 
were used: not from a strand specific assay; model for counting reads over the 
supplied gene model set to intersection strict; gene annotations used from Ensembl 
(www.ensembl.org, release 67).  
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4.2.13 Differential gene expression analysis 
 
Currently, there are many different methods available for studying differential gene 
expression, with each method differing in their normalisation methods, isoforms 
expression analysis and correction of multiple testing (Rapaport et al., 2013).  I chose 
to analyse differential gene expression in fetal hearts using three common methods: 
CuffDiff (Trapnell et al., 2012), DESeq (Anders & Huber, 2010) and EdgeR 
(Robinson et al., 2010), each of which utilise the Benjamini-Hochberg method for 
controlling false discovery rate (Benjamini & Hochberg, 1995). Default parameters 
were used for each program. Genes were considered differentially expressed if they 
had an adjusted p value of < 0.005 (after false discovery correction) and a fold 
change > 1.2.  CuffDiff was found to be the most stringent with 228 genes identified 
as differentially expressed in Rlf MommeD28/MommeD28 hearts (Appendix VIII), followed 
by EdgeR with 293 genes (Appendix IX) and DEseq 316 genes (Appendix X). 
Figure 4.20 shows the agreement between the three analysis methods, with 162 
genes identified as differentially expressed in all three programs.  In each of the 
programs slightly more genes were found to be down-regulated versus up-regulated 
in Rlf MommeD28/MommeD28 fetal hearts, Table 4.4, correlating with previous data 
suggesting Rlf is required for transcriptional activation. 
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Figure 4.20: Agreement of differential gene expression across methods. 
Venn diagram showing intersection of genes identified as differentially expressed in 
three different programs – CuffDiff, EdgeR and DEseq. 
 
Table 4.4: More genes are down-regulated in Rlf MommeD28/MommeD28 hearts than 
up-regulated  
Table 4.4: Each program used to analyse differential gene expression revealed more 
genes to be down-regulated in homozygous mutant hearts. All p values were 
corrected for multiple testing (Full list of genes Appendices VIII, IX, X). 
  Up-regulated Down-regulated 
CuffDiff (p < 0.005) > 5 FC 1 2 
 > 2 FC 8 9 
 > 1.5 FC 42 55 
 > 1.2 FC 98 130 
DEseq (p < 0.005) > 5 FC 0 0 
 > 2 FC 0 7 
 > 1.5 FC 31 66 
 > 1.2 FC 111 205 
EdgeR (p < 0.005) > 5 FC 1 3 
 > 2 FC 11 38 
 > 1.5 FC 57 99 
 > 1.2 FC 108 186 
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4.2.14 Clustering of biological replicates 
 
EdgeR also allows for the similarity of each biological replicate to be analysed 
using multi dimensional scaling. Three of the wild-types (i - iii) were found to cluster 
tightly together; however one wild-type embryo (iv) was separated from the group, 
Figure 4.21A. A likely reason for this may be due to a slight difference in overall 
body morphology observed between this embryo and its wild-type littermates, 
Figure 4.21B. Removal of this sample and repeating the EdgeR bioinformatic 
analysis with three wild-type replicates found no impact upon the list of differentially 
expressed genes. Rlf MommeD28/MommeD28 hearts were found to cluster into two groups, 
independent of sex, (a and b; c and d), Figure 4.21A-B. Again removal of individual 
replicates had no impact upon gene expression analysis.    
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A.  B.  
 
	  
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Replicate clustering and similarity of Rlf +/+ and Rlf MommeD28/MommeD28 samples.  
A. EdgeR multidimensional scaling (MDS) plot displaying the similarity amongst samples, following analysis. The four homozygous mutants 
cluster into two groups of two (red), whilst one wild-type sample did not cluster near the other three wild-type samples (black). B. Gross 
morphology of wild-type (i-iv) and homozygous (a-d) embryos use for RNA-seq analysis. i, ii and iii clustered together, but not iv; homozygous 
embryos a, b clustered together whilst c and d clustered separately. Embryos were removed from the uterus in cold PBS images taken with a 
Leica DFC320 camera. Scale bar = 5 mm.   
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4.2.15 Differentially expressed genes in the fetal heart 
	  
 
Table 4.5 and Table 4.6, show the top 20 significantly up- and down-regulated 
genes between Rlf MommeD28/MommeD28 and Rlf +/+ E13.5 fetal hearts as calculated by 
EdgeR using a p value < 0.005 and fold change > 1.5 (for full list refer Appendix 
IX). Analysis of up- and down-regulated genes found them to be associated with 
several pathways including Notch signalling and cardiac hypertrophy. Notch 
pathway genes found to be altered by loss of Rlf included those encoding Jagged1 
(Jag1), Jagged2 (Jag2), Hey1, Cntn1 and Dll1 (Figure 4.22A). Ingenuity’s Upstream 
Regulator Analysis identified Notch1 (z score = -2.356), Myod1 (z = n-2.132), and 
Csll1 (z = -2.00) as inhibited upstream regulators, and Gata1 (z = 2.393), Rnf2 (z = 
2.236), and Nrli2 (z = 2.219) as activated upstream regulators (Figure 4.22B).  Vegfa 
and Conexin40 (Gja5), genes important for heart chamber development, were also 
found to be differentially expressed.  
	  
 
Pages 195 and 196: 
 
Table 4.5:  Top 20 down-regulated genes respectively in Rlf MommeD28/MommeD28 fetal 
heart compared to wild-type following RNA-seq analysis. Fetal heart was collected 
from four individual E13.5 embryos for each genotype; all embryos were from the 
same litter. RNA-seq was performed by AGRF on the Illumina HiSeq 2000 and 
bioinformatic analysis in EdgeR by myself. Adjusted p value controls for false 
discovery rate through the use of the Benjamini-Hochberg procedure. (Full list 
Appendix IX). 
Table 4.6: Top 20 up-regulated genes respectively in Rlf MommeD28/MommeD28 fetal heart 
compared to wild-type following RNA-seq analysis. Fetal heart was collected from 
four individual E13.5 embryos for each genotype; all embryos were from the same 
litter. RNA-seq was performed by AGRF on the Illumina HiSeq 2000 and 
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bioinformatic analysis in EdgeR by myself. Adjusted p value controls for false 
discovery rate through the use of the Benjamini-Hochberg procedure (Full list 
Appendix IX).  
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Table 4.5: Top 20 Down-regulated Genes in Rlf MommeD28/MommeD28 Fetal Heart. 
Symbol Gene Name Log Fold Change 
Adjusted 
P value 
Apoc1 Apolipoprotein C-I  18.28 4.50E-18 
Tex11 Testis expressed gene 11  10.64 8.49E-12 
Cpa1 Carboxypeptidase A1 9.64 3.56E-31 
Tdrd1 Tudor domain containing 1 4.58 2.29E-06 
Ap3b2 Adaptor-related protein complex 3, beta 2 subunit  4.28 5.95E-35 
Cpa4 Carboxypeptidase A4 3.95 6.83E-08 
Slc36a2 Solute carrier family 36 (proton/amino acid symporter), member 2  3.72 1.29E-10 
Cilp2 Cartilage intermediate layer protein 2 3.47 1.83E-06 
Pcdh10 Protocadherin 10 3.24 2.03E-08 
Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 3.22 7.84E-05 
Col2a1 Collagen, type II, alpha 1 3.13 1.85E-43 
Zfp783 Zinc finger protein 783 2.97 5.75E-07 
Lrrtm4 Leucine rich repeat transmembrane neuronal 4 2.90 4.04E-07 
Gm1564 Predicted gene 1564 2.89 2.86E-06 
Tesc Tescalcin; similar to Tescalcin 2.86 5.72E-07 
Pcdhb7 Protocadherin beta 7 2.80 1.87E-10 
Tnnt3 Troponin T3, skeletal, fast 2.78 2.18E-06 
Pilra Paired immunoglobin-like type 2 receptor alpha 2.65 1.85E-06 
Mal Myelin and lymphocyte protein, T-cell differentiation protein 2.59 1.89E-05 
Acta1 Alpha 1, skeletal muscle 2.58 3.14E-33 
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Table 4.6: Top 20 Up-regulated Genes in Rlf MommeD28/MommeD28 Fetal Heart. 
Symbol Gene Name Log Fold Change Adjusted P value 
Prap1 Proline-rich acidic protein 1 9.22 5.63E-09 
Aldh1a7 Aldehyde dehydrogenase family 1, subfamily A7  3.08 1.82E-09 
Treml1 Triggering receptor expressed on myeloid cells-like 1  2.60 4.40E-06 
Gpat2 RIKEN cDNA A530057A03 gene 2.59 0.000101 
Vtcn1 V-set domain containing T cell activation inhibitor 1 2.46 2.62E-05 
Ppbp Pro-platelet basic protein 2.40 9.21E-07 
Gdf10 Growth differentiation factor 10 2.38 0.001085 
Tubb1 Tubulin, beta 1 2.32 1.19E-05 
Gp9 Glycoprotein 9 2.29 3.26E-05 
Ptprq Protein tyrosine phosphatase, receptor type, Q 2.26 1.73E-05 
Gp1bb Glycoprotein Ib, beta polypeptide 2.19 3.37E-05 
Gdpd3 Glycerophosphodiester phosphodiesterase domain containing 3 2.14 0.000721 
Gstm6 Glutathione S-transferase 2.10 0.000118 
Pf4 Platelet factor 4   2.09 2.18E-10 
Ptgds Prostaglandin D2 synthase (brain) 2.07 0.000136 
Il23a Interleukin 23, alpha subunit p19 1.99 2.47E-05 
Fcgr2b Fc receptor, IgG, low affinity IIb 1.98 0.000148 
Hpdl 4-hydroxyphenylpyruvate dioxygenase-like 1.97 0.001163 
Rinl Ras and Rab interactor-like   1.96 2.73E-06 
Cd14 CD14 antigen 1.96 9.47E-05 
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Figure 4.22:  Transcriptome analysis shows dysregulation of the NOTCH 
signalling pathway in Rlf MommeD28/MommeD28 hearts 
A. GOplot representation of the analysis of canonical pathway enriched in the 511 
differentially expressed genes in RlfMommeD28/MommeD28 fetal hearts. B-H P value, 
Benjamini-Hochberg-adjusted P value. B. Putative upstream regulator analysis 
showing activated upstream regulators (red) and inhibited upstream regulators (blue), 
predicted utilising differentially expressed genes identified following RNA-seq 
analysis (511 genes). 
A 
B 
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Recent studies undertaken by our collaborator, investigating the expression of a 
subset of Notch target genes identified in RNA-seq, confirmed their dysregulation 
following in-situ hybridisation analysis (Dr G Del Monte Nieto, personal 
communication).  Additionally, immunohistofluorescence of activated Notch1 found 
no expression of activated Notch1 in Rlf MommeD28/MommeD28 mutant hearts, whilst 
expression in wild-type hearts was normal (Dr G Del Monte Nieto, personal 
communication). These findings support the RNA-seq and pathway analysis 
performed suggesting Rlf is an important requirement for the developing heart.  
 
Furthermore, in-situ hybridisation analysis for Rlf mRNA expression has also 
found Rlf to be expressed only in the endocardium and epicardium of the heart (Dr G 
Del Monte Nieto, personal communication). These two cell types make up a small 
percentage of the total cell population within the heart (~15%) (Banerjee et al., 
2007). This may account for the small fold-changes observed in Notch1 target genes 
in our data being a result of dilution, as multiple cardiac cell types were analysed.  
 
Ideally, undertaking RNA-seq in a single cardiac cell type, such as endocardial 
cells in which Rlf expression has been observed, may be more informative. This may 
reveal specific changes in gene expression earlier in development that lead to the 
heart defect observed in Rlf MommeD28/MommeD28 hearts. However, performing RNA-seq 
in a single cardiac cell type from the developing heart would be technically difficult 
due to the small amount of tissue/RNA available. Recently, commercial kits have 
been designed that allow for immunomagnetic isolation of cardiomyocytes and have 
been successfully used in research applications (O’Meara et al., 2015). However, a 
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significant number of hearts (5 – 10) are still required to generate one replicate that is 
suitable for RNA-seq analysis. The further development of such kits for isolating 
epicardial and endocardial cells, and improvements in single cell RNA-seq would 
greatly enhance our understanding of how loss of Rlf influences the cardiac 
phenotype observed.  
 
 
4.2.16 Investigation of a fetal liver Rlf-DMR that overlaps an active enhancer 
mark in the heart 
 
As we had previously noted our fetal liver Rlf-DMRs overlapped regulatory 
regions that are active in other tissue types, I asked whether any overlapped with 
regulatory regions in the fetal heart. Almost half of the Rlf-DMRs were found to 
overlap with at least one histone mark associated with active and or poised regulatory 
elements (589 of 1,329 Rlf-DMRs), Figure 4.23A. Some of which have been 
validated as active enhancers in transgenic mouse assays (data not shown) (Visel et 
al., 2007). I chose to study one of the candidate Rlf-DMRs that was found to overlap 
with the active enhancer marks H3K4me1 and H3K27ac in the fetal heart, Figure 
4.23B. This Rlf-DMR overlapped a previously identified active enhancer, mm87, 
located on Chromosome 10: 44,948,419 - 44,951,592 (Visel et al., 2007). This 
enhancer, showed cardiac specific expression at E11.5 in seven embryos, a 
representative embryo is shown in Figure 4.23C (Visel et al., 2007). Making this a 
suitable candidate for determining whether the Rlf-DMR observed in the fetal liver is 
also present in the fetal heart.    
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Figure 4.23: A fetal liver Rlf-DMR overlaps with an active enhancer in the fetal 
heart. 
A. Venn diagram of E14.5 Rlf-DMRs that overlap with histone marks associated 
with regulatory elements in the heart (H3K4me1, enhancer mark; H3K27ac, active 
enhancer mark; H3K4me3, active promoter mark). B. UCSC Genome Browser tracks 
of a validated E11.5 enhancer mm87 (red bar) overlapping active enhancer marks 
H3K4me1 and H3K27ac, but not the promoter mark H3K4me3 on Chromosome 10. 
C. Transgenic mouse assay data from the VISTA database shows expression of 
enhancer mm87 is cardiac specific, (Visel et al., 2007). 
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I then asked whether any difference in methylation at this enhancer is observed 
in Rlf mutant fetal hearts at different stages in development. I undertook bisulphite 
sequencing of this enhancer in E13.5 and E18.5 whole hearts, as described 
previously.  The MommeD28 mutant line, in which GWBS was originally 
undertaken, was chosen for validation to minimise any differences that may occur 
between the different Rlf mutant strains.  DNA from two Rlf +/+ and two                   
Rlf MommeD28/MommeD28 E18.5 and E13.5 whole fetal hearts was converted and 
sequenced as described previously, refer Section 3.2.4.  
 
At E13.5 a small increase in methylation, p <0.0001, was observed in             
Rlf MommeD28/MommeD28 whole hearts (92% methylated) compared to Rlf +/+ (77% 
methylated) whole hearts, Figure 4.24A. This difference in methylation between 
genotypes was maintained, p <0.0242, at E18.5 (Rlf MommeD28/D28 – 93% methylated, 
Rlf +/+ – 85% methylated), Figure 4.24B. At both time-points the percentage of 
methylation at this enhancer was relatively high (> 75%). As active enhancers have 
been commonly found to be hypomethylated this suggests this enhancer is not active 
at these time-points in this tissue (Hon et al., 2013a; Lister et al., 2009). Enhancer 
mm87 was identified by Visel et al., 2007, as being active at E11.5. Investigations in 
the future into methylation state at earlier time-points in the heart may reveal 
methylation of this enhancer to be time-point specific. Alternatively, the methylation 
observed in whole fetal hearts may not be illustrative of underrepresented cardiac 
cell types, such as endocardial cells in which Rlf mRNA expression has been 
observed. As such, undertaking bisulphite sequencing in whole fetal hearts may be 
diluting possible cell type specific methylation effects that are influencing the 
phenotype observed. This will be further discussed in Section 4.3. 
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Figure 4.24: Methylation analysis of enhancer mm87 in Rlf +/+ and                     
Rlf MommeD28/MommeD28 whole fetal heart. 
A, B. Bisulphite sequencing of enhancer mm87 of whole E13.5 (A) and E18.5 (B) 
hearts reveals a significant difference in DNA methylation in Rlf MommeD28/MommeD28 
compared to wild-types (n = 2 per genotype). Each column represents DNA from a 
single heart, each row is the sequence from a single cell and each circle represents 
one CpG site. Filled circles represent methylated CpGs. Black circles represent 
methylated CpGs, white circles represent unmethylated CpGs, and lines (-) 
represents a non CpG or ambiguously sequenced position where a CpG exists in the 
genomic sequence. (X2, p < 0.0001 A, p <0.05 B).  
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4.3 DISCUSSION 
 
Many groups have shown the importance of epigenetic modifiers in 
development. Studies involving a large number of different modifiers have shown 
that global deletion often results in embryonic or postnatal lethality (Ashe et al., 
2008; Daxinger et al., 2013; Montgomery et al., 2007; Okano et al., 1999).  The 
effect of loss of Rlf on viability and weight (Table 4.1, Figure 4.8 and Figure 4.9) is 
reflective of results observed in other epigenetic mutant mouse lines both from the 
Whitelaw group and other research groups (Ashe et al., 2008; Daxinger et al., 2013; 
Lee et al., 2000). This result directly addresses the central hypothesis of this thesis; 
Rlf is required for normal development.  
  
Here I have identified a putative heart defect in two different null Rlf mutant 
mouse lines and shown loss of Rlf results in perinatal lethality (Table 4.1 and Figure 
4.10A-B). Recent studies from our collaborator Dr G. Del Monte Nieto, VCCRI, 
have shown that Rlf mRNA is expressed in the endocardium and epicardium of the 
developing heart (Dr G. Del Monte Nieto, personal communication). The 
endocardium plays an important role in proper formation of the trabecular 
myocardium, whilst the epicardium contributes to multiple cardiac lineages, 
including smooth muscle cells and cardiac fibroblasts (Stankunas et al., 2008; Zhou 
et al., 2008). Non-compaction defects such as those observed in Rlf null mutants 
have been shown to arise from dysregulation within either the myocardial or 
endocardial layer (Chen et al., 2013; Luxan et al., 2013; Yang et al., 2012). Indeed, 
aberrant gene expression in the endocardium results in non-compaction phenotypes 
similar to those observed in Rlf mutant mice. For example, loss of Fkbp1a (FK506 
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binding protein 1a) in the endocardium resulted in ventricular hypertrabeculation and 
non-compaction, as a result of disrupted Notch1 signalling (Chen et al., 2013). 
Notch1 signalling has been found to be crucial for ventricular development, via 
mediating endocardial and myocardial interactions, and inactivation of Notch1 in the 
endocardium results in a non-compaction defect in mice (Grego-Bessa et al., 2007).  
 
Following RNA-seq analysis of Rlf mutant hearts, no difference in Notch1 
expression was observed. This was not an unexpected result as Notch1 proteins are 
activated upon ligand binding (Grabher et al., 2006). Chen et al., 2013, found both 
over expression and loss of Fkbp1a had no impact on Notch1 mRNA expression, but 
did alter Notch1 protein expression and mRNA expression of Notch1 target genes. 
Further investigation of gene expression in Rlf mutant hearts revealed a small but 
significant decrease in expression of Notch1 target genes (Hey1, Erbb2, and Bmp2, 
fold change 1.3, 1.2, and 1.2 respectively), as well as two Notch1 ligands (Jag1, fold 
change 1.2 and Jag2, fold change 1.3) (Appendix X). Analysis by our collaborator 
further found a reduction in activated Notch1 expression in Rlf mutant hearts, 
supporting the findings presented here (Dr G Del Monte Nieto, personal 
communication).  
 
A recent publication found the Notch ligands Jag1 and Jag2 play important 
roles in trabecular compaction and the maturation of cardiac chamber development 
(D'Amato et al., 2016). The authors found loss of Jag1 or Jag2 in the mouse resulted 
in a phenotype reminiscent of human LVNC, similar to that observed in Rlf mutants. 
It could be proposed that loss of Rlf results in down regulation of the Jagged ligands 
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which in turn results in lost Notch1 activation leading to the phenotype observed in 
Rlf mutants. However, further investigation is needed to determine the specific 
mechanisms by which loss of Rlf impacts the Notch pathway.   
 
While a putative heart defect has been observed in these mice it is important to 
note that the placenta also plays an important role in regulating heart development 
(Barak et al., 1999). While the presence of heart defect may be the result of placental 
defects, this is not always the case (Wang et al., 2004). Barak et al., 1999, 
investigated Ppar-γ, peroxisome proliferator–activated receptor γ, and found loss of 
this gene resulted in defects in placental vascularisation, thinning of the myocardium 
in the heart and death at E10. Aggregation of mutant Ppar-γ embryos with wild-type 
placentas found the cardiac defect was corrected when no placental defect was 
present. In knockout mice of the chromatin remodeler Pbrm1, Polybromo 1, Wang et 
al., 2004, observed defects compromising fetal-maternal exchange in the placenta, 
incomplete development of the ventricle walls and death between E12 – E15. 
However, unlike Barak et al.’s, 1999, study, when knockout Pbrm1 embryos were 
aggregated with wild-type placentas normal heart development was not restored and 
the cardiac defect remained in these embryos. These embryos were sacrificed at mid-
gestation (E14.5) and the impact of the cardiac defect on development or neonatal 
survival not investigated (Wang et al., 2004). 
 
In this study I analysed placentas from wild-type and homozygous MommeD28 
E14.5 embryos and found subtle differences in fetal placenta vasculature between the 
two genotypes (Figure 4.15 and Figure 4.16). Due to time and financial constraints, 
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no further functional, transcriptomic or histological studies were undertaken in the 
Rlf mutant mice. Defects in placenta vascular morphology, such as that observed in                           
Rlf MommeD28/MommeD28 placentas can decrease the surface area available for nutrient, 
oxygen and waste exchange (Gong et al., 2011). Additionally, fetal growth has been 
shown to be closely linked to this exchange, and deficiency in exchange can result in 
intrauterine growth restriction, cardiovascular defects and perinatal morbidity 
(Fowden et al., 2008). As Rlf MommeD28/MommeD28 mice have been found to be 
significantly smaller at mid- and late gestation, the defect in placenta vasculature 
observed at E14.5 may impact on fetal growth in these mice. Undertaking embryo 
aggregation (aggregating homozygous Rlf embryos with wild-type placentas), as 
performed in the studies by Barak et al., 1999, and Wang et al., 2004, would be the 
most beneficial in determining whether the placental vascular defect present in Rlf 
mutants is the cause of or independent to the defects in cardiac development and fetal 
growth observed.  
 
The cardiac and placental morphology presented here give rise to alternate 
theories as to how the phenotype may be altered in Rlf null mice. The cardiac defect 
identified in Rlf null mice may be the result of aberrant gene expression in the 
endocardium, as a consequence of loss of Rlf, leading to the non-compaction 
phenotype observed. The differences in placental vasculature may be preventing 
appropriate cardiac and fetal development as a consequence of insufficient maternal 
and fetal exchange. Alternatively, the phenotype observed in Rlf null mice could be 
due to differences in both the placenta and cardiac development. The development of 
conditional knockout mouse models, or producing chimeras by aggregating Rlf null 
embryos with wild-type placentas, will help to address these questions in the future.  
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Previously, tsDMRs have been shown to mark enhancers that were once active 
at early stages of development. These tsDMRs retain their hypomethylated state in 
adult tissue but active histone marks once present at earlier time-points are no longer 
present (Hon et al., 2013a). From the Rlf-DMRs identified in the fetal liver some 
were also found to overlap with sites enriched for active histone marks in the fetal 
heart (Figure 4.23).  Here I investigated one of these Rlf-DMRs in E13.5 and E18.5 
whole hearts as it had already been validated as an active enhancer in E11.5 hearts 
and overlapped with active histone marks in E14.5 fetal heart (Figure 4.23) (Visel et 
al., 2007).  A significant increase in methylation was observed comparing the two 
genotypes, regardless of the already highly methylated state in wild-type hearts at 
both E13.5 and E18.5 (77% and 85% respectively) (Figure 4.24B-C).  Interestingly, 
this statistical significance decreased with the age of pups (E13.5 p<0.0001; E18.5 
p<0.05). Further investigation of this enhancer at E11.5, the time point in which it 
was identified at Visel et al., 2007, may reveal a greater change in methylation 
between genotypes, pointing towards this enhancer being active early in the 
developing heart. 
 
Alternatively, undertaking methylation analysis in a single cardiac cell type 
population may be a superior method and yield greater information. Rlf has been 
found to be expressed in the endocardium and epicardium of the developing heart 
(Dr G. Del Monte Nieto, personal communication). These two cell types make up a 
small percentage of the total cell population within the heart (~15%) (Banerjee et al., 
2007). Investigation of a single cardiac cell type population may reveal these 
methylation changes are cell type specific and may elucidate potential mechanism 
through which loss of Rlf results in the phenotype observed. 
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4.4 FUTURE DIRECTIONS 
 
This is the first study investigating Rlf and the effect of loss of Rlf on 
phenotype. Here we identified a putative heart defect in mice lacking Rlf expression.  
 
In Australia congenital heart defects account for 20% of perinatal deaths, still 
births or death within the first 28 days of life (Australian Institute of Health and 
Welfare, 2011). However the genetic cause for many of these cases is unknown. As 
the heart defect identified in Rlf mutant mice is similar to left ventricular non-
compaction (LVNC) observed in humans, undertaking genetic sequencing for Rlf 
will determine whether mutations in Rlf are also present in humans with the same 
defect. A collaboration has been established with Professors Chris Semsarian 
(University of Sydney) and Jose de la Pompa, (Centro Nacional de Investigaciones 
Cardiovasculares, Spain), who both oversee large collections of clinical LVNC 
samples. Undertaking sequencing of these clinical samples for RLF may enhance the 
current genetic screening, diagnosis and management strategies for patients with 
LVNC.  
 
Undertaking detailed analysis of cardiac function and structure of either Rlf 
Momme mutants or a conditional cardiac Rlf knockout in early neonatal or late 
postnatal pups would be beneficial. Results from this study suggest that homozygous 
Rlf null mice (Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34) are likely to die shortly 
after birth, however no investigation into the impact of this defect on cardiac 
function was undertaken. The studies by Montgomery et al., 2007, and Wang et al., 
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2004, which investigated the impacts of loss of the epigenetic modifiers Hdac2 and 
Pbrm1, found loss of either modifier resulted in decreases in heart rate prior to death. 
Therefore, determining whether Rlf mutants have altered cardiac function prior to or 
after birth may help to define the role of Rlf in the heart. Furthermore, while the 
majority of homozygous MommeD28 and MommeD34 mutants die shortly after 
birth, a small number survive to weaning. Identifying clearly how loss of Rlf alters 
cardiac structure and function in the mouse may identify strategies with which to 
overcome this lethality.  
 
Further analysis of the placental defects observed will be undertaken 
(dependent on funding) in the future in collaboration with Dr David Simmons 
(University of Queensland). Investigating markers specific to different placenta cell 
types, such as Gcm1 (glial cells missing homolog 1) and Syna (Syncytin a), markers 
specific to fetal and maternal blood vessels respectively, may help to define the role 
of Rlf in vascular development in the placenta. Due to the collapsed appearance of 
fetal vessels in Rlf mutant placentas utilising stereology to define the structural and 
spatial arrangements within the whole placenta, and the individual placenta layers, 
may more accurately define the phenotype observed in these placentas.  
 
Co-immunoprecipitation experiments (co-IP) experiments performed by the 
Whitelaw laboratory have identified putative binding partners of Rlf in-vitro that 
have established roles in transcription and chromatin modification, or in replication 
and DNA repair (Harten et al., 2015).  Undertaking co-IP of wild-type and 
homozygous Rlf hearts followed by Mass spectrometry identification of protein 
binding partners would help to define the role Rlf plays in the developing heart. In 
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order to be able to gain significant results, hearts of late gestational embryos would 
be the best developmental time-point for co-IP investigation. A greater amount of 
protein can be extracted from the larger, late gestation hearts; reducing the number of 
embryos from across different litters that would otherwise need to be collected at 
earlier developmental stage and reducing inter- litter variation. The identification of 
Rlf binding partners’ in-vivo may identify protein binding partners that are critical in 
cardiac development.  
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Chapter 5: Investigating the consequence of 
reduced Rlf expression in adult 
mice 
5.1 INTRODUCTION 
In contrast to complete absence of an epigenetic modifier, many studies have 
shown mice with reduced levels of a particular epigenetic modifier are viable, fertile 
and phenotypically normal (Okano et al., 1999; Stopka & Skoultchi, 2003).  For this 
reason, few studies focus on the impact of heterozygosity or reduced dosage of 
epigenetic modifiers on phenotype. The MommeD28 and MommeD34 Rlf null lines 
do not produce viable homozygous mutants at three weeks of age, however the 
hypomorphic MommeD8 line does produce homozygous offspring that are viable and 
fertile (Daxinger et al., 2013). In this chapter two hypomorphic Rlf mouse mutants, 
Rlf MommeD8/MommeD34 and Rlf MommeD8/MommeD8, which have reduced Rlf expression, will 
be used to determine whether differences in Rlf expression impacts upon phenotype, 
viability and fertility.  
 
5.1.1 Reduced dosage of epigenetic modifiers impacts on viability 
 
Mice with reduced levels of epigenetic modifiers display similarities in their 
effects on viability and phenotype to that observed in Rlf mutant mouse lines. 
Heterozygous mutants from a number of mouse lines identified in the Momme screen 
are viable and display no overt changes in phenotype.  For example, Hdac1 and 
Smarca5 heterozygous mutant mice, but not homozygous mutants, are viable at 
weaning but weigh less than their wild-type littermates (Ashe et al., 2008; Chong et 
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al., 2007). This is similar to observations made in the MommeD28 and MommeD34 
null Rlf lines (this study and Daxinger et al., 2013). Mice with hypomorphic 
mutations have been shown to have varying impacts on phenotype. Mice carrying 
two hypomorphic Dnmt3b alleles are viable at weaning, although not at the expected 
Mendelian ratio, and are fertile. Mice with two hypomorphic Setdb1 (SET domain, 
bifurcated 1) alleles also survive to adulthood but have decreased fertility (Daxinger 
et al., 2013; Youngson et al., 2013). These findings are similar to the hypomorphic 
MommeD8 mouse line. Whilst the viability of homozygous MommeD8 mice has 
previously been addressed, no further research investigating Rlf MommeD8/MommeD8 or 
Rlf MommeD8/MommeD34 mice has been undertaken.  
 
5.1.2 Epigenetics and ageing 
 
Ageing is a result of decline in regeneration and reproduction, and as a result of 
this decline an organism may become more susceptible to disease, stress and injury 
(Moskalev et al., 2014). Recently, studies in the field of ageing have identified 
gerontogenes, genes that control ageing and longevity (Moskalev et al., 2014). 
Additionally, epigenetic modifiers have been found to play key roles in the ageing 
process. For example, mice deficient for the histone deacetylase Sirt6, sirtuin 6, 
exhibit premature signs of ageing, including sudden loss of subcutaneous fat and 
bone density, curvature of the spine, and premature death at approximately three 
weeks of age (Mostoslavsky et al., 2006).  Whilst mice over- expressing Sirt6 were 
found to have an increased lifespan of approximately 15% in males compared to 
wild-type littermates, no difference was observed in females over-expressing Sirt6 
(Kanfi et al., 2012).  No previous studies have investigated how reduced Rlf 
expression may impact upon ageing or onset of adult disease in the mouse.  
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5.1.3 Transgenerational epigenetics 
 
Inbred mouse colonies make it possible to study transgenerational epigenetic 
inheritance in mice that are genetically identical. The viability of Rlf MommeD8/MommeD8 
mice, and their ability to reproduce successfully, presents a unique opportunity to 
examine the effects of reduced Rlf expression across multiple generations. Such 
studies have been performed in hypomorphic Dnmt3b mice. Investigating the effect 
of reduced Dnmt3b expression across generations found a recovery in bodyweight in 
F2 offspring versus F1 offspring. No other differences in weight were observed 
across other generations (Youngson et al., 2013). As Dnmt3b is required for de novo 
DNA methylation, Youngson et al., 2013, also investigated the impact of reduced 
Dnmt3b expression on methylation of the X-linked gene Hprt. No cumulative effect 
was observed in late generation Dnmt3b offspring, however the authors do not rule 
out a role for Dnmt3b in transgenerational epigenetic inheritance.  
Both Rlf and Dnmt3b expression has been observed in the zygote, two cell and 
four cell embryo using single cell RNA-seq profiling (Yan et al., 2013). These are 
cell types in which epigenetic reprograming is occurring following fertilisation of the 
zygote, with the maternal and paternal genome are undergoing passive and active 
DNA demethylation, respectively (Smallwood & Kelsey, 2012). The presence of Rlf 
expression at this developmental time-point suggests it may play a role in epigenetic 
reprogramming in the mouse.   
 
As loss of Rlf has previously been shown to alter bodyweight and methylation 
in the different Rlf Momme lines, investigating the role of Rlf across generations may 
reveal a role for Rlf in inheritance of epigenetic state across generations.  
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5.2 RESULTS 
5.2.1 Presence of the MommeD8 allele alters gene expression in the fetal liver 
 
Previous experiments by the Whitelaw lab have shown Rlf protein expression 
is reduced in Rlf MommeD8/MommeD8 fetal head lysates (Daxinger et al., 2013).  Loss of 
Rlf has also been shown to alter gene expression in both MommeD28 and 
MommeD34 homozygous E14.5 liver (Section 3.2.2). Heterozygosity for the Rlf 
MommeD34 allele was also shown to result in significant changes in gene 
expression. Following on from these results, I was interested in determining whether 
reduced dosage of Rlf, as observed in homozygous MommeD8 mice, could have a 
similar effect. Analysis of four up- and four down-regulated genes analysed in 
Section 3.2.2 was undertaken using Rlf +/+ and Rlf MommeD8/MommeD8 E14.5 liver (n = 5 
per genotype). A significant difference in gene expression, in all but one gene, was 
observed between the two genotypes following qRT-PCR, Figure 5.1. This data 
shows that reduced expression of Rlf in Rlf MommeD8/MommeD8 mice is capable of 
impacting gene expression. Whilst no putative Rlf binding sites, following ChIPseq 
in the fetal liver, were found to overlap differentially expressed genes, whether their 
change in expression is directly due to loss of Rlf is still unknown.  
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Figure 5.1: The hypomorphic MommeD8 allele alters expression of some genes 
in the fetal liver. 
qRT-PCR analysis of eight significantly differentially expressed genes identified 
from RNA-seq show all but one to also be differentially expressed in                       
Rlf MommeD8/MommeD8 E14.5 liver. mRNA expression was normalised to β-actin and 
wild-type controls. Error bars represent SEM and Student’s t-test was used to 
calculate p values (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001). n = 5 
for each genotype.   
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As Rlf MommwD8/MommeD8 mice still produce some Rlf protein (hypomorphic 
allele), whereas Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 mice do not produce 
any Rlf protein (null alleles), I was interested in determining whether                      
Rlf MommwD8/MommeD8 mice have similar gene expression patterns to Rlf MommeD34/+ mice. 
I chose the MommeD34 line as it had previously been used for qRT-PCR validation 
of RNA-seq results. The mean normalized fold change in expression following qRT-
PCR was used for comparison between the MommeD8 and MommeD34 lines. The 
mean normalized fold change of gene expression in Rlf MommeD8/MommeD8 mice was 
observed to be slightly lower (for up-regulated genes) than Rlf MommeD34/MommeD34 
mice, but higher than Rlf MommeD34/+ mice, Figure 5.2A. The opposite was observed 
when analysing the down- regulated genes, Figure 5.2B. This suggests that carrying 
two of the hypomorphic Rlf MommeD8 alleles has a greater impact on endogenous 
gene expression than carrying one copy of the Rlf MommeD34 allele and one wild-
type Rlf allele.  
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A. 
  
 
B. 
 
 
 
Figure 5.2: Endogenous gene expression is reduced in Rlf MommeD8/MommeD8 fetal 
liver more than Rlf MommeD34/+ fetal liver.  
A, B. Mean normalised fold change comparison of up- and down-regulated genes in 
the MommeD34 and MommeD8 mouse lines reveals a stronger change in                 
Rlf MommeD8/MommeD8 compared to Rlf MommeD34/+ mice but not as strong as                    
Rlf MommeD34/MommeD34 mice. Error bars represent SEM. n = minimum of 4 per 
genotype.  
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5.2.2 Western blotting and gene expression analysis of tissue extracted from 
compound heterozygous (Rlf MommeD8/MommeD34) mice 
 
Previously it has been shown that Rlf protein expression is reduced in             
Rlf MommeD8/MommeD8 mice and not present in Rlf MommeD28/MommeD28 and                         
Rlf MommeD34/MommeD34 mice (Daxinger et al., 2013). However, no experiments have 
determined the level of Rlf expression in mice compound heterozygous for different 
Rlf Momme alleles, or the impact of compound heterozygosity on endogenous gene 
expression.  
 
Compound heterozygous Rlf MommeD8/MommeD34 mice are predicted to have low 
protein activity, as a result of the presence of a null allele (MommeD34) and a 
hypomorphic allele (MommeD8). To assess this Rlf MommeD8/MommeD34 mice (bred from 
a Rlf MommeD8/MommeD8 x Rlf MommeD34/+ cross) and age matched wild-type adult mice 
were used for Western blotting analysis, and no overt change in Rlf protein level was 
observed (data not shown). Reasons for the lack of change in Rlf protein expression 
in these mice are currently unclear. 
 
Next, I asked whether expression of Hpd mRNA, a gene previously found to be 
significantly differentially expressed in fetal liver from both of the Rlf null Momme 
lines (refer Figure 3.), and also hypomorphic Rlf MommeD8/MommeD8 mice (refer Figure 
5.1). mRNA was collected from fetal liver from Rlf MommeD8/+ and Rlf MommeD8/MommeD34 
littermates (n = minimum 3 per genotype), and also Rlf +/+ and Rlf MommeD28/MommeD28 
littermates (n = 3 per genotype). A significant decrease in Hpd mRNA expression 
was observed in Rlf MommeD28/MommeD28, but not Rlf MommeD28/+ E14.5 liver, compared to 
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wild-type littermates, Figure 5.3. The expression of Hpd mRNA in Rlf MommeD8/+ mice 
was similar to that observed in Rlf +/+ mice, whilst a significant decrease in 
expression was observed in Rlf MommeD8/MommeD34 mice compared to Rlf MommeD8/+ 
littermates, Figure 5.3.   
 
The results obtained here in Rlf MommeD8/MommeD34 offspring reflect those 
observed in the Rlf MommeD8/MommeD8 mice, with the presence of two hypomorphic 
alleles having a greater impact on gene expression than presence of one Rlf null and 
one Rlf wild-type allele.  
 
 
 
 
Figure 5.3: qRT-PCR of Rlf MommeD8/MommeD34 mice. 
qRT-PCR analysis of Hpd identified as being differentially expressed from RNA-seq 
data was performed on RNA extracted from the   Rlf +/+, Rlf MommeD28/+,                    
Rlf MommeD28/MommeD28, Rlf MommeD8/+, and Rlf MommeD8/MommeD34 E14.5 liver.   mRNA 
expression was normalised to β-actin and wild-type controls. Error bars represent 
SEM and Student’s t-test was used to calculate p values (**p < 0.005, ****p < 
0.0001).  n = min. 3 per genotype. 
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5.2.3 Predicted Rlf activity in the different mutant mouse lines 
 
As differences in Rlf protein expression have been observed amongst the 
different Rlf Momme mutant lines, I wanted to try to define how the activity of Rlf 
compares across each of the different mutant mouse lines. To do this I investigated 
endogenous Hpd mRNA expression in each of the Rlf Momme lines collected during 
this PhD, and compared these to previously published data investigating Rlf protein 
expression from Western blotting, and GFP expression in the independent Rlf lines. 
 
Hpd mRNA expression, quantified from qRT-PCR performed in this PhD 
showed a reduction in Hpd expression in each of the mutant lines compared to wild-
type mice, Table 5.1. Expression was reduced the most in Rlf MommeD28/MommeD28 and 
Rlf MommeD34/MommeD34 mice (5%), followed by Rlf MommeD8/D34 (10%), Rlf MommeD8/D8 
(20%), Rlf MommeD28/+ (40%), Rlf MommeD34/+ (60%) and Rlf MommeD8/+ mice (100% 
expression, Table 5.1.  Furthermore, in lines where multiple genes were analysed the 
effect on expression was consistent across the genes analysed. The differences in 
Hpd mRNA expression observed correlates with previous findings investigating GFP 
and Rlf expression in the Momme lines. Combining all of these characteristics it can 
be predicted that the activity of Rlf is most severely altered in Rlf MommeD28/MommeD28 
and Rlf MommeD34/MommeD34 mice (no activity), followed by Rlf MommeD8/MommeD34 and          
Rlf MommeD8/MommeD8 (low activity), Rlf MommeD28/+, Rlf MommeD34/+ (moderate activity), 
and Rlf MommeD8/+ mice (complete activity) (Table 5.1). 
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Table 5.1: Predicted activity of Rlf in different mutant mouse line 
 
 
 
 
 
 
 
 
 
Table 5.1: Predicted Rlf protein activity in each of the Momme mouse lines, estimated from published data and data from this PhD. Rlf Protein 
and GFP expression were estimated from previously published Western blots and Western blots performed during this PhD, Hpd mRNA 
expression was calculated for each of the Rlf Momme lines in Chapters 3 and 5 of this PhD, and together this information was used to predict Rlf 
activity. 1 Daxinger et al., 2013; 2 Figure 5.3, this study; 3 Ashe et al., 2008; 4 Figure 5.4, this study; 5 Figure 5.1, this study; 6 Figure 3.2, this 
study.   
Genotype Hpd mRNA 
expression 
GFP 
expression 
Protein 
Expression 
Predicted 
Rlf activity 
Rlf +/+ 100% 2,5,6 55% 1 100% 1 Complete activity 
Rlf MommeD8/+ 100% 5 41% 3 100% 1 Complete activity 
Rlf MommeD28/+ 40% 2 44% 1 50% 1 Moderate activity 
Rlf MommeD34/+ 60% 6 39% 1 50% 1 Moderate activity 
Rlf MommeD8/MommeD8 20% 5 15% 3 50% 1 Low activity 
Rlf MommeD8/MommeD34 10% 2 13% 4 100% 2 Low activity 
Rlf MommeD34/MommeD34 5% 6 11% 1 0% 1 No activity 
Rlf MommeD28/MommeD28 5% 6 7% 1 0% 1 No activity 
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5.2.4 Reduced dosage of Rlf alters viability and weight of mice 
 
Whilst viability in each of the Rlf null lines (no Rlf activity) has been addressed 
the effect of reduced dosage on viability has not. Rlf MommeD28/MommeD28 and               
Rlf MommeD34/MommeD34 mice have been found to die shortly after birth while                  
Rlf MommeD8/MommeD8 offspring survive in less than expected numbers (Table 4.1 and 
Daxinger et al., 2013).  No previous work has investigated the viability of               
Rlf MommeD8/MommeD34 mice.  
 
To determine whether Rlf MommeD8/MommeD34 mice were viable after birth, I 
crossed a MommeD8 homozygous mouse to a MommeD34 heterozygous mouse to 
produce    Rlf MommeD8/+ and Rlf MommeD8/MommeD34 (compound heterozygous) offspring. 
Homozygous MommeD8 mice were used to increase the likelihood of breeding mice 
carrying both the MommeD8 and MommeD34 allele. Almost half of the expected 
number of Rlf MommeD8/MommeD34 offspring was observed at weaning (expected 50%, 
observed 30%), Figure 5.4A. I then wanted to determine whether hypomorphic     
Rlf MommeD8/MommeD34 mice had an altered GFP expression similar to the other Rlf 
Momme mouse lines. In Rlf MommeD8/MommeD34 mice the percentage of GFP expressing 
erythrocytes was markedly reduced (13% ± 2) compared to their Rlf MommeD8/+ 
littermates (41% ± 5), Figure 5.4B. The difference in GFP expression in 
hypomorphic Rlf MommeD8/MommeD34 mice reflects that observed in Rlf MommeD8/MommeD8 
hypomorphic mice (Daxinger et al., 2013). These results suggests carrying both the 
MommeD8 and MommeD34 alleles has a greater impact on viability than carrying 
one copy of the MommeD8 allele and a wild-type allele, and correlates with the 
predicted activity of Rlf in these mice.  
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As reduced numbers of Rlf MommeD8/MommeD34 offspring were observed at three 
weeks of age, I asked whether this impacted upon litter size. No statistical difference 
in litter size between pups born from a wild-type cross or Rlf MommeD8/D8 x                
Rlf MommeD34/+ cross was observed, Figure 5.4C.  Although a trend towards decreased 
litter size was observed with litters born from a Rlf MommeD8/MommeD8 x Rlf MommeD34/+ 
containing less mice (average 5.9 pups) compared to those born from wild-type 
parents (average 7.3 pups). This is consistent with the decrease in viability of         
Rlf MommeD8/MommeD34 offspring observed.  
 
Hypomorphic Rlf MommeD8/MommeD8 offspring have been previously found to 
weigh less than their wild-type litter mates at weaning (Ashe et al., 2008). As a result 
of this I wanted to determine whether hypomorphic Rlf MommeD8/MommeD34 mice were 
also reduced in weight at weaning. Although a large variation in pup weight was 
observed in both genotypes, Rlf MommeD8/MommeD34 offspring were found to weigh 
significantly less (8.85 g, ± 0.604) than their Rlf MommeD8/+ littermates (11.06 g, ± 
0.30) at three weeks of age, Figure 5.4D. The reduced weight and viability observed 
in compound heterozygous offspring suggests reduced dosage of Rlf plays an 
important role in development and survival.   
 
 
In the following sections hypomorphic Rlf MommeD8/MommeD34 mice will be used in 
a series of preliminary experiments investigating the effect of reduced Rlf expression 
on longevity, ovarian morphology and cardiac structure and function.  
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A.  
 
B.  
 
 
C.      D.  
 
  
Figure 5.4: Rlf MommeD8/MommeD34 offspring 
are smaller and less viable than          Rlf MommeD8/+ offspring. 
A. Fewer Rlf MommeD8/MommeD34 offspring from a Rlf MommeD8/MommeD8 x Rlf MommeD34/+ 
mating are observed at three weeks (weaning) compared to heterozygous                 
Rlf MommeD8/+ offspring. Tabulated data shows the number of observed mice and (% of 
total). B. Percentage of GFP expressing erythrocytes in Rlf MommeD8/+ and                 
Rlf MommeD8/MommeD8 littermates at three weeks of age (mean ± SEM). C. No difference 
is observed when comparing litter sizes from a Rlf MommeD8/MommeD8 x  Rlf MommeD34/+ 
cross to litter sizes born from a Rlf +/+ intercross (n = 14 and 21 litters respectively). 
Each data point represents an independent litter, where the number of pups equals 
zero this refers to litters observed at birth but no longer present at weaning. D.  
Weights of offspring at three weeks showing Rlf MommeD8/MommeD34 offspring are 
significantly smaller than their Rlf MommeD8/+ littermates. Each data point represents an 
individual embryo. Error bars represent SEM and Student’s t-test was used to 
calculate p values (***p < 0.001), n = 8 litters. 
Viability Age Rlf 
MommeD8/+ 
Rlf 
MommeD8/MommeD34 
Rlf MommeD8/MommeD8 X Rlf MommeD34/+ 3 weeks 51 (72%) 20 (28%) 
GFP Expressing cells Rlf MommeD8/+ Rlf MommeD8/MommeD34 
Rlf MommeD8/MommeD8 X Rlf MommeD34/+ 41% ±5 13% ±2 
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5.2.5 Reduced dosage of Rlf has no major impact on longevity 
 
The compound heterozygous mice bred in Section 5.2.4 were then used to 
study the effects of reduced dosage of Rlf on longevity. The cohort consisted of six  
male and four female Rlf MommeD8/MommeD34 mice (generated from a Rlf MommeD8/MommeD8 
x Rlf MommeD34/+ cross), and eight male and four female age matched wild-type mice 
(generated from a Rlf  +/+ x Rlf +/+ cross). Table 5.2 shows the dates of birth, weaning 
and death, and sex for each of these mice. All mice were housed at 21 – 23 °C with a 
12 hour light and dark cycle and unlimited access to food and water.  
 
From the male mouse cohort one Rlf MommeD8/MommeD34 was found dead in cage at 
21 months of age, an autopsy found this male had an inflated bladder but no other 
abnormalities (data not shown). A second Rlf MommeD8/MommeD34 male was culled, at 17 
months of age, due to signs of physical distress, presenting with a distended stomach. 
An autopsy of this male revealed this mouse also had an inflated bladder (data not 
shown). The findings in these males are also commonly observed in aged wild-type 
FVB/NJ mice maintained by our laboratory (Dr S. Harten, personal communication). 
As none of the other males in the cohort displayed any overt signs of distress or 
atypical behaviour, no further investigation into this phenotype was undertaken. The 
remaining mice were then used to study the effect of reduced dosage of Rlf on heart 
structure and function in Section 5.2.6.  
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Table 5.2: Compound heterozygous and wild-type mice bred for longevity study.    
Rlf MommeD8/MommeD34 males (pale blue), Rlf +/+ males (dark blue), Rlf MommeD8/MommeD34 
females (pink), Rlf +/+ females (red). Date of birth (DOB), date of weaning (DOW), 
dead in cage (DIC), age at death in months (mths), and ECG (echocardiogram). 
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Table 5.2: Longevity study cohort of Rlf MommeD8/MommeD34 and Rlf +/+. 
Genotype ID # Sex DOB DOW Approx. Age 
at Death 
Notes 
Rlf MommeD8/MommeD34 14.5.10 M 19.4.13 10.5.13 21mths Found DIC 12/01/2015, inflated bladder observed 
Rlf MommeD8/MommeD34 14.5.20 M 13.7.13 02.8.13 20 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf MommeD8/MommeD34 23.12.27 M 16.9.13 11.10.13 17 mths Culled 30/01/15, due to distended stomach caused by inflated bladder 
Rlf MommeD8/MommeD34 23.12.30 M 16.9.13 11.10.13 18 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf MommeD8/MommeD34 23.12.32 M 16.9.13 11.10.13 18 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 52 M 03.7.13 22.7.13 20 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 34 M 10.8.13 30.8.13 20 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 35 M 10.8.13 30.8.13 18 mths Culled 30/01/15, for histology match to Rlf MommeD8/MommeD34 23.12.27 
Rlf +/+ 36 M 10.8.13 30.8.13 19 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 37 M 10.8.13 30.8.13 18 mths Culled 30/01/15, for histology match  Rlf MommeD8/MommeD34 23.12.27 
Rlf +/+ 20 M 15.8.13 11.9.13 19 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 21 M 15.8.13 11.9.13 19 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 22 M 15.8.13 11.9.13 19 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf +/+ 23 M 15.8.13 11.9.13 19 mths Used for ECG and culled 26/02/2015, heart collected for histology 
Rlf MommeD8/MommeD34 G2.1.7.14 F 7.11.12 28.11.12 24 mths Culled 26/11/14, eyes deteriorated and had growth on right ovary 
Rlf MommeD8/MommeD34 23.12.8 F 10.5.13 31.5.13 20 mths Culled 08/01/15, one eye deteriorated and had growth on right ovary 
Rlf MommeD8/MommeD34 23.12.23 F 5.8.13 26.8.13 17 mths Culled 08/01/15, no ovarian growth, right kidney had cyst 
Rlf MommeD8/MommeD34 23.12.25 F 5.8.13 26.8.13 17 mths Culled 08/01/15, no abnormalities observed 
Rlf +/+ 14 F 9.5.13 30.5.13 20 mths Culled 08/01/15, for histology match 
Rlf +/+ 16 F 9.5.13 30.5.13 20 mths Culled 08/01/15, for histology match 
Rlf +/+ 40 F 10.8.13 31.8.13 17 mths Culled 08/01/15, for histology match 
Rlf +/+ 41 F 10.8.13 31.8.13 17 mths Culled 08/01/15, for histology match 
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From the females of this cohort two Rlf MommeD8/MommeD34 mice (aged 24 and 20 
months) were culled due to signs of physical distress, examination of each revealed 
they both had a fluid filled growth on their right ovary, Figure 5.5 and data not 
shown. Following the observation of this phenotype in the second female the 
decision was made to cull the rest of the female cohort (aged 17 – 20 months). Of the 
two remaining Rlf MommeD8/MommeD34 females no ovarian growth was observed in either 
mouse. Although a cyst on the right kidney of one female was observed (data not 
shown). None of the female wild-type mice displayed any gross morphological 
abnormalities. Furthermore, this phenotype has not been observed in larger numbers 
(n = 50) of aged wild-type females maintained by our laboratory (Dr S. Harten, 
personal communication).  
 
 
 
 
 
   
 
 
 
Figure 5.5: Ovarian growth observed in compound heterozygote female 
mutants.  
Ovarian growth observed in Rlf MommeD8/MommeD34 female right ovary. The left ovary 
and uterine horn from same mouse also included showing no growth present. Scale 
bar = 1 cm. 
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From each female I collected both the left and right ovaries and fixed them in 
4% PFA for histological analysis, ovaries were then sectioned by QIMRB 
histopathology services. Slides were assessed in collaboration with Prof Dagmar 
Wilhelm, Monash University, an expert in gonad development and reproduction. 
Whilst ovarian growths were observed on two right ovaries of the four Rlf 
MommeD8/MommeD34 females, histology of the remaining right and left ovaries showed 
differences in morphology compared to wild-type ovaries. In mammals, the ovary 
contains a number of different cell types including oocytes and somatic cells 
(granulose, theca and stoma cells), which act together to determine the development 
of follicles and ovulation (Richards & Pangas, 2010). No oocytes or follicles were 
observed in Rlf MommeD8/MommeD34 ovaries (Prof. D. Wilhelm, personal communication); 
Figure 5.6E-H and Figure 5.7. The Rlf MommeD8/MommeD34 right ovary with the fluid 
filled growth, Figure 5.6E and Figure 5.7, also appeared to have more stoma and 
granulose cells than normal, and were similar in appearance to follicular cysts (Prof. 
D. Wilhelm, personal communication).  Due to time constraints in this PhD it was not 
feasible to generate a larger independent cohort of aged females to study this 
phenotype in greater detail. Additionally, it would also be important to determine 
whether this phenotype is present in younger females or arises from earlier in 
development, this will be discussed in Section 5.3.   
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Figure 5.6: Ovarian growth found in Rlf MommeD8/MommeD34 aged females may be 
granulose cell tumours. 
Haematoxylin and eosin staining of aged ovaries from Rlf +/+ and Rlf MommeD8/MommeD34 
females. Right ovaries E and F were observed to have large growths following 
dissection. n = min. 4 per genotype, scale bar = 2 mm.   
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Figure 5.6A: Ovarian growth found in RlfMommeD8/MommeD34 aged females may be granulose cell tumours. 
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Figure 5.7: Higher magnification images of representative Rlf +/+ and                  
Rlf MommeD28/MommeD28 aged ovaries.   
Representative higher magnification images of wild-type (A) and Rlf MommeD8/MommeD34 
(E) (Figure 5.6), females highlighting follicles, and corpus lutea (F, CL) in wild-type 
mice not observed in mutant mice, and stromal (St), and granulosa (Gr) cells 
observed in Rlf MommeD8/MommeD34  ovaries.  Scale bar = 500 µm 
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5.2.6 Reduced dosage of Rlf has no impact on adult heart function 
 
Following the observation of a heart defect in Rlf MommeD28/MommeD28 and                
Rlf MommeD34/MommeD34 embryos, I wanted to determine whether reduced dosage for Rlf 
impacts upon heart structure and function in adult mice. The remaining males from 
the aged mice cohort generated and studied in Section 5.2.5 were used for analysis.  
Although this was a small number of mice (n = 7 Rlf +/+, 3 Rlf MommeD8/MommeD34), this 
study was proposed to gather preliminary information on adult mouse heart structure 
and function. Compound heterozygous mice were used for this study due to 
MommeD28 and MommeD34 homozygous mice dying shortly after birth.  As there 
are no facilities for performing echocardiography (ECG) at QIMRB                        
Rlf MommeD8/MommeD34 and Rlf +/+ males were transferred to the University of 
Queensland, and experimentation carried out in conjunction with Dr E. Porello, who 
is experienced in performing mouse ECGs. ECG is a non-invasive and popular 
method for evaluating changes in left ventricular (LV) structure and function in 
transgenic mice (Gardin et al., 1995; Montgomery et al., 2007; Tanaka et al., 1996).  
 
The structural characteristics evaluated in these mice were interventricular 
septal thickness (IVS), LV internal diameter (LVID), and LV posterior wall 
thickness (LVPW). Each of these was measured at both systole (contraction) (IVSs, 
LVIDs, LVPWs) and diastole (relaxation) (IVSd, LVIDd, LVPWd). A trend of 
decreased LVID was observed at both systole and diastole in Rlf MommeD8/MommeD34 
versus wild-type mice, however this was not statistically significant, Figure 5.8A. 
This trend in decreased internal diameter could be the result of reduced bodyweight 
in Rlf MommeD8/MommeD34 mice compared to Rlf +/+ mice (Figure 5.4B), as body mass 
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has been shown to correlate with LV mass (Gardin et al., 1995). In order to 
determine whether the trend in decreased LVID is a true effect, a minimum of 27 
mice per genotype would need to be analysed (using a confidence level of 80% and 
5% margin of error). Due to the reduced viability of Rlf MommeD8/MommeD34 offspring, 
obtaining these numbers in an aged cohort may be unfeasible, thus undertaking this 
study in a younger cohort of mice may be a more appropriate study. This will be 
discussed further below. No difference was observed for the remaining structural 
measurements between the two genotypes, Figure 5.8A.  
 
Ejection fraction (the percentage of blood pumped from the heart during 
systole) and fractional shortening (an estimate of myocardial contractility calculated 
from LV diameter at end systole and diastole), were the two functional 
characteristics investigated. A non significant increase in both ejection fraction and 
fractional shortening was observed in the Rlf MommeD8/MommeD34 mice compared to 
wild-types, Figure 5.8B. Studies in humans have shown increases in LV dilation can 
lead to reductions in ejection fraction (Lewis & Sandler, 1971). This correlates with 
the difference observed in LV internal diameter and ejection fraction between 
genotypes in this study.  
 
In order to confirm this is a true difference between genotypes, a minimum of 
18 mice per genotype would need to be analysed (using a confidence level of 80% 
and 5% margin of error). Again, due to the reduced viability of Rlf MommeD8/MommeD34 
offspring, obtaining these numbers in an aged cohort may be unfeasible, thus 
undertaking this study in a younger cohort of mice may be a more appropriate study 
 Investigating the role of a novel epigenetic modifier, Rearranged L-Myc Fusion, in the mouse 245 
design. For example, analysing late gestation homozygous null (MommeD28 or 
MommeD34) embryos may provide more information on how loss of Rlf affects 
cardiac structure and function. Studies investigating cardiac function in pre-natal and 
neonatal mice are regularly reported in the current epigenetic/cardiovascular 
literature (Montgomery et al., 2007; Wang et al., 2004). 
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Figure 5.8: No differences in cardiac structure or function was observed in aged 
Rlf MommeD8/MommeD34 mice. 
A.  Interventricular septal thickness (IVS), left ventricular internal diameter (LVID), 
and left ventricular posterior wall thickness (LVPW) at both diastole (IVSd, LVIDd, 
LVPWd) and systole (IVSs, LVIDs, LVPWs) were measured to analyse structural 
differences between Rlf MommeD8/MommeD34 and Rlf +/+ mice. A trend of decreased 
LVIDd and LVIDs was observed in compound heterozygous mice, but this was not 
statistically significant. B. No significant difference in ejection fraction or fractional 
shortening was observed Rlf MommeD8/MommeD34 and Rlf +/+ mice. Error bars represent 
SEM and Student’s t-test was used to calculate p values, n = 7 Rlf +/+ and 3            
Rlf MommeD8/MommeD34 mice.  
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5.2.7 Presence of the MommeD8 allele alters methylation at endogenous loci  
 
A second Rlf hypomorphic line with low Rlf protein activity is the MommeD8 
mouse line. Similar to hypomorphic Rlf MommeD8/MommeD34 mice, Rlf MommeD8/MommeD8 
mice display reduced viability and weight that is not as severe as that observed in Rlf 
null mice (Ashe et al., 2008). Previous research has also found methylation of the 
GFP transgene is increased in Rlf MommeD8/MommeD8 offspring (Daxinger et al., 2013), 
making these mice ideal for studying the effects of reduced Rlf expression on 
endogenous methylation.  
 
To address this I undertook bisulphite sequencing analysis, of the 
Smad3/Smad6 loci previously identified as being differentially methylated in both       
Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 E14.5 liver (Section 3.2.5). DNA from   
Rlf +/+ and Rlf MommeD8/MommeD8 littermates (n = 2 per genotype) was bisulphite 
converted and sequenced as described previously (Section 3.2.4). In earlier studies I 
observed that in Rlf MommeD28/MommeD28 fetal liver a 26% increase in methylation at the 
Smad3/Smad6 region was observed, and a 40% increase observed in                        
Rlf MommeD34/MommeD34 fetal liver compared to wild-type littermates (Figure 3.11) 
(Harten et al., 2015). Bisulphite sequencing of fetal liver from the MommeD8 mouse 
line found a ~14% increase in methylation, p <0.0014, in Rlf MommeD8/MommeD8 embryos 
compared to Rlf +/+ littermates, Figure 5.9. These findings suggest that carrying two 
copies of the hypomorphic MommeD8 allele impacts upon methylation at 
endogenous loci, but the effect is not as large as in offspring carrying two null Rlf 
alleles, and this correlates with previous findings investigating endogenous gene 
expression (Figure 5.2).   
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Figure 5.9: Methylation analysis of the Smad3/Smad6 region in Rlf +/+ and        
Rlf MommeD8/MommeD8 fetal liver. 
The MommeD8 mutant allele results in an increase in methylation at a Rlf-DMR 
between Smad3 and Smad6 on Chromosome 9.  Each column represents DNA from a 
single embryo (n = 2 for each genotype), each row is the sequence from a single cell 
and each circle represents one CpG site. Black circles represent methylated CpGs, 
white circles represent unmethylated CpGs, and lines (-) represents a non CpG or 
ambiguously sequenced position where a CpG exists in the genomic sequence. (X2, p 
<0.05). 
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5.2.8 Rlf MommeD8/MommeD8 dams produce smaller litters that weigh less than litters 
born from Rlf MommeD8/MommeD8 sires 
 
To assess the fertility and viability of MommeD8 mutants I crossed three       
Rlf MommeD8/MommeD8 sires to three wild-type dams and also performed the reciprocal 
cross with three Rlf MommeD8/MommeD8 dams and wild-type sires. Mice were checked for 
the presence of a vaginal plug to determine mating had occurred and monitored for 
litters as a result of mating over 30 weeks. All offspring produced were heterozygous 
for the MommeD8 allele.  
 
The number of pups in each litter produced from crossing a Rlf MommeD8/MommeD8 dam 
to a wild-type sire was found to be significantly smaller at both birth (average litter = 
6.9 pups) and weaning (average litter = 5.4 pups) when compared to litters produced 
from a Rlf MommeD8/MommeD8 sire mating at birth (9.3 pups) and wean (7.8 pups), Figure 
5.10A. Comparison of numbers at birth versus weaning found no significant 
difference from either reciprocal cross, Figure 5.10A. A significant difference at 
weaning in litter size from Rlf MommeD8/MommeD8 dams (5.38 pups), but not                    
Rlf MommeD8/MommeD8 sires (7.8 pups), compared to wild-type controls (7.30 pups) was 
also observed, Figure 5.10B.  Slightly more females than males were observed at 
weaning from the Rlf MommeD8/MommeD8 sire cross (n = 47 females, 39 males), and 
similar numbers of males to females were observed from the Rlf MommeD8/MommeD8 dam 
cross (n = 48 and 49 respectively), Figure 5.10C.  
 
No difference in survival rates of pups born from small versus large litters, or 
males versus females, from either cross was observed. With the same numbers in pup 
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death observed between the respective groups (data not shown). This suggests the 
differences observed between the reciprocal crosses may be due to differences in 
maternal fertility as the number of pups per litter is significantly reduced from birth.  
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A.            B.        C. 
Figure 5.10: Rlf MommeD8/MommeD8 dams produce smaller litters than litters born from Rlf MommeD8/MommeD8 sires or wild-type parents. 
A. Litters from crosses between ♀Rlf MommeD8/MommeD8 and ♂Rlf +/+ mice have reduced number of offspring, when compared to the reciprocal cross 
of ♂Rlf MommeD8/MommeD8 and ♀ Rlf +/+ (n =11 and 18 litters respectively). The difference in litter size is observed from birth. Each data point 
represents an individual pup. Error bars represent SEM and Mann-Whitney U-test (A,B) or X2 test (C) was used to calculate p values (* p <0.05, 
** p < 0.01). B.  Weaning data from (A) showing litters born from Rlf MommeD8/MommeD8 dams are smaller than those from wild-type parents and Rlf 
+/+ sires. (n = 18 (wild-type), 11 (sire) and 18 (dam) litters). C. Similar ratios of male (blue, n = 86) to female (red, n = 97) offspring were 
observed when comparing crosses undertaken between ♀Rlf MommeD8/MommeD8 and ♂ Rlf +/+ and ♂ Rlf MommeD8/MommeD8 x ♀ Rlf +/+ mice. 
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Following the observation of differences in litter sizes produced from                     
Rlf MommeD8/MommeD8 dams and sires, I wanted to also investigate whether there was any 
maternal or paternal impact on weight. The weights of all offspring was measured at 
weaning (21 days), and offspring conceived from Rlf MommeD8/MommeD8 dams were 
found to weigh significantly less (9.88 g, ± 0.254) than offspring conceived from    
Rlf MommeD8/MommeD8 sires (10.73 g, ± 0.166), Figure 5.11A. Females produced from 
Rlf MommeD8/MommeD8 dams weighed significantly less (9.43 g, ± 0.341) than females 
conceived from Rlf MommeD8/MommeD8 sires (10.73 g, ± 0.246), but did not weigh less 
than their male littermates, Figure 5.11A.  
 
When bodyweight was normalised for each litter so as to compare the weight 
of pups to the average weight of the litter in which they were born.  Only female 
offspring born from a Rlf MommeD8/MommeD8 sire were found to have reduced weight 
compared to their male littermates, but this did not impact upon the overall weight of 
all offspring, Figure 5.11B. No difference was observed when comparing male and 
female offspring born from Rlf MommeD8/MommeD8 dams or comparing sexes across the 
reciprocal crosses, Figure 5.11B. Large variability in pup weight was observed 
across litters born from both Rlf MommeD8/MommeD8 dams and Rlf MommeD8/MommeD8 sires, 
suggesting more factors may be responsible for the fluctuations in weights observed, 
including competition for food amongst littermates which would differ based on litter 
size.  
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Figure 5.11: Rlf MommeD8/MommeD8 dams produce litters that weigh less than litters 
born from Rlf MommeD8/MommeD8 sires.   
A. Bodyweights of offspring from different crosses reveals a reduction in 
bodyweight in offspring born from a Rlf MommeD8/MommeD8dams (n = 97) cross 
compared to those born from a Rlf MommeD8/MommeD8 sires (n = 86). B. The weight of 
offspring were normalized to the average weight of the litter in which they were 
born. Only females born from a Rlf MommeD8/MommeD8 sire were found to be smaller on 
average versus their male littermates. Each data point represents an individual pup. 
Error bars represent SEM and Student’s t-test was used to calculate p values (** p < 
0.01). 
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5.2.9 Effect of reduced Rlf expression on weight across generations 
 
To investigate the effect of reduced Rlf expression across generations, matings 
of Rlf MommeD8/MommeD8 mice were established to produce a transgenerational cohort. 
F1 offspring were produced from a Rlf MommeD8/+ intercross resulting in wild-type, 
heterozygous and homozygous offspring. F1 litter sizes were found to be 
significantly smaller than litters born from two wild-type parents, Figure 5.12A. 
This was consistent with previous findings from Ashe et al., 2008. These authors also 
found MommeD8 homozygotes from Rlf MommeD8/+ intercrosses weigh significantly 
less than both their wild-type and heterozygous littermates at weaning (Ashe et al., 
2008).  In this study I found F1 MommeD8 homozygous offspring to weigh 
significantly less than heterozygous littermates but not wild-type littermates, Figure 
5.12B. While the difference in weight between wild-type and homozygous 
MommeD8 offspring was not significant, a trend towards decreased weight in 
homozygotes was observed, reflecting the results found by Ashe et al., 2008.  Also of 
note is that the mean weights of mice in this study were larger (Rlf +/+ 10.54g;         
Rlf MommeD8/+ 11.26g; Rlf MommeD8/MommeD8 9.41g) than those previously published     
(Rlf +/+ 8.54g; Rlf MommeD8/+ 8.65g; Rlf MommeD8/MommeD8 6.60g), but did not conflict 
with previous results.  
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Figure 5.12: Rlf MommeD8/+ intercross F1 litters are smaller than Rlf +/+ litters, and 
homozygous offspring weigh less.   
A. The number of pups in each litter born from a Rlf MommeD8/MommeD8 intercross is 
reduced to the number of pups born from a Rlf +/+ intercross (n = 14 and 21 litters 
respectively). Each data point represents an independent litter B. Homozygous 
offspring from a Rlf MommeD8/MommeD8 intercross are smaller at weaning than               
Rlf MommeD8/+ littermates but not wild-type littermates. Each data point represents an 
individual mouse. Error bars represent SEM and Mann-Whitney U-test was used to 
calculate p values (* p < 0.05, ** p < 0.01).  
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Homozygous MommeD8 F1 offspring were then mated together to produce F2 
offspring, where all offspring were MommeD8 homozygotes. F2 offspring were then 
mated together to produce F3 offspring and this mating was continued for 8 
generations. Analysis of litter size at each generation compared to wild-type litter 
size found a significant reduction in the number of pups in each generation, except 
for F5, versus wild-type, Figure 5.13A. A significant decrease in litter size was also 
observed in F6 versus F5, Figure 5.13A.  This is likely due to a reduction in the 
number of F6 litters surviving to weaning. No significant difference in litter size was 
observed comparing each of the other homozygous generations to one another.   
 
The weights of offspring across generations was also analysed. Significant 
reductions in weights were observed in F4 versus F3 offspring and F7 versus F6 
offspring, Figure 5.13B. In contrast, significant increases in weights were observed 
in F6 offspring versus F5, and F8 offspring versus F7, Figure 5.13B. Interestingly, 
the increased weight of F6 pups at weaning versus F5 correlates with the decrease in 
F6 litter size observed, Figure 5.13A.  No statistical differences in litter sizes were 
observed between the other generations in which statistical differences in mouse 
weight were observed. A trend towards increased weight in mice from smaller litters 
and decreased weights in mice from large litters was also observed. To determine the 
correlation between litter size and weight analysis was undertaken on data collected 
across all of the generations. A negative correlation (R 2 = 0.09237, p < 0.0001) 
between litter size and weight was observed, Figure 5.14, and these results were 
comparable to independent studies investigating the same parameters (Chahoud & 
Paumgartten, 2009; Johnson et al., 2001). The absence of a cumulative effect 
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towards increased or decreased weights suggests it is unlikely reduced Rlf expression 
is responsible for the differences observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next Page: 
Figure 5.13: No cumulative effects on litter size or offspring weight is observed 
across MommeD8 generations.  
A. Litter size at weaning reveals a reduction in size in F1-8 litters versus wild-type 
litters, and F6 litters versus F5. Each data point represents an independent litter. B.  
Weight of offspring at weaning reveals a correlation between litter size (A) and 
offspring weight (B), whereby offspring from smaller litters are likely to have larger 
bodyweights than those from large litters. Each data point represents an individual 
mouse. Error bars represent SEM and Mann-Whitney U-test was used to calculate p 
values (* p < 0.05, ** p < 0.01, **** p < 0.0001). 
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Figure 5.13:  No cumulative effects on litter size or offspring weight is observed across MommeD8 generations.
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Figure 5.14: A slight correlation between litter size and pup weight is observed 
across all MommeD8 generations. 
Relationship between litter size and pup weight at wean for all litters born across 
eight MommeD8 generations, shows a slight correlation between the two (R2 = 
0.09237) (n = 46 litters, 207 pups). Line represents linear regression slope as 
calculated by GraphPad Prism 6.  
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5.2.10 Effect of reduced Rlf dosage on methylation at endogenous loci across 
generations 
 
Reduced Rlf expression has previously been shown to alter methylation of the 
GFP transgene in Rlf MommeD8/MommeD8 mice compared to Rlf +/+ mice (Daxinger et al., 
2013).  As a result of this previous finding I chose to investigate methylation of the 
GFP transgene in early and late generation (F1 and F8) adult liver. Tissue was 
collected from 3 week old mice from each generation (n = 2 per generation), as well 
as wild-type controls (n = 2), and underwent bisulphite conversion and sequencing as 
described previously (Section 3.2.4). A small increase in methylation in F1             
Rlf MommeD8/MommeD8 was observed compared to wild-type controls (69% and 63% 
respectively), however this was not significant, p 0.0996, Figure 5.15. A further 
small increase in F8 offspring (73%) was observed compared to F1 offspring (69%), 
but this was also not statistically significant, p < 0.0931, Figure 5.15. Whilst these 
increases are small, carrying out breeding for a greater number of generations may 
reveal that this methylation changes increases slowly but steadily across the 
generations.  
 
Following the observation of a small difference in methylation between 
generations at the GFP transgene, I wanted to investigate the impact of reduced Rlf 
expression across generations on methylation of an endogenous region. The 
Smad3/Smad6 region, found to be differentially methylated in fetal liver in each of 
the Rlf Momme lines (Figure 3.11 and Figure 5.9), was chosen for further 
investigation. Methylation of this region in Rlf +/+ adult liver was observed to be 
much higher (81%) than in Rlf +/+ fetal liver (53%), Figure 5.15 and Figure 5.9.  
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Again, small increases in methylation in F1 and F8 Rlf MommeD8/MommeD8 offspring at 
this region were observed compared to wild-types (F1- 84%, p=0.4831; F8- 88%, 
p=0.0152; and wild-type 81%), Figure 5.15. However, the difference in methylation 
between F1 mice and wild-types (3%, p=0.4831) was not as great as that observed in               
Rlf MommeD8/MommeD8 fetal liver compared to wild-types (14%, p=0.0014, Figure 5.9). 
As such investigating methylation of this region in adult liver may not have been an 
appropriate tissue choice. Repeating the experiment using fetal liver tissue across the 
generations may reveal the small changes observed in adult liver to be more 
pronounced in fetal liver tissue, helping to define whether reduced Rlf expression has 
an effect on epigenetic inheritance across generations. This will be discussed further 
in Section 5.3.  
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Figure 5.15: Methylation is not altered in late generation MommeD8 
homozygotes.  
Bisulphite sequencing of the GFP transgene (A) and Smad3/Smad6 region (B) 
reveals subtle differences in DNA methylation in Rlf MommeD8/MommeD8 mice compared 
to wild-types (n = 2 per genotype). Each column represents DNA from a single heart, 
each row is the sequence from a single cell and each circle represents one CpG site. 
Filled circles represent methylated CpGs. Black circles represent methylated CpGs, 
white circles represent unmethylated CpGs, and lines (-) represents a non CpG or 
ambiguously sequenced position where a CpG exists in the genomic sequence. (X2, 
GFP transgene: p=0.0996 WT v F1, p=0.0931 WT v F8, p=0.9259 F1 v F8; 
Smad3/Smad6: X2, p=0.4831 WT v F1, p=0.0152 WT v F8, p=0.2523 F1 v F8). 
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Figure 5.15: Methylation is not altered in late generation MommeD8 homozygous offspring.  
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5.3 DISCUSSION 
 
Both MommeD28 and MommeD34 homozygous offspring are non-viable at 
weaning, whereas MommeD8 homozygous offspring are viable but present in less 
than expected numbers (Table 4.1 and Daxinger et al, 2013). Each of the Rlf Momme 
lines have also been shown to alter expression and methylation of the GFP transgene, 
which was designed to be sensitive to epigenetic silencing (Ashe et al., 2008; 
Daxinger et al., 2013). In this chapter I have further investigated the effect of 
reduced Rlf in Rlf MommeD8/MommeD8 mice on endogenous gene expression and 
methylation. Most of the loci previously found to be either differentially expressed or 
methylated in Rlf MommeD28/MommeD28 or Rlf MommeD34/MommeD34 mice were also found to 
be significantly differentially expressed (Figure 5.1) or methylated (Figure 5.9) in 
Rlf MommeD8/MommeD8 mice. Furthermore, the presence of two MommeD8 alleles had a 
greater impact on gene expression than that observed in MommeD34 heterozygous 
mice, but less than that observed in MommeD34 homozygous mice (Figure 5.2). 
This data supports the previous findings investigating viability of the Rlf Momme 
mouse lines; that carrying two copies of the MommeD8 allele has a greater impact on 
survival and expression than carrying one copy of the MommeD34 allele in the 
mouse (Ashe et al., 2008; Daxinger et al., 2013).  
 
The previous studies investigating the effect of mutations in Rlf on viability in 
the mouse investigated the different Rlf Momme lines independently from each other. 
Here I undertook breeding of Rlf MommeD8/MommeD8 mice with Rlf MommeD34/+ mice to 
investigate the viability of compound heterozygous (Rlf MommeD8/MommeD34) mice. The 
presence of both the MommeD8 and MommeD34 alleles in mice was found to reduce 
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viability and also weight of Rlf MommeD8/MommeD34 offspring at weaning (Figure 5.4). 
No difference in Rlf expression was observed in Rlf MommeD8/MommeD34 mice, however 
Hpd mRNA expression was significantly altered in these mice compared to wild-
type and heterozygous MommeD28 and MommeD8 mice (Figure 5.3). The 
development of compound heterozygous/ hypomorphic mouse lines are beneficial 
for studying the biological impact of mutations in cases where null expression results 
in lethality. The availability of the different Rlf mutant mouse lines provides a unique 
tool for studying the effects of reduced Rlf expression on phenotype that may reflect 
occurrences in the human population. 
 
Unlike the null Rlf mouse lines, MommeD28 and MommeD34, some compound 
heterozygous mice are viable at three weeks of age (Figure 5.4). Following the 
observation of differences in cardiac morphology in homozygous null Rlf embryos, 
the viability of Rlf MommeD8/MommeD34 mice provided an opportunity to determine 
whether reduced Rlf expression alters cardiac structure and function in the adult 
heart. No difference in either cardiac structure or function was observed between   
Rlf +/+ and Rlf MommeD8/MommeD34 adult mice (Figure 5.8). This lack of difference in 
structure and function alongside of reduced survival of Rlf MommeD8/MommeD34 offspring 
to adulthood may reflect incomplete phenotypic penetrance in compound 
heterozygous mice. Potentially, the Rlf MommeD8/MommeD34 offspring that do not survive 
to adulthood may present with a more severe cardiac phenotype that is reminiscent of 
the phenotype observed in the null Rlf lines, compared to offspring that do survive to 
adulthood. Undertaking analysis of cardiac function and structure in late stage 
embryos may allow us to more accurately define whether compound heterozygous 
embryos display different severities in cardiac phenotype and in turn enable the 
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detection of which offspring will survive to adulthood and which offspring may 
require the implementation of intervention strategies for survival.  
 
Two of the Rlf MommeD8/MommeD34 aged females were found to have ovarian 
growths (Figure 5.5), and while no growths were observed on other                         
Rlf MommeD8/MommeD34 ovaries, histological analysis found all of the ovaries examined 
had no oocytes or follicles present compared to wild-type ovaries (Figure 5.6). The 
reduced expression of Rlf in these mice may lead to impaired follicle development, 
resulting in the phenotype observed. Oocytes arise from primordial germ cells 
(PGCs), precursors of the postnatal female (and male) germ cell lineages, and 
become surrounded by somatic cells, forming primordial follicles (Ginsburg et al., 
1990). The pool of primordial follicles formed just after birth makeup the entire 
supply of ovarian follicles during a mouse’s reproductive life, thus reduced 
expression of Rlf early during development may impact upon the development and/or 
growth of primordial follicles. Investigating factors that are important for follicle 
growth, such as oestradiol (required for primordial follicle formation) and new ovary 
homeobox (required for primordial follicle growth), may define a specific time-point 
in which reduced Rlf is influencing follicle development.  
 
The dysregulation of the passage of PGCs to oocytes can also influence 
tumorigenic transformation (Kraggerud et al., 2013). Many studies investigating 
ovarian tumorigenesis have utilised mice on the FVB/NJ background, of which the 
Momme mice are also on. FVB/NJ mice have been shown to be more susceptible to 
benign teratomas and granulosa cell tumours than other mouse strains (Mahler et al., 
1996). This could mean that the Momme mice are more susceptible to defects in 
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ovarian development than other mouse strains, and a combination of factors could be 
influencing the ovarian phenotype observed in Rlf mutants (Hsu et al., 1996; 
Peltoketo et al., 2010; Youngson et al., 2011). Although the absence of changes in 
morphology in the wild-type aged mice from this cohort suggest the phenotype is 
due to reduced Rlf expression in Rlf MommeD8/MommeD34 mice. 
 
During this study litters born to Rlf MommeD8/MommeD8 dams were found to contain 
fewer offspring than those born to Rlf MommeD8/MommeD8 sires or wild-type dams, 
(Figure 5.10). Whilst ovarian morphology in the MommeD8 line has not previously 
been investigated, the differences observed in Rlf MommeD8/MommeD34 females may be 
linked to the reduction in litter size observed. Studies in ageing female mice have 
shown small litter size coincides with the degeneration of oocytes (Castrillon et al., 
2003; Danilovich & Sairam, 2002). These studies have analysed serum levels of 
follicle stimulating hormone and luteinizing hormone, with increased levels of these 
hormones being linked to accelerated oocyte loss and follicle degeneration 
respectively (Danilovich & Sairam, 2002; Kumar & Sait, 2011). As                          
Rlf MommeD8/MommeD34 ovaries were found to contain no oocytes or follicles, an increase 
in the serum levels of these hormones may explain the histological observations. 
Alternatively, counting the number of oocytes released by compound heterozygous 
mice, by inducing superovulation, and may reveal whether the reduced litter sizes 
observed are due to Rlf MommeD8/MommeD8 dams having fewer eggs available for 
fertilisation. 
 
Intrauterine growth restriction (IUGR) may also be a contributing factor to the 
reduced litter sizes observed from Rlf MommeD8/MommeD8 dams. IUGR is classified as a 
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lack of nutrient, oxygen and blood supply from the mother to the fetus (Corstius et 
al., 2005). Whilst we have not directly investigated the placentas of mice from the 
MommeD8 mouse line, we have previously noted subtle differences in placental 
morphology of Rlf MommeD28/MommeD28 embryos (Section 4.2.8). As such, it is possible 
that the reduction in litter size may be the result of differences in placental 
morphology affecting nutrient supply to embryos, resulting in a reduced number of 
pups at birth.  
 
In contrast to homozygous MommeD28 and MommeD34 mice the majority of 
homozygous MommeD8 mice are viable and fertile, presenting an opportunity to 
examine the effects of reduced Rlf expression across multiple generations.              
Rlf MommeD8/MommeD8 mice have also been found to have decreased bodyweight (Figure 
5.12) and increased methylation of the GFP transgene (Daxinger et al., 2013) 
compared to wild-type littermates. To determine whether reduced Rlf can influence 
epigenetic reprogramming in the mouse, the weight of offspring across multiple 
generations and also methylation of the GFP transgene and an endogenous region 
were investigated. No large accumulation of either of these phenotypes across the 
MommeD8 generations was observed. Instead, the maintenance of bodyweight 
(Figure 5.13) and GFP methylation (Figure 5.15) in late generation                        
Rlf MommeD8/MommeD8 mice support the resetting of epigenetic state between each 
generation. The study of bodyweight across generations was found to be highly 
variable across generations (Figure 5.13) and may have been influenced by external 
factors, such as intermittent building works in the animal house at the time of the 
experiment, which could not be controlled for.  
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Methylation of the endogenous Smad3/Smad6 locus was also investigated, and 
a small difference in methylation observed comparing wild-type, F1 and F8 Rlf 
MommeD8/MommeD8 mice (Figure 5.15).  The Smad3/Smad6 region and GFP transgene 
were originally identified as being differentially methylated in E14.5 liver and adult 
spleen (Figure 5.9 and Daxinger et al., 2013). As the methylome has been shown to 
undergo remodelling during development and to also be different between different 
lineages (Hemberger et al., 2009; Okano et al., 1999), the investigation of adult liver 
may not have been an appropriate tissue choice. The collection of either fetal liver 
and/or adult spleen for methylation analysis may have been more appropriate tissue 
choices. Alternatively, undertaking genome-wide methylation analysis in liver tissue 
from these mice may more appropriate define regions in the genome that escape 
epigenetic reprogramming in MommeD8 mice.  
 
While the expression of Rlf in homozygous MommeD8 mice is reduced, the 
activity of Rlf may not be altered in a manner in which large changes in phenotype 
would be observed. This may result in only subtle alterations in phenotype occurring 
across multiple generations of MommeD8 mice. Additionally, the reduced viability 
of Rlf MommeD8/MommeD8 mice may suggest these mice are compensating for the loss of 
Rlf in some way or that there is incomplete penetrance in these mice. This may be 
influencing the results observed in that the Rlf MommeD8/MommeD8 mice that survive and 
are used for breeding the next generation are passing on a less severe phenotype than 
that which may be present in non-viable Rlf MommeD8/MommeD8 mice. In order to 
determine whether Rlf has an impact on transgenerational epigenetic inheritance in 
these mice a greater number of generations would need to be investigated for the 
accumulation of these subtle effects to be identified with greater specificity.   
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The results presented here in the hypomorphic mouse lines further support the 
overall hypothesis of this PhD in that Rlf plays a key role in development and 
disease progression.  
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5.4 FUTURE DIRECTIONS 
 
In this chapter I have found a potential role for Rlf in ovarian and follicular 
development. Due to time and financial constraints no studies of how reduced Rlf 
impacts the reproductive system were able to be undertaken. Female and male        
Rlf MommeD8/MommeD34 mice have not previously been used for breeding, leaving their 
fertility status unknown. Crossing Rlf MommeD8/MommeD34 dams and wild-type sires, and 
undertaking the reciprocal cross, may reveal whether the differences in ovarian 
morphology observed impact upon litter size.  Investigating follicle development, 
growth, numbers and serum hormones in females of different ages would more 
clearly define a time-point or ovarian follicle growth pathways that require Rlf for 
correct development. Alternatively, the production of a conditional Rlf knockout in 
the ovary may better allow for studying the effect of loss of Rlf rather than reduced 
expression on ovarian development. 
 
No difference in cardiac structure and function was observed in adult             
Rlf MommeD8/MommeD34, however not all Rlf MommeD8/MommeD34 mice survive to adulthood. 
This may reflect incomplete phenotypic penetrance amongst compound heterozygous 
offspring.  Western blotting performed in this study was undertaken in adult            
Rlf MommeD8/MommeD34 mice, repeating Western blotting in fetal tissue may reveal 
differences in Rlf protein expression that could point towards differences in Rlf 
expression amongst compound heterozygous offspring. Similarly, investigating the 
cardiac function and structure of neonatal or late gestational mice using 
echocardiography may be able to define which mutants are likely to survive and 
which would require therapeutic intervention.  
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Investigation of multiple generations of MommeD8 homozygous offspring 
found no significant change in methylation between F1 and F8 mice at both the GFP 
transgene and Smad3/Smad6 region in adult liver. As epigenetic reprogramming 
occurs following fertilisation of the zygote and during the establishment of the 
primordial germ cells (Hajkova et al., 2002), an earlier time-point may be more 
beneficial for investigating loci that escape this reprogramming. More suitable loci 
for investigation may be non-imprinted genes that have been found to inherit 
methylation from the parental gametes and are thought to escape reprogramming 
(Borgel et al., 2010). Moving to this early time-point would provide the ability to 
study mice that are null for Rlf. Utilising this mouse line would provide greater detail 
into the effects of loss of Rlf on transgenerational epigenetic inheritance than the 
hypomorphic MommeD8 mouse line. 
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Chapter 6: Overall Discussion and Future 
Directions 
This is the first study to investigate the molecular and phenotypic 
consequences of loss of Rlf in the mouse. The results presented here have directly 
addressed the main hypothesis of this PhD. That Rlf is a novel epigenetic modifier of 
critical importance in development and disease.  
 
The research undertaken here has investigated three key aims which will be 
addressed below.  
Aim 1:  Loss of Rlf alters the transcriptome and methylome in E14.5 
fetal mouse liver 
Both the methylome and transcriptome were found to be altered in Rlf null fetal 
liver. RNA-seq identified a number of genes that were both up- and down-regulated 
in E14.5 liver. More genes were found to be down-regulated, supporting a role for 
Rlf in transcriptional activation, and these genes displayed higher fold changes in 
expression than those that were up-regulated. ChIPseq, using two independent Rlf 
antibodies, also identified putative Rlf binding sites located at or near TSS. Further 
supporting a role for Rlf in transcriptional activation.  
 
Methylation in Rlf null fetal liver was found to be increased at a number of 
distinct loci across the genome. Many of these differentially methylated regions 
overlapped with putative regulatory elements, although these did not overlap with 
putative Rlf binding sites. This overlap is reminiscent of tissue specific DMRs that 
retain an epigenetic memory from early in development. Our results suggest that Rlf 
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is also involved in the maintenance of hypomethylation at such regions. It is thought 
tissue specific differential methylation of CpG island shores may be transcription 
factor dependent, and this is supported by our findings that loss of Rlf results in 
increased methylation of CpG island shores. 
 
Here I have proposed a model that Rlf binding to TSS may stabilise the binding 
of an independent factor to the Rlf-DMR, facilitating the demethylation and 
expression of these genes. Further study, utilising methods such as chromosome 
conformation capture, will help to uncover the precise mechanism through which Rlf 
influences gene expression. 
  
Aim 2: Rlf is of critical importance in mouse development 
Here I have shown that Rlf is expressed widely during development, and mice 
with reduced or no expression of Rlf are not present at adulthood in the expected 
numbers. Homozygous MommeD28 and MommeD34 mid-gestation (E14.5) embryos 
were found to display defects in cardiac development, reminiscent of left ventricular 
non-compaction (LVNC) observed in humans. RNA-seq performed in E13.5 hearts, 
prior to the observation of the heart defect, revealed small but significant changes in 
the expression of genes that are implicated in pathways that are critical for cardiac 
development. For example, a number of dysregulated genes form a part of the 
Notch1 signalling pathway which is essential for compaction of the heart wall. This 
dysregulated signalling, as a result of down regulation of Notch1 ligands, may lead to 
the cardiac defect observed. Future use of these first Rlf mouse mutants may allow 
for a greater understanding of LVNC and how it arises.  
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As the Momme mice used in this study display global loss of Rlf expression, 
the development of conditional Rlf knockouts in cardiac specific cells, e.g. 
endocardial cells, may confirm whether the cardiac defect observed in these mice is 
specific to loss of Rlf in one cell type or multiple cell types within the heart. 
Additionally, no studies have previously linked Rlf with LVNC in humans; 
undertaking sequencing of clinical samples in the future may enhance current 
screening, diagnosis and management strategies for these patients.  
 
The placenta also plays an important role in regulating cardiovascular growth 
and fetal development. Here I have identified subtle defects in placental fetal 
vasculature in Rlf mutants at E14.5. This difference in morphology from mid-
gestation may be responsible for the reduction in weight observed in late gestation 
Rlf null embryos. Aggregating wild-type embryos with Rlf mutant placentas, or the 
reciprocal aggregation, may be able to more clearly define the relationship between 
the cardiac defect, weight reduction and placental defect observed.  
 
Aim 3:  Reduced Rlf expression alters phenotype in the adult mouse  
I have shown hypomorphic Rlf MommeD8/MommeD8 and Rlf MommeD8/MommeD34 mice, 
with reduced Rlf expression, have a greater impact on endogenous gene expression 
than Rlf MommeD28/+ and Rlf MommeD34/+ mice but not as great an effect as                      
Rlf MommeD28/MommeD28 and Rlf MommeD34/MommeD34 mice.  This suggests the different Rlf 
Momme mutants have varying impacts on Rlf activity within the mouse.  The 
availability of these different Rlf mouse mutants provide a unique tool with which to 
study the effect of reduced Rlf expression on phenotype that may reflect occurrences 
in the human population.  
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Hypomorphic Rlf mutants were used to study the effect of loss of Rlf on 
phenotype across generations. No significant accumulation of phenotype was 
observed in these mice, suggesting the epigenetic state is reset between each 
generation. The methods used in this study however, would not have been sufficient 
for detecting subtle changes in phenotype. Additionally, only two loci were 
investigated that may not have been representative of the whole genome or loci that 
escape reprogramming. Future studies investigating an earlier developmental time 
point, for example following the fertilisation of the zygote or imprint erasure in 
primordial germ cells, may determine whether Rlf affects the clearing of DNA 
methylation between generations.   
 
Differences in ovarian morphology were also observed in a preliminary cohort 
of hypomorphic Rlf female mice. The absence of oocytes and follicles may arise 
from reduced Rlf expression early in development, when primordial follicles are 
being established. Future investigations of the developing follicles during 
embryogenesis may reveal a critical role for Rlf in follicle development, which may 
in turn influence fertility and/or tumorigenic transformation.   
 
The use of these first known mouse mutants for Rlf  in future investigations 
will be valuable in advancing our knowledge of cardiac development, epigenetic 
reprogramming and ovarian development. 
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Chapter 7: Appendices  
Appendix I: PCR Primer Sequences 
PCR primers for genotyping  
Primer 
 Name 
Forward Sequence (5' to 3') Reverse Sequence (5' to 3') 
MommeD8 GCAGCCAGAAAGTAGCAAATGAGCG TGTTTGGGAGGGGCACACTGC 
MommeD28 TCTGCCAGTCTCTGAAGAAAAGGCA CTGTGGCTTTCATTCTGGAAGGGAA 
MommeD34 GTTGCCCATTTTAGGGGAG TGGATTGCACCCTGGACTAC 
 
Primers for qRT-PCR  
Primer Name Forward Sequence (5' to 3') Reverse Sequence (5' to 3') 
Hpd AGGTAGTCAGCCACGTCATC CAATGTGGTCGCAGTCTTCC 
Timd2 ATGGTGGTCCCTATTGCTGT GGCCTCTGGTTTGTAGGTCT 
Apoc1 CATCGCTCTTCCTGTCCTGA ATATGTTCAATGGCTGCCCG 
Prss50 GGTTCATTCCAGCAACCTCC GAAGCGATAAGGATGCCAGC 
Atp2b2 CCTCAAAACCTCGCCTGTTG GTGGGTGGTAGAAGGACAGT 
Crispld2 GGTACGACGAGGTGAAGGAT TACACGGCATTCTCCCAAGT 
Psma8 ACTGTGAGGAAAATCTGCGC TACCAAAAGGCCTTCGTCCA 
Upb1 AGGAATCTCGATCTGCCCAG ATTGACTCCACACATTGCGG 
Mgam TTGTTCTGCTGCTTGTCCTG ACTGGGCAATTGGGAGAGTT 
Myo5c GGCTGAAATCGCAAAGGACT CTCATGGAGGTAGCTGAGGG 
Vldlr TCGGGCTTTGTTTACTGGTC AGTAGAGGCGGCTTTTGACA 
Aldh1a7 GCAGGGAAAAGCAATCTGAA TCTGACCCTGGTGGAAGAAC 
 
Primers for Bisulphite Sequencing 
Primer Name Sequence (5' to 3') Tm 
(°C) 
Product 
Size 
Smad3/6  
External Forward 
AAGTGGAATTTTTTAGTGGTAGATG 53 493 
Smad3/6  
External Reverse 
AACTACTTTAATAAAAAATAACATAACC 53 493 
Smad3/6  
Internal Forward 
TTGGTATGTGTTGTTTTTAGTTTTG 51 493 
Smad3/6  
Internal Reverse 
ACAATTTAACTATTCATTATATCTCTAACA 51 493 
Hpd  
External Forward 
TTTAGAATTTAGAGGTAGTAGGGTAAAT 60 300 
Hpd  
External Reverse 
ACAAAATATACCCTAACACTCAACTCAT 60 300 
Hpd  
Internal Forward 
GGATTTTAAATGATAGTTGGGAGATTTT 60 300 
Hpd  CCTAACCAAAACTCAAATCACATCTA 60 300 
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Primer Name Sequence (5' to 3') Tm 
(°C) 
Product 
Size 
Internal Reverse 
Prss50  
External Forward 
GGTATAGGGATTTAGAGAAAGGG 60 326 
Prss50  
External Reverse 
TTAGGAGTTTGAGGAAAGATATAAGGTA 60 326 
Prss50  
Internal Forward 
ACCAAATAACCTATAAAAAATCTCCA 60 326 
Prss50  
Internal Reverse 
ACCTAAAAAACAAATACCTCTAAAACC 60 326 
Basp1  
External Forward 
GAGGTTAAAAAGATTGAGGTTTT 47 309 
Basp1  
External Reverse 
TCCAATTTAAAACAAATTAATATAAAATAA 47 309 
Basp1  
Internal Forward 
GTTAAGGTAGAGGAGAAGGAGGT 47 309 
Basp1  
Internal Reverse 
AATAAAACACATCCTCTTTATTTTT 47 309 
GFP enhancer 
External Forward 
AAAATAAAATTTTTGGATTGTTATTATTATAA 60 162 
GFP enhancer 
External/Internal 
Reverse 
AATCTCTACTCACTACAAACTCCATCTC 60 162 
GFP enhancer 
Internal Forward 
ATATTTGTAATTTTAGTATTTTGGGAGGTT 60 162 
Enhancer mm87  
External Forward 
GGTAGGAGATAATGGGTTTAAAGGT 56 350 
Enhancer mm87  
External Reverse 
TCAACTCCCAAAAAATAAACTAAAC 56 350 
Enhancer mm87 
Internal Forward 
TGGGTTTAAAGGTGTTGAATTAGTT 56 350 
Enhancer mm87 
Internal Reverse 
TAAATAAAATAAAACCCACTCCTCCC 56 350 
SP6 TATTTAGGTGACACTATAG 55 Variable 
T7 TAATACGACTCACTATAGGG 55 Variable  
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Appendix II: Differential expression analysis comparing RNA-seq datasets from 
Rlf +/+ and Rlf MommeD28/MommeD28 E14.5 liver. 
Please view the accompanying Excel spreadsheet of the DESeq Differential 
expression analysis comparing RNA-seq datasets from Rlf +/+ mice to                      
Rlf MommeD28/MommeD28 mice. The column headings represent: 
Column Header Information 
Ensembl gene ID Ensembl identification number 
Gene Name Short gene name (symbol) 
baseMean The mean of the counts divided by the size factors for the counts for both conditions (wild-type and homozygous)  
baseMeanA The base mean i.e., mean of the counts divided by the size factors for the counts for Rlf +/+ 
baseMeanB The base mean for i.e., mean of the counts divided by the size factors for the counts for Rlf MommeD28/MommeD28 
FoldChange Ratio meanB/meanA 
Log2FoldChange Log2 of the fold change 
Pval p value for rejecting the null hypothesis ‘meanA==meanB’ 
padj adjusted p values (adjusted with ‘p.adjust) 
 
 
Appendix III: Differential expression analysis comparing RNA-seq datasets 
from Rlf +/+ and Rlf MommeD28/+ E14.5 liver. 
Please view the accompanying Excel spreadsheet of the DESeq Differential 
expression analysis comparing RNA-seq datasets from Rlf +/+ mice to Rlf MommeD28/+ 
mice. The column headings represent:   
Column Header Information 
Ensembl gene ID Ensembl identification number 
Gene Name Short gene name (symbol) 
baseMean The mean of the counts divided by the size factors for the counts for both conditions (wild-type and heterozygous)  
baseMeanA The base mean i.e., mean of the counts divided by the size factors for the counts for Rlf MommeD28/+ 
baseMeanB The base mean for i.e., mean of the counts divided by the size factors for the counts for Rlf +/+ 
FoldChange Ratio meanB/meanA 
Log2FoldChange Log2 of the fold change 
Pval p value for rejecting the null hypothesis ‘meanA==meanB’ 
padj adjusted p values (adjusted with ‘p.adjust) 
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Appendix IV: Rlf-DMRs identified using genome-wide bisulphite sequencing of 
DNA from Rlf +/+ and Rlf MommeD28/MommeD28 E14.5 liver. 
Please view the accompanying Excel spreadsheet of the GWBS differential 
methylated analysis comparing Rlf +/+ to Rlf MommeD28/MommeD28 fetal liver. The column 
headings represent:   
Column Header Information 
Chr  Chromosome number 
Start  Start coordinate of Rlf-DMR  
End  End coordinate of Rlf-DMR 
CpGs Number of CpGs within Rlf-DMR 
mCG difference Difference in methylation between genotypes 
Rlf +/+ mean mCG Mean methylation for wild-type replicates 
Rlf MommeD28/MommeD28 mean mCG Mean methylation for the homozygous replicates 
Direction  Direction in which methylation is occurring in   Rlf MommeD28/MommeD28 fetal liver 
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Appendix V: Rlf peaks detected in chromatin extracted from Rlf +/+ E14.5 liver 
following ChIPseq with Abcam Rlf antibody. 
Please view the accompanying Excel spreadsheet ChIPseq analysis of Rlf +/+ fetal 
liver following ChIP with the Abcam Rlf antibody. The column headings represent:  
Column Header Information 
Active Region Unique identifier assigned to each Active Region 
Chromosome  Chromosome number 
Start Nucleotide position on chromosome where Active Region starts (if on + strand) or ends (if on – strand) 
End Nucleotide position on chromosome where gene ends (if on + strand) or starts (if on – strand) 
Length Length of Active Region in base pairs 
IntervalCount Number of Intervals that make up the Active Region 
Wild_1_AvgValue Value Average of fragment densities of all the bins within the Active Region 
Wild_2_AvgValue Value Average of fragment densities of all the bins within the Active Region 
Wild_1_Peak Value Peak Value Peak fragment density of the Active Region (Value at “Summit”) 
Wild_2_Peak Value Peak Value Peak fragment density of the Active Region (Value at “Summit”) 
CGIslandCount Number of UCSC-annotated CpG Islands within a set distance of each Active Region 
Promoter Count 
Number of Promoters (-7500 to +2500 bp relative to gene 
starts) overlapping with each Active Region  (only for tables 
with <65,530 rows) 
GeneCount Number of NCBI annotated genes within a set distance (GeneMargin) of each Active Region 
Gene List Names (symbols) of genes found within a set distance (GeneMargin) of Active Region 
Dist to Start Distance of midpoint of Active Region to gene start 
Position Location of midpoint of Active Region relative to gene 
UCSC Link Link to display Active Region +/- 0.5 kb flanking sequence in browser 
Wild_1Present 
 
Present Presence of an Interval from [Sample x] in an 
Active Region is denoted by "1" and absence is denoted by 
"0". These columns are useful for sorting data to determine 
patterns between samples 
Wild_2 Present 
Present Presence of an Interval from [Sample x] in an 
Active Region is denoted by "1" and absence is denoted by 
"0". These columns are useful for sorting data to determine 
patterns between samples 
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Appendix VI: Rlf peaks detected in chromatin extracted from Rlf +/+ E14.5 liver 
following ChIPseq with a custom Rlf antibody. 
Please view the accompanying Excel spreadsheet ChIPseq analysis of Rlf +/+ fetal 
liver following ChIP with the Abcam Rlf antibody. The column headings represent:  
Column Header Information 
Active Region Unique identifier assigned to each Active Region 
Chromosome  Chromosome number 
Start Nucleotide position on chromosome where Active Region starts (if on + strand) or ends (if on – strand) 
End Nucleotide position on chromosome where gene ends (if on + strand) or starts (if on – strand) 
Length Length of Active Region in base pairs 
IntervalCount Number of Intervals that make up the Active Region 
Wild_5_AvgValue Value Average of fragment densities of all the bins within the Active Region 
Wild_6_AvgValue Value Average of fragment densities of all the bins within the Active Region 
Wild_5_Peak Value Peak Value Peak fragment density of the Active Region (Value at “Summit”) 
Wild_6_Peak Value Peak Value Peak fragment density of the Active Region (Value at “Summit”) 
CGIslandCount Number of UCSC-annotated CpG Islands within a set distance of each Active Region 
Promoter Count 
Number of Promoters (-7500 to +2500 bp relative to gene 
starts) overlapping with each Active Region  (only for tables 
with <65,530 rows) 
GeneCount Number of NCBI annotated genes within a set distance (GeneMargin) of each Active Region 
Gene List Names (symbols) of genes found within a set distance (GeneMargin) of Active Region 
Dist to Start Distance of midpoint of Active Region to gene start 
Position Location of midpoint of Active Region relative to gene 
UCSC Link Link to display Active Region +/- 0.5 kb flanking sequence in browser 
Wild_5Present 
 
Present Presence of an Interval from [Sample x] in an 
Active Region is denoted by "1" and absence is denoted by 
"0". These columns are useful for sorting data to determine 
patterns between samples 
Wild_6 Present 
Present Presence of an Interval from [Sample x] in an 
Active Region is denoted by "1" and absence is denoted by 
"0". These columns are useful for sorting data to determine 
patterns between samples 
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Appendix VII: Histology sections of cohorts used for defining cardiac defect in 
Rlf mutant mice. 
Please view the accompanying PDF file of the E14.5, E9.5 and E11.5 Rlf +/+ and        
Rlf MommeD28/MommeD28 cohorts used for histological analysis of the heart.  
 
 
Appendix VIII: CuffDiff Differential expression analysis comparing RNA-seq 
datasets from Rlf +/+ and Rlf MommeD28/+ E13.5 hearts. 
Please view the accompanying Excel spreadsheet of the CuffDiff differential 
expression analysis comparing RNA-seq datasets from Rlf +/+ and                           
Rlf MommeD28/MommeD28 fetal hearts. The column headings represent:   
 
Column Header Information 
Gene  The gene_name(s) or gene_id(s) being tested 
Ensembl gene ID Ensembl identification number 
Locus  Genomic coordinates for easy browsing to the genes or transcripts being tested. 
Sample  1  Label (or number if no labels provided) of the first sample being tested 
Sample  2  Label (or number if no labels provided) of the second sample being tested 
Test status 
Can be one of OK (test successful), NOTEST (not enough 
alignments for testing), LOWDATA (too complex or 
shallowly sequenced), HIDATA (too many fragments in 
locus), or FAIL, when an ill-conditioned covariance matrix 
or other numerical exception prevents testing. 
Mean Wild-type FPKM of the gene in sample wild-types replicates 
Mean Homozygous FPKM of the gene in sample homozygous replicates 
FoldChange Ratio MeanHomozygous/meanWild-type 
log2(FPKMy/FPKMx) The (base 2) log of the fold change y/x 
Test  stat  The value of the test statistic used to compute significance of the observed change in FPKM 
p The uncorrected p-value of the test statistic 
q The FDR-adjusted p-value of the test statistic 
Significant  
Can be either “yes” or “no”, depending on whether p is 
greater than the FDR after Benjamini-Hochberg correction 
for multiple-testing 
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Appendix IX: EdgeR Differential expression analysis comparing RNA-seq 
datasets from Rlf +/+ and Rlf MommeD28/+ E13.5 hearts. 
Please view the accompanying Excel spreadsheet of the EdgeR differential 
expression analysis comparing RNA-seq datasets from Rlf +/+ and                           
Rlf MommeD28/MommeD28 fetal hearts. The column headings represent:   
Column Header Information 
Gene name The gene_name(s) or gene_id(s) being tested 
Ensembl gene ID Ensembl identification number 
Sample (x) Counts per million (CPM) mapped reads scaled by the number of fragments sequenced for each replicate 
BaseMean Homo  Mean of the counts divided by the size factors for the counts for Rlf MommeD28/+ 
BaseMean Wild Mean of the counts divided by the size factors for the counts for Rlf +/+ 
FoldChange Ratio meanB/meanA 
Log2FoldChange Log2 of the fold change 
p val p value for rejecting the null hypothesis 
‘meanHomo==meanWild’ 
Adj p val adjusted p values  
 
Appendix X: DESeq Differential expression analysis comparing RNA-seq 
datasets from Rlf +/+ and Rlf MommeD28/+ E13.5 hearts. 
Please view the accompanying Excel spreadsheet of the DESeq differential 
expression analysis comparing RNA-seq datasets from Rlf +/+ and                           
Rlf MommeD28/MommeD28 fetal hearts. The column headings represent:   
Column Header Information 
Gene name The gene_name(s) or gene_id(s) being tested 
Ensembl gene ID Ensembl identification number 
baseMean The mean of the counts divided by the size factors for the counts for both conditions (wild-type and heterozygous)  
FoldChange Ratio meanB/meanA 
Log2FoldChange Log2 of the fold change 
lfcSE Standard error: Rlf MommeD28/MommeD28:Rlf +/+ 
Stat Wald statistic: Rlf MommeD28/MommeD28:Rlf +/+ 
pval p value for rejecting the null hypothesis ‘meanA==meanB’ 
padj adjusted p values (adjusted with ‘p.adjust) 
NReads   
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Appendix XI: Histological sections of aged female Rlf+/+ and Rlf MommeD8/MommeD34 
ovaries. 
Please view the accompanying PDF file of the histological ovarian sections from 
aged female cohort.  
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